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The production of viable germ cells during human embryonic development 
determines adult reproductive success.  This is particularly true for females, as 
development of germ cells (GCs) into primordial folicles before birth is imperative 
for future fertility.  During fetal development GCs migrate to the genital ridge to 
form the gonad, after which several tightly regulated events, including proliferation, 
differentiation, and association with somatic cells, must occur to form a functional 
gonad.  In the ovary these processes also include the initiation and subsequent arrest 
of meiosis.   These developmental processes are orch st ated by local autocrine and 
paracrine factors, many of which remain to be identifi d in the human. 
In order to decipher further the pathways by which the gonad and GCs develop, 
potential regulators including prostaglandin (PG) E2, the interleukin (IL)6-type 
cytokines, and the prokinetecins (PROKs), were examined in the human fetal ovary 
and PROKs in the human fetal testis.  Patterns of gene expression, protein 
localisation, function, and interaction of the potential mediators throughout human 
development (8-20 weeks gestation) were determined.  Primary fetal tissue was 
investigated, in addition to immortalized GCs (T-Cam2 cells) and a murine model of 
fetal ovarian development. 
PGE2 interacts with known regulators of GC development in non-reproductive 
organs.  It was postulated PGE2 may regulate GC progression by modulating these 
factors.  Examination of PGE2 receptors and precursor enzymes in the fetal ovary 
revealed that all were present and some were developm ntally regulated, with 
mRNA expression increasing with gestation.  These developmentally regulated 
components were localised to the GCs.  The PGE2 receptors were among those 
differentially expressed, with one localised solely to mature GCs.  Culture of human 
fetal ovary confirmed that PGE2 regulates known regulators of GC development, 
increasing expression of survival and anti-apoptotic factors.  To test the hypothesis 
that PGE2 is necessary for female GC development, paracetamol, an inhibitor of 
PGE2 precursor enzymes, was utilised in a murine model of fetal exposure.  Fetal 
ovaries from this experiment displayed disruption of rmal development. 
v 
The IL6-type cytokines are also postulated to be involved in early gonad 
development, and are known to regulate proliferation and differentiation of mouse 
embryonic stem and GCs in vitro.  A significant increase in transcript levels of the 
shared receptor components was determined in second trimester human ovaries, as 
well as developmental increases of several of the IL6-type ligands. Both common 
receptor components were located specifically in the GCs identifying them as the 
target of IL6 action in the human fetal ovary. 
The PROKs regulate cell migration, proliferation and differentiation, and modulate 
secretion of PGE2 and expression of some IL6-type cytokines. To-date, PROKs have 
not been examined in the human fetal gonad.  Transcipt levels were higher in the 
fetal testis compared to the ovary, with receptor and ligand components increasing 
with gestation.  Most components also increased with gestation in the ovary.  
However, location of PROK components was strikingly different between the two 
tissues, with GCs being the primary target of PROK action in the fetal ovary, and 
Leydig and interstitial cells being the target in the testis.  PROKs interaction with 
other regulators of gonad development was examined utilising a GC line in the case 
of the ovary and primary interstitial cell cultures in the case of the testis. 
These studies have identified new factors involved in human fetal gonad 
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COX cyclooxygenase 
CXCR4 chemokine receptor 4 
Dazl deleted in azoospermia like 
DKK1 dikkopf homolog 1 
e embryonic day 
ECM extracellular matrix 
EP PGE2 receptor 
ER estrogen receptor 
ES embryonic stem (cell) 
FIGLA factor in the germline alpha 
FOXL2 forkhead box L2 
FOXO3a forkhead box O3a 
GC germ cell 
GDF9 growth differentiation factor 9 
GFP green flouroscent protein 
gp130 glycoprotein-130 
H2O water 
HRP horse radish peroxidase 
ID inhibitor of differentiation 
IL6  interleukin 6 
IL6R interleukin 6 receptor 
Jak Janus kinases 
KL Kit ligand 
l liter 
LHX8 LIM homeobox 8 
LIF leukemia inhibitory factor 
LIFR leukemia inhibitory factor receptor 
MAPK Mitogen-Activated Protein Kinase 
Mcl-1 myeloid leukemia sequence-1 
min minute 
MIS Müllerian inhibiting substance 
MOF multiple oocyte follicle 
MVH mouse VASA homologue 













NS normal serum 
NSAID non-steroidal anti-inflammatory drug 
NT4 neurotrophin-4 
OSM  oncostatin-M 
OSMR oncostatin-M receptor 
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PG  pre-granulosa cell 
PGC primordial germ cell 
PHH3 phospho-histone H3 
pnd postnatal day 
POI premature ovarian insufficiency 
PROK prokineticin 
PROKR prokineticin receptor 
PTGES prostaglandin E synthase 
RA  retinoic acid 
RAR retinoic acid receptor 
rpm revolutions per minute 
RSPO1 roof plate-specific spondin-1 
SDF1 stromal derived factor 1 
sec second 
SF1 steroidogenic factor 1 
SM  somatic cell 
Socs suppresor of cytokine signaling 
 
SOHLH 
spermatogenesis and oogenesis  
specific basic helix-loop-helix 
Stat 
signal transducer and activator of 
transcription 
Stra8 stimulated by retinoic acid 
TBS tris buffered saline 
TGFβ transforming growth factor β 
TNAP 
tissue non-specific alkaline 
phosphatase 
TRK tropomyosin-related kinase 
VEGF vascular endothelial growth factor 
WNT4 
wingless-type MMTV integration site 
4 
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Chapter 1. Literature Review 
1.1 Introduction 
Fetal ovarian development is comprised of many complex rocesses, initiating with 
germ cell specification and migration to form the bi-potential gonad, followed by sex 
determination and entry to meiosis, culminating in primordial follicle formation 
(Edson et al, 2009).  Proper development of the ovary and primordial follicles during 
fetal life will define a female's future reproductive capacity (McGee & Hsueh, 2000; 
Adhikari & Liu, 2010; Reddy et al, 2010).    
Fetal ovarian development is regulated by the germ cell niche; a milieu of autocrine, 
juxtacrine and paracrine factors of both germ cell and somatic cell origin that govern 
the processes necessary for fetal ovarian function.  The germ cell niche is not only 
important for regulation of the ovarian processes dcribed above, but also oocyte 
survival and proliferation, in concert with germ cell atresia.  In the human fetal 
ovary, germ cell numbers reach 7 million at 20 weeks (Baker, 1963), followed  by 
rapid depletion of the oocyte population via apoptosis, such that ~85% of oocytes are 
lost by birth and over 99% by puberty (Baker, 1963; Forabosco et al, 1991) (Figure 
1.1).  This dynamic interplay between survival and poptosis regulates which oocytes 
are available for future ovulation, disruption of which can lead to premature ovarian 
insufficiency (POI) or infertility.   
Although some factors have been identified as regulators of these processes, their 
interaction with other regulators and the overall mechanisms governing fetal ovarian 
development remain unclear.  For this reason, examin tion of the established factors 
involved in fetal ovarian development, and their interactions with possible novel 








Figure 1.1 Schematic of human ovarian development. 
Demonstrating germ cell number changes before birth leading up to follicle formation.  
Figure adapted from (Kaipia & Hsueh, 1997). 
 
1.2 Fetal Gonad Development 
The following sections will focus predominantly on human data; however due to 
limitations in availability and age range of human fetal tissue, most factors are 
initially examined in murine models before being characterised in human tissue.  
Therefore, key processes and known regulators of early ovarian development will be 
discussed as characterised in the mouse with further more limited information in the 
human fetal ovary.  In addition, although mouse ovarian development and primordial 
follicle formation involves similar processes to thse in the human, there are key 
species-specific differences.  Notably, mouse gestation is ~20 days, with primordial 
follicle formation occurring postnatally and nest breakdown being governed by 
estrogen, whereas human primordial follicle formation happens prenatally and 
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steroidogenic cues have not been identified-althoug it remains possible that they 
contribute.  Table 1.1 summarises the key stages of ovarian development and their 
timing in both species. 
Estimation of gestational age is done in one of two ways in the human; it is either 
estimated as weeks post fertilisation (wpf) or gestational age as determined from the 
last menstrual period (gestation) (Lynch & Zhang, 2007).  Fertilisation generally 
occurs 2 weeks after the last menstrual period in a women with a regular 28 day 
cycle, thus development deemed gestational age is 2 weeks later than wpf age.  
 
 
Table 1.1 Gestational comparison of ovarian development between the 
human and mouse 
(Abbreviations: e, embryonic day; pnd, postnatal day; wpf, weeks post fertilization) 
Event Human Human Reference Mouse Mouse Reference 
GC Specification ≤3 w gestation (Falin, 1969) e 5.5 (Saitou, 2009) 
GC Migration 
4-5 w gestation 
 (Fujimoto et al, 
1977) e 7.5 
(Anderson et al, 2000) 
Colonisation of the 
Gonad 
4 wpf  
(6 w gestation) 
(Francavilla et al, 
1990) e10.5 
(Molyneaux et al, 2001) 
Sex Determination 
6-7 wpf 
(8-9 w gestation) 
 (Moore, 1967) e 12.5 (Adams & McLaren, 2002) 
Initiation of Meiosis 11 w gestation  (Motta et al, 1997) e 13.5 (Hilscher et al, 1974) 
Primordial Follicle 
Formation 
18 w gestation 
(Hertig & Adams, 
1967) 
pnd 0 (Epifano & Dean, 2002) 
Length of Gestation 
40 w gestation 
(Guerrero & Florez, 
1969) 20-21 d 
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1.2.1 Germ Cell Specification 
During mammalian fetal development, precursor cells which will develop into 
primordial germ cells (PGCs) originate in the proximal epiblast (Chiquoine, 1954a; 
Lawson & Hage, 1994), and are induced by signals from the adjacent stroma to 
become the germline, a process which is deemed epigenesis and occurs between 
embryonic days (e)5.5-7.5 in the mouse (Saitou, 2009).   
Key to initiation of PGC specification is signalling from the bone morphogenic 
proteins (Bmp) 2, 4, and 8.  Bmp4 and 8b signal from the extra embryonic ectoderm 
(Lawson et al, 1999; Ying et al, 2000) whereas Bmp2 signals from the visceral 
endoderm (Ying & Zhao, 2001).  These factors signal to the proximal epiblast via 
their transducer proteins Smad1 and 5 which are translocated to the cell nucleus via 
the mediator protein Smad4 in order to interact with other transcriptional activators 
and modulate gene expression.  Bmp signalling promotes expression of further PGC 
factors, which as a whole interact to suppress somatic genes and initiate the PGC 
pathway in a subset of cells at ~e5.5 in the mouse (Lawson et al, 1999).  The 
importance of Bmp signalling was confirmed with targeted disruption of Bmp4 and 
Bmp8 in rodent models: these have a reduced number of PGCs which are unable to 
migrate or proliferate as a result of disruption of specification (Lawson et al, 1999; 
Ying et al, 2000).  Mouse models with disruptions of Smad1 or 5 also display 
reduced numbers of PGCs (Chang & Matzuk, 2001; Tremblay et al, 2001), as does 
disruption of their intracellular mediator Smad4 (Chu et al, 2004).   
Bmp signalling in precursor PGCs promotes expression of several PGC factors, most 
notably; interferon-inducible gene 3 (Ifitm3/fragilis), PR domain-containing 
1(Prdm1/Blimp1), and POU domain 5f1 (Pou5f1/Oct4) (Ying & Zhao, 2001; Saitou 
et al, 2002; Tanaka & Matsui, 2002; Ohinata e  al, 2005; Vincent et al, 2005; 
Okamura et al, 2008).  Bmp4 expression up-regulates fragilis, which was 
hypothesised to be key for PGC specification, as cell expressing fragilis at high 
levels initiate expression the PGC marker Stella and repress somatic genes such as 
Hoxa1, Hoxb1, Lim1 and Evx1 (Saitou et al, 2002).  However, expression of fragilis 
does not confine a cell to the PGC fate pathway (Saitou et al, 2002; Tanaka & 
Matsui, 2002) and deletion of fragilis from embryos does not result in a phenotype 
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(Lange et al, 2008).  Further, four other related genes (fragilis2-5) have been 
identified, of which fragilis2 and 3 are also implicated in PGC specification (Saitou 
et al, 2003).   
Bmp signalling also regulates Blimp1, a post-transcriptional repressor which 
functions in precursor PGCs to suppress somatic gene expression (Ohinata et al, 
2005; Yabuta et al, 2006; Hayashi et al, 2007).  Blimp1 expression commits the fate 
of a cell, and is therefore thought to be the earlist PGC-specific marker (Ohinata et 
al, 2005).  Along with repression of somatic genes, Blimp1 also promotes 
maintenance and/or resumption of pluripotency associated genes, such as Sox2 and 
Nanog (Ohinata et al, 2005; Yamaguchi et al, 2005; Yabuta et al, 2006).  This role 
was confirmed by deletion of Blimp1 in vitro, which resulted in lack of somatic gene 
repression, as well as only 50% of PGC-related gene induction (Saitou et al, 2005).  
Further, systemic deletion of Blimp1 in mouse embryos resulted in a small cohort of 
PGC-like cells which were unable to migrate or proliferate (Ohinata et al, 2005; 
Robertson et al, 2007).  Prdm14, a Blimp1 related factor, has alsorecently been 
deemed essential for PGC specification (Yabuta et al, 2006; Yamaji et al, 2008).  In 
addition to the pluripotency- associated factors up-regulated by Blimp1, Oct4 
expression is maintained in cells destined to become the germline; becoming 
restricted solely to these cells by e7.5 in the mouse (Scholer et al, 1990; Ohmura et 
al, 2004) and is also essential for PGC specification (Okamura et al, 2008).   
1.2.2 Primordial Germ Cell Migration 
Once PGCs have been specified they begin their journey to the genital ridge to form 
the gonad.  This process is well documented in the mouse, with PGC migration 
initiating in the primitive streak at e7.5 (Clark & Eddy, 1975; Anderson et al, 2000), 
after which the PGCs move through the hindgut at e8.0-9.5, and arrive at the genital 
ridge at e10.5-e11.5 (Lawson & Hage, 1994; Molyneaux et al, 2001).  In the human 
migration occurs at 4-5 week gestation (Fujimoto et al., 1977).  Migration is 
controlled by several factors including chemoattracants, guiding the cells, and 
regulators, initiating expression of motility factors within the PGC population.  Early 
studies hypothesised that PGCs responded to a signal or trigger that initiated 
migration (Godin et al, 1990) and change in morphology of the PGCs prior to 
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initiation of migration was noted, with the cells becoming polar with cytoplasmic 
protrusions allowing for motility (Anderson et al, 2000).  It is thought this trigger 
might be expression of Kit ligand (KL/Scf), a somatic cue necessary for PGC 
motility (Runyan et al, 2006; Gu et al, 2009), which functions via a tyrosine kinase 
receptor, c-kit, located on the PGCs themselves to promote migratory competence.  
Absence of KL results in a dramatic decrease of PGC migration (Godin et al, 1991; 
Manova et al, 1990).  Bmp proteins are thought to regulate KL expr ssion, as 
inhibition of Bmp signalling by the antagonist Noggin results in decreased KL 
expression and disruption of migration (Dudley et al, 2007). 
Stromal derived factor 1 (Sdf1/Cxcl12) is a chemoattrac ant expressed by the genital 
ridge, which signals through the chemokine receptor 4 (Cxcr4) expressed by PGCs 
and is thought to guide the PGCs to the gonad (Ara et al, 2003; Molyneaux et al, 
2003b; Stebler et al, 2004).  Targeted disruption of Cxcr4 results in a failure of PGC 
migration (Molyneaux et al, 2003b).  The PGCs also utilise several components of 
the extracellular matrix (ECM) to aid progression of migration toward the gonad 
including collagen III-V, fibronectin, and laminin (Ffrenchconstant et al, 1991; 
GarciaCastro et al, 1997; Anderson et al, 1999; Soto-Suazo et al, 2004), all of which 
PGCs are able to adhere to, suggesting the ECM aids in progression of the cells.  It 
has been suggested the ECM may be involved in concentrating other growth factors 
which directly regulate PGC migration (Bendel-Stenzel et al, 1998). 
Finally, it is further postulated that cell-cell interaction is able to promote migration 
and survival of the PGCs.  Linkage of PGCs to form a network during migration has 
been noted in the fetal mouse (Gomperts t al, 1994; Molyneaux et al, 2001).  This 
hypothesis is supported by the expression of e-cadherin, Pecam1, and β1-integrin by 
PGCs during migration, which are factors necessary for cell-cell adhesion and 
interaction (Bendel-Stenzel t al, 1998; Anderson et al, 1999; Di Carlo & De Felici, 
2000; Wakayama et al, 2003). This may promote not only interaction with adjacent 
PGCs but also the surrounding stromal cells.   
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In addition to promotion of motility and guidance of the PGCs, several factors have 
been implicated in survival of the PGC cohort during migration including nanos 
homolog 3 (Nanos3) and dead end homolog 1 (Dnd1) (Tsuda et al, 2003; Youngren 
et al, 2005; Suzuki et al, 2009). 
 
1.2.3 Proliferation and Colonisation of the Gonad 
PGCs proliferation occurs during migration and continues upon arrival to the gonad, 
such that germ cells number between ~10,000-25,000 at 6 wpf in the human (8 
weeks gestation) (Monk & McLaren, 1981; Byskov, 1986; Lawson & Hage, 1994; 
Bendsen et al, 2006).  This proliferation is regulated by several factors implicated in 
migration including KL (Dolci et al, 1991; Buehr et al, 1993; Pesce t al, 1993a) and 
SDF1, but also by the fibroblast growth factors (FGFs) (Resnick et al, 1992; Kawase 
et al, 2004) and possibly the interleukin-6 (IL6)-type cytokines (Defelici & Dolci, 
1991; Matsui et al, 1991; Pesce t al, 1993a) which will be further discussed later in 
this chapter. 
Upon arrival in the gonad the PGCs lose their ability to migrate (Defelici et al, 1992; 
Gomperts et al, 1994; GarciaCastro et al, 1997)  and their morphology changes to a 
larger, rounded profile (Donovan et al, 1986).  In addition, the PGCs lose expression 
of several pluripotency-associated genes (Chiquoine, 1954b; Tsuda et al, 2003) and 
genome-wide demethylation occurs (Lopes et al, 2008).  However, expression of 
some pluripotency-associated genes is maintained, icluding Oct4 (Scholer et al, 
1990) , but this may be because Oct4 is necessary for later function in germ cell 
development (Kehler et al, 2004).  In contrast, developing germ cells begin to 
express a new set of gene markers including deleted in azoospermia like (Dazl) 
(Selgman and Page) and mouse-vasa homologue (Mvh/VASA) (Toyooka et al, 
2000).  This change in expression of germ cell markers is also observed in human 
fetal ovaries (Anderson et al, 2007), although the change in expression of OCT4 to 
VASA or DAZL occurs later in ovarian development in the human. 
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1.2.4 Sex Determination 
Following germ cell migration, the gonad remains bipotential with little initial 
organisation of the somatic, interstitial or germ cells (Figure 1.2, page 8).  In the 
human the process of sex determination is initiated by expression of the sex-
determining region-Y (SRY) gene positioned on the Y chromosome in male offspring 
at ~6-7 weeks gestation (Gubbay et al, 1990; Sinclair et al, 1990; Tilmann & Capel, 
1999; Tilmann & Capel, 2002).  If an embryo has inherited a Y chromosome from 
the paternal donor, the SRY gene it carries prompts a signalling cascade resulting in a 
male phenotype including testis and secondary sex organs including Wolffian ducts 
and penis.  Proof that the SRY gene is critical for sex determination was provided by 
Koopman et al, who demonstrated that a male phenotype results if the SRY gene is 
expressed in embryonic XX fetuses (Koopman et al, 1991). 
SRY expression in Sertoli precursor cells triggers sex determination, although the 
exact mechanism by which this happens has yet to befully elucidated (Albrecht & 
Eicher, 2001; Wilhelm et al, 2005).  SRY prompts expression of downstream 
transcription factors and cytokines which induce testis formation.  More specifically, 
SRY is likely to promote the up-regulation of a chemoattractant that allows for the 
mesonephroic cells to enter the testis for the formation of seminiferous tubules 
(Capel et al, 1999).     
Some of SRY’s downstream targets have been identifid.  Of known importance are 
the genes SOX9 and steroidogenic factor-1 (SF1) (Ramkissoon & Goodfellow, 
1996).  SOX9 is expressed slightly after SRY in XY gonads (Koopman et al, 2001; 
Kobayashi et al, 2005), and is therefore likely to be downstream of SRY.  It is 
thought the increase in SOX9 expression is via direct regulation of a SOX9 enhancer 
by SRY (Sekido & Lovell-Badge, 2008).  However, XX genotypes expressing an 
additional copy of the SOX9 gene develop testes; expression of SOX9 alone can 
promote a male phenotype without the expression of SRY (Huang et al, 1999).  
SOX9 and SF1 promote masculinisation of the Sertoli and Leydig cells in the testis, 
thereby promoting the expression of Anti-Müllerian hormone (AMH, also known as 
Müllerian inhibiting substance (MIS)) and testosterone, preventing the development 
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of the Müllerian ducts and promoting the formation of seminiferous tubules 
respectively (Shen et al, 1994; Arango et al, 1999). 
Until recently it was considered that the female/ovarian fate pathway was a ‘default’ 
based upon Alfred Jost’s experiments in the late 1940s (Jost, 1947).  He noted that 
regardless of chromosomal sex (XX or XY), castrated fetal rabbits would develop 
female secondary sex organs (Wolffian ducts and external genitalia).  However, the 
idea of a ‘default setting’ is becoming less favoured, with the consensus shifting 
towards the hypothesis that active signalling is necessary for both testis and ovarian 
development  (Yao et al, 2002).   
Starting as early as the 1980s several factors have been identified as opposing forces 
to the male SRY signalling pathway.  This derives from the finding that XY 
individuals expressing two copies of an active gene o  the X chromosome developed 
ovarian structures (Bernstein et al, 1980; Bardoni et al, 1994).  This gene was 
identified as dosage-sensitive sex reversal-congenital adrenal hypoplasia critical 
region on the X chromosome protein-1 (DAX1) and appears to work in an 
antagonistic fashion against the male pathway by limiting SF1 expression (Nachtigal 
et al, 1998; Swain et al, 1998).  Additionally, the wingless-type MMTV integration 
site 4 (Wnt4) gene has been proven to be essential for ovarian development.  Female 
mice homozygous null for Wnt4 fail to form ovaries, and the structures that do form 
express AMH and testosterone production enzymes (Vainio et al, 1999).  Moreover, 
Wnt4-/- mice have demonstrated the protein is able to regulate follistatin expression to 
inhibit the formation of the male coelomic vessel (Yao et al, 2004).   
WNT4 signals via canonical β-catenin signalling, along with another ovarian 
regulating factor, roof plate-specific spondin 1 (RSPO1; (Tevosian & Manuylov, 
2008).  Rspo1-null XX gonads are partially sex reversed (Chassot et al, 2008; 
Tomizuka et al, 2008), as are human female patients with mutations in the RSPO1 
gene (Parma et al, 2006).  Rspo1 may be up-stream or regulate Wnt4, as up-
regulation of Wnt4 during early ovarian development is not seen in Rspo1-null mice 
(Chassot et al, 2008; Tomizuka et al, 2008).  Wnt4 expression is down-regulated 
after the onset of SRY expression in the testes, denoting there is indirect regulation 
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of WNT4 by SRY, further promoting the male pathway (Bernard et al, 2008).  Part 
of this down-regulation is due to the expression of Dickkopf homolog 1 (DKK1)  
(Manuylov et al, 2008), as this factor has been shown to repress Wnt4/Rspo1 β-
catenin signalling (Manuylov et al, 2008) and is up-regulated specifically in the 
testes (Combes et al, 2011).    
Another factor known to be essential for ovarian development is forkhead box L2 
protein (FOXL2), as it is capable of repressing expr ssion of SOX9 and its 
downstream pathway (Ottolenghi et al, 2005; Wilhelm et al, 2009).  Over-expression 
of FOXL2 in XY individuals results in disrupted tesicular formation and mass 
disorganisation (deemed ovo-testes) (Ottolenghi et al, 2007).  FOX factors are also 
able to interact with estrogen receptor genes (ESRs) (Carroll et al, 2005), which are 
actively involved in gonad development in other species (Crisponi et al, 2001; 
Cocquet et al, 2002a; Loffler et al, 2003) and have recently been characterised in the 
human fetal ovary (Fowler et al, 2011). 
With these mediators in mind (summarised in Figure 1.2), it can be stated that 
ovarian development is not a default as suggested previously, but rather both testes 
and ovaries require active signalling for functional gonad development, as well as the 















Figure 1.2 Summary of sex determination 
Summary of major signalling factors involved in sex determination as discussed in the 
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1.3   Fetal Ovarian Development 
As the majority of this thesis focuses on ovarian development, further discussion of 
the literature will be limited to ovarian development and maturation, whereas 
discussion of testis development will be reserved for later chapters.  
1.3.1 Germ Cell Proliferation 
Although there is some argument regarding when the population of germ cells in the 
gonad become oogonia as opposed to PGCs, for this sake of clarity once sex 
determination has occurred (prior to meiosis) the germ cells in the ovary will be 
referred to as oogonia in this literature review.  The difference is both morphological 
and based on activity; PGCs are irregular in shape, making them less distinct from 
interstitial and stromal cells (Gondos et al, 1986) and are smaller in size than oogonia 
(Gosden, 1995; Gougeon, 1996).  Mitotically active PGCs express OCT4, rather than 
the more mature germ cell marker VASA which is exprssed from ~12 weeks 
gestation in the human (Stoop et al, 2005; Anderson et al, 2007).  Oogonia are 
rounded and can also be identified by globular mitochondria associated with mitotic 
division (Gondos et al, 1986).  These oogonia undergo mass proliferation, and by 
late first trimester, the number of germ cells has increased by ten-fold from the 
original cohort of PGCs that migrated to the gonad (11 weeks gestation ~240,000; 
(Bendsen et al, 2006)).  The oogonia undergo incomplete cytokinesis upon mitotic 
division (Gondos & Zamboni, 1969), creating cluster of oogonia termed ‘germ cell 
nests’ or syncytia (de Cuevas et al, 1997; Skinner, 2005) connected by cyotoplasmic 
bridges between cells (de Cuevas et al, 1997; McNatty et al, 2000) which can be 
seen as early as 10 weeks gestation (Gondos et al, 1986) (Figure 1.3).  These 
cytoplasmic bridges allow for the exchange of nutrients between cells and may also 
be involved in synchronous division (Pepling & Spradling, 1998; Epifano & Dean, 
2002).  Outwith the germ cell nests, the gonad alsocontains somatic cell populations 
which remain fairly unorganised until roughly 12 weeks gestation (Byskov, 1986).   
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The two main populations of somatic cells in the fetal ovary include the pre-
granulosa cells and the mesenchymal stromal cells (in addition to the epithelial lining 
of the ovary and endothelial cells lining blood vess l ).  During first trimester, 
somatic cells and germ cells are arranged in an apparently chaotic manner.  However, 
during proliferation of oogonial nests, the pre-granulosa cells integrate with germ 
cells becoming part of the oogonial nests and the mesenchymal stromal cells form 
separate channels or streams amongst the nests (Figure 1.3) (Gondos & Zamboni, 
1969; Wartenberg, 1982). 
1.3.2 Entry into Meiosis 
In late first trimester ~11 weeks gestation, some oogonia progress from mitotic 
division to meiotic division (Baker & Franchi, 1967; Motta et al, 1997), a process 
which is asynchronous in the human, and occurs progressively through second and 
third trimester, with oogonia in the interior of the ovary initiating meiosis while 
oogonia near the epithelium continue to proliferate via mitosis (Skrzypczak et al, 
1981; Anderson et al, 2007).  However, in mice this process is more synchronised, 
with initiation in an anterior-posterior wave occurring between e13.5-15.5 (Menke et 
al, 2003).   
One of the first factors implicated in regulation of meiosis was Dazl, expression of 
which is required for germ cells to become meiotically competent (Lin et al, 2008). 
Human studies have identified DAZL mutations associated with subfertility in 
females (Hertig & Adams, 1967; Lynch & Zhang, 2007) and that another closely 
related gene BOULE may also be involved (Kee et al, 2009).  Dazl up-regulates 
protein levels of factors necessary for meiosis, including Synaptonemal Complex 
Protein 3 (Sycp3) (Reynolds et al, 2007), a component of the synaptonemal complex 
necessary for the first phase of meiosis (Costa & Cooke, 2007), which also functions 
in the repair of double-strand breaks during meiotic recombination (Pittman et al, 
1998; Yoshida et al, 1998). 
Dazl is also thought to be upstream of stimulated by retinoic acid (Stra8), as Dazl -/- 
gonocytes have reduced Stra8 expression (Lin et al, 2008).  Stra8 regulates initiation 
of meiosis I and is required for pre-meiotic DNA replication (Baltus et al, 2006).  
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Stra8 is activated by retinoic acid (RA) secreted from the mesonephros in the mouse 
(Di Carlo et al, 2000; Bowles et al, 2006; Koubova et al, 2006; Anderson et al, 
2008), however recent data indicates STRA8 expression in the human is reliant on 
ovarian RA regulation rather than extrinsic sources (Le Bouffant et al, 2010; Childs 
et al, 2011).  After initiation, prophase I of meiosis progresses through leptotene 
(chromosome condensation); zygotene (chromosomal pairing); pachytene (initiation 
of recombination) and diplotene (chromosomes begin to separate but remain 
attached) before arresting (Baillet, 2011).  Arrival at diplotene stage of meiosis I is 
required for oocyte arrest and the formation of primordial follicles (Hilscher, 1991).  
Proliferation of all ovarian cell types occurs during early second trimester prior to 
meiosis, after which oocytes cannot undergo further mitotic replication leaving 
somatic cells to proliferate further (Fulton et al, 2005).  
1.3.3 Apoptosis and germ cell nest breakdown  
Following nest breakdown all oogonia/oocytes enter one of two fate pathways; they 
either degrade or they continue to mature and associate with stromal cells to form 
primordial follicles (Vaskivuo et al, 2001).  Around the time of meiotic entry, 
oogonia/oocytes also begin to degrade in a process termed atresia (Kaipia & Hsueh, 
1997).  Although the exact timing of this event is uncertain, it is thought to initiate 
between 13-14 weeks gestation (Vaskivuo et al, 2001; Hussein, 2005).  The number 
of germ cells that go through degradation prior to birth is great (~80%) resulting in a 
drastic reduction throughout the remainder of gestation (Baker, 1963; De Pol et al, 
1997).  It is proposed the major mechanism of germ cell degradation is programmed 
cell death, apoptosis (De Pol et al, 1997; Costa & Cooke, 2007).  The peak of 
apoptosis is reported to occur around the initiation of primordial follicle formation 
(Baker, 1963; Fulton et al, 2005) with one to two thirds of oocytes being lost during 
nest breakdown prior to this process (Pepling & Spradling, 2001; Bristol-Gould et al, 
2006).  It is hypothesised this clearing of germ cells acts as a quality control measure, 
eliminating oogonia exhibiting chromosomal or mitoch ndrial defects (Tilly, 2001).  
This is supported by high levels of germ cell apoptosis in fetuses with chromosomal 
abnormalities (Modi et al, 2003; Di Giacomo et al, 2005; Hunt & Hassold, 2008) or 
mitochondrial deficiencies (Perez & Sanville, 2000).   
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During human fetal ovarian development, the majority of the cells detected 
undergoing apoptosis are indeed germ cells (Vaskivuo et al, 2001; Abir et al, 2002; 
Hussein, 2005), with four main factors identified in the regulation of apoptosis; 
BCL-2 associated X protein (BAX) and BCL-2 associated agonist of cell death 
(BAD) as pro-apoptotic factors, and B-cell lymphoma/leukemia-2 (BCL-2) and 
myeloid leukaemia sequence-1 (MCL-1) as anti-apoptotic (Boise et al, 1993; Tilly, 
1996).  BAX and BAD are expressed in somatic and germ cell populations; whereas 
BCL-2 and MCL-1 were exclusively located in the somatic and germline 
respectively (Hartley et al, 2002).  BCL-2 expression is seen as early as 6 weeks 
gestation (Quenby et al, 1999) and is maintained until roughly 18 weeks getation 
(Albamonte et al, 2008), at which time, MCL-1 is highly expressed and may play a 
role in the inhibition of cell death after follicle assembly (Hartley et al, 2002).  These 
factors interact with the pro-apoptotic factors to determine cell fate (Hsu et al, 1997).  
The pro-apoptotic factor BAX is expressed from week 12 of gestation onwards, and 
with expression not restricted like that of BCL-2 (Vaskivuo et al, 2001; Hartley et al, 
2002; Albamonte et al, 2008).  Protein expression of BAX as determined via 
immunohistochemistry was also seen to be more intense a d stable than that of BCL-
2 after initiation of meiosis, which is consistent wi h the onset of apoptosis 
(Albamonte et al, 2008).     
It is thought the pro-apoptotic members BAX and BAD function via dimerization, 
increasing mitochondrial permeability and forming large channels within targeted 
cells, resulting in release of cytochrome c from the mitochonidria and activating 
caspases (Cory & Adams, 2002).  This is supported by the detection of cleaved 
caspase-3 (the active form of this pro-apoptotic caspase) in the human fetal ovary in 
oocytes before primordial follicle assembly, but is absent in oocytes within 
primordial follicles (Fulton et al, 2005).  Observations from mice lacking functional 
Bax also support its role in oocyte apoptosis and nestbreakdown, as these animals 
have three times as many oocytes as their wild-type counterparts (Perez et al, 1999).  
Disruption of caspase-2 also results in increased primordial follicle number 
(Bergeron et al, 1998). 
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It is postulated that the purpose of generating of so many ‘unnecessary’ oocytes is to 
produce additional nutrients and organelles that are then donated to the surviving 
oocytes via autophagy (Baum et al, 2005). This is supported by the finding of 
mitochondria between oogonia within cytoplasmic bridges (Pepling & Spradling, 
2001).  The hypothesis behind this mechanism suggests the oocytes remaining after 
germ cell atresia will have additional cellular resources and are therefore best suited 
to withstand the decades of meiotic arrest.  The autophagy theory is supported by 
evidence that apoptosis, although likely to be the main cause of germ cell death, 
cannot account for the large number of germ cells lost during fetal development 
(Lobascio et al, 2007; De Felici et al, 2008).  Consistent with this theory, various 
mouse models generated with disruption of autophagy genes display marked 
reduction in primordial follicle numbers at birth (Gawriluk et al, 2011).  These data 
not only support the conclusion that germ cell death is necessary for primordial 
follicle formation but also that autophagy is a vital pathway for normal fetal ovarian 
development.   Apart from apoptosis and autophagy, clearing of germ cells has also 
been demonstrated via exfoliation from the ovarian surface epithelium (Motta et al, 
1997).    
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Figure 1.3 Schematic of fetal human ovarian development 
 (1st trimester)  Once germ cells (pink; at this point deemed PGCs) enter the ovary they integrate with mesenchymal stromal cells (blue) and pre-
granulosa interstitial cells (orange) in an unorganised fashion. (Early 2nd trimester)  During a mass mitotic event the germ cells (now deemed 
oogonia) undergo incomplete division to form germ cell nests with pre-granulosa cells intertwined, after which entering meiosis (now deemed 
oocytes). (Late 2nd trimester)  Oocytes grow in diameter as they mature and begin to break away from germ cell nests (as a majority of the 
oocytes degrade) and associate with pre-granulosal cells to form primordial follicles.
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1.3.4 Primordial Follicle Assembly 
The breakdown of germ cell nests allows the surviving oocytes (~20%) to closely 
associate with intermixed pre-granulosal cells (Pepling & Spradling, 2001) (Figure 
1.3). During nest breakdown the cytoplasmic bridges ar  either retracted or degraded 
via protease action of the pre-granulosa cells (Tingen et al, 2009), which form a 
protective layer around the remaining oocytes.  Oocytes that do not associate with 
pre-granulosa cells to form primordial follicles are lost (Byskov, 1986; McLaren, 
1991; Coucouvanis et al, 1993; De Pol et al, 1997; Pepling & Spradling, 2001).  The 
maturing oocyte with somatic cell association is called a primordial follicle, and 
although initiation of follicle assembly in the human is reported at different stages in 
second trimester (Abir et al, 2002; Sforza et al, 2003), our laboratory reports the 
onset of primordial follicle formation to occur around 18 weeks gestation (Fulton et 
al, 2005).  The primordial follicle complex is then eclosed in an individual 
basement membrane (Rajah et al, 1992) separating it from the mesenchymal stromal 
cell environment (Figure 1.3). 
In the mouse fetal ovary, breakdown of germ cell nests allowing for primordial 
follicle formation is governed by estrogenic signalli g (Iguchi et al, 1986).  During 
gestation the fetal oocytes are exposed to maternal strogen which keeps oocytes 
within germ cell nests (Kezele & Skinner, 2003; Chen et al, 2009), at parturition this 
signalling is removed signalling for the nests to breakdown which allows for 
primordial follicle formation via the integration of pre-granulosa cells into germ cell 
nests allowing for association with oocytes.  Exposure to estrogenic signalling 
postnatally results in multiple oocyte follicles or MOFs (Jefferson et al, 2002), which 
are created by the disruption of nest breakdown; whereas premature removal from 
estrogenic signalling results in premature nest breakdown (Chen et al, 2007b).  
However, in the human, although estrogen receptors are present (Fowler et al, 2011) 
primordial follicle formation occurs during mid-gestation, and thus removal of 
maternal estrogen is not possible as a signalling cue for germ cell nest breakdown 
highlighting another species-specific difference during ovarian development.   
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However, the non-human primate, like the human, initiates primordial follicle 
formation during mid-gestation, and thus has served as a good model for identifying 
possible estrogenic roles in fetal follicle formation.  A recent baboon model of 
estrogen deprivation during in utero development, resulted in a significant reduction 
in primordial follicle number, suggesting estrogen does play a role during fetal 
ovarian development (Zachos et al, 2002).  Further studies demonstrated estrogen 
regulates several factors important for primordial follicle formation, including the 
ratio of Activin : Inhibin expression, development of oocyte microvilli, and 
expression of the transferrin receptor (Billiar et al, 2003; Billiar et al, 2004; Zachos 
et al, 2004; Zachos et al, 2008).  Further, estrogen is able to directly regulate baboon 
oocytes via estrogen receptor β (ERβ), but estrogen receptor α (ERα) is not expressed 
(Bocca et al, 2008).    
Arrested oocytes within primordial follicles remain quiescent until recruitment for 
growth and ultimately ovulation later in life, and are reliant on stromal support to 
maintain the follicle throughout the female’s reproductive lifespan, which in the 
human lasts some 3 decades (Pincus & Enzmann, 1935;Borum, 1961; Maheshwari 
& Fowler, 2008). 
 
1.4 Alternate sources of follicles during adulthood ? 
It is widely accepted that the number of follicles a female produces during fetal life 
will determine the number of follicles that she will have for ovulation during 
adulthood (Morita & Tilly, 1999a).  There are however, reports purporting the 
existence of female germ-line stem cells in the adult ovary (Johnson et al, 2004), 
from which primordial follicles could potentially be derived postnatally.  In these 
reports, it is postulated that ovarian germline stem c lls could be located in the 
surface epithelium of the ovary or in bone marrow (Johnson et al, 2004; Johnson et 
al, 2005).   Subsequent studies from other groups have demonstrated bone marrow is 
not involved in the formation of functional oocytes (Eggan et al, 2006), but factors 
from the bone marrow may regulate the growth of newoocytes especially following 
ovarian damage (Lee et al, 2007).   
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More recently, cells purported to be germline stem cells have been isolated from the 
ovarian epithelium of adult and prepubertal mice via immune-magnetic isolation of 
MVH/VASA positive cells (Zou et al, 2009).  The isolated cells were cultured for ~6 
months, allowing for all non-proliferating (meiotic) ells to perish leaving only MVH 
positive mitotic cells; the cells were then infected with a GFP virus and transplanted 
into the ovaries of sterilised recipient female mice. Upon further analysis, recipients 
had GFP positive oocytes within follicles at all stages and bore offspring, 28% of 
which were GFP positive (Zou et al, 2009). 
Although, this research is exciting, as it suggests a pool of oogonia which could 
maintain fertility outwith the finite cohort of primordial follicles formed at birth, it 
seems unlikely this is the full story, as several animal models (as referenced in 
(Skinner, 2005) and women (Telfer t al, 2005) fail to demonstrate any 
replenishment of this cohort of follicles.  Indeed, initial studies reported isolated 
ovarian stem cells to be few per ovary (Johnson et al, 2004; Tilly et al, 2009).  
Additionally, it is unclear how these studies in rodent models equate to human 
physiology.   Therefore, the relevance of ovarian stem cells remain to be further 
elucidated.  Additionally the existence of functional stromal cells including granulosa 
stem cells in vivo would need to be considered, as follicle formation would require 
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1.5 Repercussions of fetal follicle formation   
Consistent with the currently accepted theory that primordial follicles determine the 
cohort of oocytes ovulated in adulthood, failure to form sufficient primordial follicles 
during fetal life results in premature ovarian insufficiency (POI) or infertility 
(Mattison et al, 1983; Byskov, 1986; Byskov et al, 2005).  Although the field is 
progressing, POI remains relatively common, occurring in 1% of women (Coulam, 
1986; Goswami, 2005).  Primordial follicle regulation and preservation are also of 
interest in current cancer therapies, as intensive courses of either radio- or 
chemotherapy can result in the loss of primordial follicles leading to infertility 
(Sonmezer & Oktay, 2004).  Understanding the process of primordial follicle 
formation and ovarian development during fetal life could provide insight into what 
factors influence the cell fate decisions of apoptosis vs. survival, which in turn could 
be manipulated for clinical use.   
 
1.6 Known Regulation of Fetal Germ Cell Development  
Various factors have been identified as important for germ cell development leading 
to primordial follicle formation.  The following section will briefly discuss both 
secreted factors that effect ovarian cells via classical ligand-receptor signalling 
deemed growth factors, as well as transcription factors, which regulate ovarian 
development via modulation of transcription of other g nes.  These two groups of 
regulators work in concert to coordinate early ovarian development leading to 
primordial follicle formation.    
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1.7 Growth factors 
Growth factors are signalling molecules which function via receptor binding to 
activate intracellular signalling cascades in order to regulate critical cellular 
functions including; proliferation, differentiation, cell survival and apoptosis (Bianco 
et al, 2006).  Several growth factors have been established as regulators of fetal 
ovarian development and will be described in the following section (Figure 1.4). 
1.7.1 Kit ligand (KL) 
As previously discussed, KL via its receptor c-kit, regulates PGCs migration and 
survival during gonad formation as demonstrated in the mouse (Godin et al, 1991; 
Pesce et al, 1993a).  PGCs express c-kit before they leave the hindgut (Runyan et al, 
2006; Gu et al, 2009), and allows for direct KL regulation after germ cell 
specification.    It is thought KL functions as a chemoattractant during this process, 
guiding PGCs to the gonads (Farini et al, 2007).  This role was confirmed in the 
homozygous null murine models for either KL or c-kit, which result in disrupted 
migration and complete loss of the PGC cohort ((Mintz & Russell, 1957; McCoshen 
& McCallion, 1975) as discussed in (Edson et al, 2009)).      
Although early data regarding KL’s role in regulation of migration is not available in 
the human fetal ovary, it is known after gonad formation KL is expressed by 
mesenchymal stromal cells and the pre-granulosa cells closely associated with 
oogonia (Hoyer et al, 2005).  It is hypothesised KL acts to prevent precocious entry 
into meiosis at this point in ovarian development (Coutts et al, 2008; Childs & 
Anderson, 2009), allowing for continued proliferation via mitosis, which is 
consistent with the down-regulation of c-Kit expression around the initiation of 
meiosis entry.  Expression of c-Kit is resumed around initiation of follicle formation, 
and thus it is further thought to maintain meiotic arrest until follicle activation 
(Vainio et al, 1999; Jaaskelainen et al, 2010).  In vitro study of rodent oocytes 
demonstrated that KL is able to up-regulate PI3/AKT, which functions to supress 
Foxo transcription factors (such as Foxo3a which will be discussed in a subsequent 
section) (Reddy et al, 2005).  Foxo3A is known to regulate follicle activation, and 
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thus KL’s regulation of this factor may orchestrate follicle development as well as 
maintenance of follicle arrest (Castrillon et al, 2003). 
Expression of c-Kit is down-regulated upon germ cell n st formation but is up-
regulated in oocytes after meiotic division (Robinso  et al, 2001; Stoop et al, 2005).  
This expression pattern is consistent with the hypothesis that KL signalling is 
important for regulation of oocytes later in ovarian development.  In order to study 
KL effects, without perturbing initial migration and survival of PGCs, an anti-murine 
c-kit antibody, ACK2, was injected to female mice at different points during 
gametogenesis to inhibit c-kit function and to elucidate possible KL functions in later 
gestation (Yoshida et al, 1997) .  This study determined blockade of KL/c-kit 
interaction at birth (initiation of primordial follicle formation) did not result in a 
disruption of primordial follicle formation, rather it affected granulosa cell 
proliferation, thereby affecting further follicular development.  However, conflicting 
data gathered from in vitro culture of fetal murine ovaries demonstrates KL treatment 
is able to accelerate primordial follicle formation (Wang & Roy, 2004).  Thus KL’s 
role in fetal ovarian development post-migration remains unclear.   
The human fetal ovary expresses c-Kit in a similar fashion to that established in the 
mouse, with localisation restricted to mitotic oogonia, diminished in germ cell nests 
undergoing meiosis, and renewed expression in oocytes within primordial follicles 
(Robinson et al, 2001; Stoop et al, 2005).    Recent evidence demonstrates KL is 
inhibited by Activin A in the human fetal ovary, whic  may prevent precocious 
primordial follicle formation (Figure 1.5), further suggesting a role for KL in later 
gestation and demonstrating processes in the fetal ovary are highly regulated by 
interaction of several growth factors (Childs & Anderson, 2009). 
. 
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Figure 1.4 Growth factors important for germ cell maturation and primordial follicle formation 
Several growth factors are identified in regulation of early human ovarian development leading up to primordial follicle formation and beyond, 
including KL/c-Kit, WNT4, Stra8, Activin, Inhibin, Follistatin, BMP2, 4, 7, 8 and 15, GDF9, BDNF, and bFGF.  Expression patterns of each are 
demonstrated above via a continued line through the gestational period.  Repression/down-regulation is depicted as a dashed line.  Figure 
adapted from (Jagarlamudi & Rajkovic, 2011). 
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1.7.2 Wnt4 
Wnt4 action is essential for sex determination, but it has also been demonstrated to 
regulate other processes in the fetal ovary.  Wnt4 expression in the fetal female 
mouse is restricted to pre-granulosa cells of the developing ovary and is also 
expressed in the mesonephros (Vainio et al, 1999; Jaaskelainen et al, 2010).  Wnt4’s 
role in reproductive development was investigated in female mice homozygous null 
for the Wnt4 allele, which were found to be partially sex reversed with male-like 
steroidogeneic cells (Vainio et al, 1999; Heikkila et al, 2005).  In addition Wnt4-/- 
ovaries also had a distinct coelomic vessel, similar to that seen in the testis (Jeays-
Ward et al, 2003) with associated Wolffian rather than Müllerian ducts (Vainio et al, 
1999).  Thus Wnt4 represses the male pathway, later demonstrated to be via 
downstream β-catenin and follistatin signalling (Yao et al, 2004). 
However, in addition to the clearly defined role in sex determination, Wnt4-/- ovaries 
also had marked reduction in oocyte number after e14.5 (post-migration, 
proliferation, and meiosis), which was not seen in Wnt4-/- males (Heikkila et al, 
2005), demonstrating Wnt4 plays a role in oocyte-specific survival and development.  
Further investigation demonstrated a rapid depletion of ~90% of oocytes around e16 
(Yao et al, 2004) and that remaining follicle structures displayed disrupted 
morphology (Vainio et al, 1999).  Further, Wnt4 expression is notably heightened in 
fetal ovaries around initiation of primordial follic e formation, a timepoint which is 
also associated with a decline in apoptosis (Vaskivuo et al, 2001), suggesting a role 
in the regulation of oocyte survival.  However, investigation of this hypothesis 
demonstrated no change in expression of apoptotic factors in Wnt4-/-  ovaries, 
suggesting regulation of  oocyte survival via Wnt4 is may be downstream of another 
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In the human fetal ovary, WNT4 is expressed by the pre-granulosa cells, but is also 
expressed by oocytes, with increased expression duri g initiation of primordial 
follicle formation (Jaaskelainen et al, 2010).  Despite this difference in localisation, 
loss of function mutation of WNT4 in humans mimics the sex reversal seen in the 
Wnt4-/-  mouse model, with excess androgens noted as well as masculinisation of 
reproductive organs (Biason-Lauber et al, 2004); demonstrating Wnt4’s role in 
gonad development is likely conserved between species. 
1.7.3 Retinoic Acid 
Retinoic acid (RA) is an active derivative of vitamin A , and functions via the 
nuclear hormone receptors RAR-α, β, -γ, and RXR-α, -β, -γ (Bowles et al, 2006; 
Koubova et al, 2006), which are localised primarily to the germ cells of both male 
and female gonads in the mouse and human (Morita & Tilly, 1999b; Le Bouffant et 
al, 2010; Childs et al, 2011).  RA is able to promote the onset of meiosis during fetal 
ovarian development (Bowles et al, 2006; Koubova et al, 2006), and functions by 
up-regulating STRA8, which is required for DNA replication prior to initiation of 
meiosis (Baltus et al, 2006; Anderson et al, 2008).  STRA8 expression increases in 
both the human and mouse ovary with the onset of meiosis (Menke et al, 2003; 
Houmard et al, 2009; Le Bouffant et al, 2010).   
Although RA is produced by both sexes, data from mice fetal testes homozygous null 
for a retinoid degrading enzyme Cyp26b1, demonstrated this factor is up-regulated in 
the testis compared to the ovary and is able to metabolise RA (Bowles et al, 2006).  
Based upon this data it was hypothesised that Cyp26b1 functions to shield male germ 
cells from RA, thus preventing Stra8 expression in the testes and the initiation of 
meiosis.  In vitro culture of e11.5 murine fetal testes treated with RA seemed to 
support this, with induced Stra8 expression and initiation of meiosis (Trautmann et 
al, 2008).   However, a recent murine model homozygous null for the RA synthesis 
enzyme Raldh2, which renders the animal unable to synthesise or signal via RA 
demonstrates these suggested roles may be poorly understood (Kumar et al, 2011).  
Raldh2-/- ovaries express Stra8 and undergo meiosis, and inhibition of Cyp26b1 in 
Raldh2-/- testes initiates meiosis, all of which occur independently of RA interaction 
(Kumar et al, 2011).  These data suggest that although Stra8 is important for 
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regulation of meiosis, RA may be unnecessary for its production.  In addition the 
degrading enzyme Cyp26b1 is needed for prevention of meiosis in the testis, but is 
likely to degrade an RA–like substance rather than RA itself.  
Investigation in the human fetal gonad determined RA alone is not able to promote 
meiosis in fetal testes, again suggesting RA either functions in concert with other 
factors to initiate meiosis or that it is not involed in this process (Childs et al, 2011).  
However, it is likely meiosis is differentially regulated in the human compared to the 
mouse, as initiation of meiosis is asynchronous in the human and may require more 
specific regulation (Childs et al, 2011).  This hypothesis is supported by the 
heightened expression of CYP26B1 in the human fetal ovary compared to the fetal 
testis (Le Bouffant et al, 2010; Childs et al, 2011), suggesting this factor may play a 
different role in the human or may be involved in inhibiting meiosis entry in some 
cells during ovarian development.    
While the roles of RA, Stra8, and Cyp26b1 in meiosis remain to be fully understood, 
data suggest RA may regulate other functions in the fetal gonad, namely proliferation 
(Morita & Tilly, 1999b).     
 
1.7.4 TGF-β signalling 
The members of the TGFβ superfamily have been verified as ovarian regulators in 
various species.  More specifically, the actions of Activin, Inhibin, and the BMPs are 
essential for fetal ovarian development (Aaltonen et al, 1999; Galloway et al, 2002; 
Nilsson & Skinner, 2003; Ross et al, 2007b).  These cytokines function via 
serine/threonine kinase receptors to induce intracellular signalling via the SMAD 
family of proteins (Attisano & Wrana, 1996; Kawabata et al, 1999) (Figure 1.5).   
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Figure 1.5 Schematic of TGF-β signalling 
TGF-β superfamily members signal via Ser/Thr kinase receptors, with Activin and Inhibin 
utilising TGFβR2 and ALK5 and the BMPs utilising BMPR2 and ALK-1, -2, 3-, and -6.  
Activated receptors then induce phosphorylation of receptor regulated SMADs, with 
Activin/Inhibin inducing SMADs 2/3 and BMPs inducing SMADs 1/5/8.  Activated receptor 
SMADs then form heteromeric complexes with the co-transporter SMAD (4) and 
translocate to the nucleus to regulate gene expression.  Phosphorylation of receptor 
SMADs can be inhibited by inhibitory SMADs (6 and 7), allowing for cell specific 
regulation of TGF-β signalling.  Figure from (ten Dijke & Arther, 2007). 
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Activin and Inhibin 
The Activin/Inhibin family of growth factors are made up of homo- or hetero-
dimeric complexes of α and β subunits (Norton et al, 1998; Muttukrishna et al, 
2004), with two isoforms of the β subunit; βA and βB (Trombly et al, 2009b).  
Inhibin is formed by the disulphide-linkage of an α subunit and either β subunit, 
creating Inhibin A or Inhibin B respectively.  Alternatively, Activin formation does 
not require an α subunit, rather is the homo- or hetero-dimerisation of two β subunits, 
creating Activin A, Activin B, or Activin AB (Trombly et al, 2009b).  Inhibin is able 
to antagonise Activin function via competitive bindi g of the Activin receptors 
(Lewis et al, 2000), and utilisation of β subunits (McMullen et al, 2001).  The two 
components bind Activin receptors which in turn modulate gene expression via 
Smad2/3 activation and the MAPK pathway (Massague, 1998; Mulder, 2000).  
However, murine models, created to further elucidate Activin/Inhibin function have 
been largely inconclusive due to embryonic lethality and overlapping functions of the 
TGFβ family; therefore research in human primary tissue has been vital for 
determination of Activin/Inhibin function during fetal ovarian development (Matzuk 
et al, 1995; Burns & Matzuk, 2002). 
The Activin/Inhibin subunits are expressed by the germ and somatic cell 
compartments of the human fetal ovary (Rabinovici et al, 1991; Harkness & Baird, 
1997; Martins da Silva et al, 2004).  However, the βA subunit is localised solely in 
the germ cells with increasing expression in larger germ cell (diameter is indicative 
of oocyte maturation) but expression ceases once ooytes form primordial follicles 
(Martins da Silva et al, 2004).  The βB subunit is localised in both germ and stromal 
cells (Martins da Silva et al, 2004) and is expressed in relatively low levels compared 
to the βA subunit (Rabinovici et al, 1991).  In contrast, transcript and protein for the
α subunit was not detected in the human fetal ovary, determining Activin A and B to 
be the active Inhibin/Activin regulators during human fetal ovarian development 
(Martins da Silva et al, 2004).  However, other studies have demonstrated Inhibin 
expression in granulosa cells later in follicular development coincident with the 
reduction in Activin expression (Davis et al, 1987).  Several of the Activin receptors 
(ActRIIA, ActRIIB, ALK2, and ALK4) have been localised in the human fetal 
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ovary, with expression determined in both germ and somatic cells (Coutts et al, 
2008), demonstrating Activin is able to act in both an autocrine and paracrine 
fashion. 
In support of a role for Activin A in fetal ovarian regulation are data demonstrating 
regulation of germ cell survival and proliferation in human ovarian culture via 
downstream SMAD 2/3 signalling (Martins da Silva et al, 2004).  It is possible that 
Activin A regulates proliferation and survival via the anti-apoptotic factor MCL-1, as 
the two factors display similar localisation in the uman fetal ovary, but this 
mechanism has yet to be confirmed (Martins da Silva et al, 2004).  In addition, 
Activin A is able to regulate brain-derived neurotrophic factor (BDNF) action, in 
order to promote germ cell survival via downstream paracrine signalling from pre-
granulosa cells (Childs et al, 2010a). 
Further studies utilising injection of Activin A into neonatal mice resulted in a 30% 
increase in primordial follicle number (Bristol-Gould et al, 2006), suggesting a role 
in initiation of follicle formation as well as proliferation/survival.  Although 
functional studies regarding Activin A’s role in follicle formation have yet to be 
performed in the human fetal ovary, a possible mechanism has been demonstrated, as 
Activin A is able to inhibit membrane bound KL expression (Coutts et al, 2008; 
Childs & Anderson, 2009).  From this data it is hypothesised that Activin A is able to 
limit cross-talk between somatic and germ cells by inhibiting KL, thus inhibiting 
precocious nest breakdown and follicle formation (Figure 1.6) (Childs & Anderson, 













Figure 1.6 Schematic of proposed mechanism of Activin A 
Activin A (ActA) is thought to regulate initiation of primordial follicle formation via 
repression of membrane bound Kit ligand (MB-KL), while allowing signalling via soluble 
Kit ligand (S-KL).  As ActA expression decreases with nest breakdown, this allows for 
signaling via MB-KL increasing c-KIT downstream signalling and promoting initiation of 
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Follistatin 
Although not a TGFβ superfamily member itself, Follistatin mediates some of its 
ovarian function via interaction with Activin (Hillier & Miro, 1993; Muttukrishna et 
al, 2004).  Follistatin is expressed by somatic cells in in the murine fetal ov ry 
initiating at e11.5 and peaking at e12.5 concomitant with sex determination (Yao et
al, 2004).  Although unrelated to Activin, Follistatin has affinity for and binds 
Activin repressing its biological effects (Nakamura et al, 1990; Schneyer et al, 
1994).  The bound complex is then targeted by cell surface proteoglycans for 
endocytosis and is degraded (Hashimoto et al, 1997).  This antagonistic mechanism 
is noted in vivo in several species with Activin expression decreased with increase of 
Follistatin expression (Schneyer t al, 2000; Knight & Glister, 2001), and was 
confirmed ex vivo in the human fetal ovary, with up-regulation of SMAD2/3 
signalling with Activin A treatment and down-regulation of this pathway with 
Follistatin treatment (Coutts et al, 2008).  Further, three isoforms of Follistatin exist 
in vivo with differing levels of affinity for proteoglycan degradation (Inouye t al, 
1992; Sugino, 1993).  Specific deletion of the Follistatin isoform with highest 
affinity for intracellular degradation in a murine model leads to both reduced litter 
size and frequency, denoting Follistatin mediated Activin degradation may be 
important for ovarian biology (Kimura et al, 2010).   
Follistatin has also been implicated in interaction with another subset of the TGFβ 
superfamily, the BMPs.  Although, few data are available regarding this interaction 
in the fetal ovary, data from various species and tissues suggests Follistatin is able to 
inhibit the action of BMP2, 4, 7, and 15 (Fainsod et al, 1997; Otsuka et al, 2001; 
Glister et al, 2004).  However, this mechanism remains to be demonstrated in the 
fetal ovary.  
BMPs  
The BMPs  are also TGFβ superfamily factors, of which, BMP2, 4, 7, 8, 15 and 
growth differentiation factor 9 (GDF9) are of particular interest during fetal ovarian 
development.  Unlike Activin/Inhibin signalling, BMP factors utilise SMADs 1/5/8 
for intracellular signalling rather than SMAD 2/3 (Lin et al, 2003).   
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BMP2 
Bmp2 expression is restricted to the somatic cells of the fetal ovary post-sex 
determination in the mouse, which is consistent with the hypothesis it is driven by 
Wnt4 signalling (Yao et al, 2004).  Bmp2 is up-regulated around the time of germ 
cell nest formation and initiation of meiosis (Kashimada et al, 2011), with in vitro 
study of Bmp2 and Foxl2 in an ovarian cell line suggesting these factors may work in 
cooperation to suppress Follistatin (Kashimada et al, 2011).      
However, it appears BMP2 may play a different role in the human fetal ovary.  
Although function and localisation of BMP2 in the human has yet to be investigated, 
it is known to signal solely to the germ cells in the human fetal ovary and is 
developmentally up-regulated prior to primordial fol icle formation (Childs et al, 
2010b) rather than during nest formation and meiosis.  It is likely that species-




Bmp4 is important for PGC specification and migration.  Further studies have 
identified that inhibition of Bmp4 in neonatal ovarian culture led to progressive loss
of PGCs and that mice homozygous null for Bmp4 have no germ cells  (Lawson et al, 
1999; Fujiwara et al, 2001; Nilsson & Skinner, 2003), it was hypothesisd Bmp4 
might also be important for early germ cell survival post-migration (Dudley et al, 
2007).  However, this role was not supported by further work in the mouse (Ross et 
al, 2003) or in the human, where culture of fetal ovary in the presence of BMP4 
promoted germ cell apoptosis (Childs et al, 2010b).  Bmp4 regulation of apoptosis is 
also evident in development of other organs (Graham et al, 1994; Trousse t al, 
2001).  Therefore, it is likely BMP4 regulates germ cell loss in fetal ovarian 
development rather than survival. 
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In addition, BMP4 may play a role in inhibition of differentiation, in later ovarian 
biology, via regulation of the inhibitor of differentiation (ID) genes, which are 
known to regulate apoptosis, proliferation, and differentiation in other tissues 
(Miyazono & Miyazawa, 2002).  Although few published data are available 
regarding the BMP4/ID pathway in the fetal ovary, some reports suggest this 
pathway may mediate adult ovarian function and that t e Ids are localised to the 
granulosa cell compliment (Haugen & Johnson, 2010; Hogg et al, 2010) . 
BMP7 
Bmp7 is expressed in the fetal ovary from e10.5 in the mouse, with homozygous 
mutation resulting in a reduction in PGC number in both sexes (Ross et al, 2007b).  
Additionally Bmp7 appears to be involved in the primordial to primary follicle 
transition in the rodent (Lee et al, 2001; Lee et al, 2004).  However, BMP7’s role in 
human fetal development has not been investigated, nd levels of BMP7 transcript 
are relatively low compared to both BMP2 and 4, suggesting it may not be important 
for ovarian development in the human (Childs et al, 2010b).   
BMP8 
As previously discussed, Bmp8b is involved in PGC specification in both sexes, with 
homozygous deletion resulting in a reduced PGC compliment (Zhao et al, 1996; 
Ying et al, 2000).   However, there are few data clarifying ay post-migratory role 
for BMP8 during fetal ovarian development. 
BMP15 and GDF9 
Bmp15 and Gdf9 are postulated to regulate the ovary in collaboration and display 
similar structure and expression patterns in the fetal ovary (McNatty et al, 2005; 
Edson et al, 2009).  However, it is uncertain if their effects are important during fetal 
development, as expression of both factors is thougt to be restricted to oocytes in 
primary and growing oocytes, with function identified in later stage follicles in 
cumulus expansion (Dong et al, 1996; Aaltonen et al, 1999; Nilsson & Skinner, 
2002; McNatty et al, 2005).   
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However, both GDF9 and BMP15 expression is detected as early as 16 weeks 
gestation in the human fetal ovary (Sun et al, 2010), suggesting there may be a role 
for these factors earlier in development.  In addition, there have been several reports 
of mutations in either GDF9 or BMP15 in women with POI (Dixit et al, 2005; Dixit 
et al, 2006).  There is also evidence that Gdf9 may interact with other growth factors 
involved in fetal ovarian development, including Kitl (Joyce et al, 2000; Wang & 
Roy, 2004).  Therefore further evaluation of BMP15 and GDF9 during fetal ovarian 
development is needed. 
Noggin 
Noggin, like Follistatin, is not a member of the TGFβ superfamily, rather it functions 
via repression of Bmp signalling (Zimmerman et al, 1996; Groppe et al, 2002).  
Although Noggin is not well characterised in vivo in either the fetal mouse or human 
ovary; recent in vitro studies utilising granulosa cell culture have demonstrated 
Noggin is able to suppress Bmp2 and 4 signalling (Pierre et al, 2005; Haugen & 
Johnson, 2010).  Consistent with this hypothesis, mutations in NOG (gene encoding 
Noggin) have been reported in women with POI, suggesting Noggin may affect the 
primordial follicle pool (Kosaki et al, 2004). 
 
1.7.5 Neurotrophins: BDNF and NT4 
The neurotrophins are a family of growth factors know  to regulate human ovarian 
development, doing so via their tropomyosin-related kinase (Trk) receptors and the 
common p75 receptor (Bibel & Barde, 2000).  The neurotrophins were initially 
characterised in the nervous system, where they mediate survival, proliferation and 
differentiation (Davies, 2000; Bernd, 2008).   Consistent with this role, several of the 
neurotrophin signalling components are expressed in the human ovary, and are 
developmentally regulated during fetal development (A derson et al, 2002b; Childs 
et al, 2010a). 
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One of the neurotrophin receptors, TrkB, hasincreased transcript expression 
concomitant with primordial follicle formation in mouse (Spears et al, 2003), and is 
localised exclusively to the germ cells of the fetal ovary in both the mouse and the 
human (Dissen et al, 1995; Anderson et al, 2002b; Spears et al, 2003; Paredes et al, 
2004).  Targeted homozygous disruption of Ntrk2, which encodes the TrkB receptor 
results in reduced germ cell survival and primordial follicle number (Spears et al, 
2003; Kerr et al, 2009), as well as arrest of follicles later in development during the 
primary to secondary transition (Paredes et al, 2004).   These results led researchers 
to investigate further the two main ligands which utilise TrkB for signal transduction, 
in order to elucidate the ligand that might be regulating these ovarian functions; brain 
derived neurotrophic factor (BDNF) and nerotrophin-4 (NT4).  
In the rodent ovary, both Bdnf and Ntf5 (which encodes Nt4), are expressed across 
early gestation, with increased Ntf5 expression compared to Bdnf, as well as an 
increase in Ntf5 expression around the time of primordial follicle formation (Dissen 
et al, 1995; Childs et al, 2010a).  Increased expression of Ntf5 suggests this is the 
dominant neurotrophin ligand in the mouse fetal ovary;  hypothesis which is 
supported by unsuccessful attempts to localise Bdnf in the fetal mouse ovary, 
suggesting, as with transcript level, Bdnf expression is low (Childs et al, 2010a).  
However, homozygous NT4-deficiency does not result in reduced fertility suggesting 
it may not be a key regulator of follicle formation (Conover et al, 1995). 
In the human, BDNF and NFT4 (which encodes NT4) are expressed across gestation 
in the fetal ovary, with increasing BDNF leading to primordial follicle formation 
(similar to the pattern reported for rodent Ntf5 expression) (Dissen et al, 1995; Childs 
et al, 2010a).  BDNF is localised to the somatic cells of human fetal ovary from 9 
weeks gestation onwards, and is more strongly expressed by pre-granulosa cells 
associating with larger oocytes, with a similar expr ssion pattern noted for NT4 
(Anderson et al, 2002b; Childs et al, 2010a).  As TrkB receptors are expressed by the 
germ cells this suggests neurotrophin ligands regulate the oocyte by a paracrine 
mechanism.     
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As discussed earlier, Activin A is able to regulate BDNF expression in the human 
fetal ovary, but does not change the expression of NFT4; conversely, in the mouse 
fetal ovary Activin A up-regulates Nt5 and does not affect Bdnf  (Childs et al, 
2010a).  Based upon these results and differing transcript expression patterns, it is 
hypothesised the two neurotrophin ligands BDNF and NT4 may have reversed roles 
in the rodent and human (Childs et al, 2010a).  Despite this difference, it appears the 
role for neurotrophin signalling in regulation of germ cell survival in the mouse 
(Spears et al, 2003; Kerr et al, 2009) may also be relevant in the human, as a recent 
study in the human fetal ovary suggests NT4 increases the number of primordial 
follicles (Farhi et al, 2011).  However, this study did not assess the number of naked 
oocytes in addition to assembled primordial follicles, and therefore it is not possible 
to elucidate the exact effect of NT4, as increased primordial follicle number could be 
the result of several mechanisms (such as precocious activation, proliferation and/or 
survival of oocytes).  Therefore, further investigaon is necessary to truly understand 
the roles of the neurotrophins in the human fetal ov ry; although the mechanism is 
likely to be similar to that seen in the mouse, as Activin A, which up-regulates BDNF 
also increases proliferation and survival in the human fetal ovary (Martins da Silva et 
al, 2004). 
As functional roles of NT4 and BDNF have yet to explain the phenotype of TrkB-/- 
mice, two other neurotrophins have been examined for their possible reproductive 
roles: neurotrophin-3 (NT3) and nerve growth factor (NGF), which are expressed 
along with their receptors in the human fetal ovary (Anderson et al, 2002b).  
However, data from the mouse determined these factors are not likely to be the 
ligands signalling via TrkB to regulate fetal ovarian development, as Nt3 regulates 
primordial to primary transition (Nilsson et al, 2009) and that Ngf plays a role in 
theca cell differentiation (Dissen et al, 1995; Dissen et al, 2001), with no effects 
noted in primordial follicles.  However, as data from BDNF and NT4 suggests there 
may be differential regulation of the neurotrophins i  the human compared to the 
rodent, it would be interesting to see if these factors play roles in human fetal ovarian 
development. 
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1.7.6 Basic fibroblast growth factor (bFGF) 
Basic FGF is of the fibroblast growth factor (FGF) family of growth factors, and is 
well characterised as a mitogenic factor in the mature ovary, where it is localised to 
the epithelial and granulosa cells (Gospodarowicz et al, 1989; Koos & Olson, 1989; 
Nilsson et al, 2001; Ben-Haroush et al, 2005).  The function of bFGF during fetal 
ovarian development has been hypothesised based upon in vitro culture of rodent 
fetal ovaries, which indicate bFGF is able to promote primordial to primary follicle 
transition (Nilsson et al, 2001). Further in vitro data suggests bFGF is able to do this 
via up-regulation of KL (Nilsson & Skinner, 2004). 
The function of bFGF remains to be elucidated in the human fetal ovary.  However, 
localisation of bFGF in the human fetal ovary is ret icted to oocytes (Koike & 
Noumura, 1994; Ben-Haroush et al, 2005) and transcript expression has been 
reported across early gestation along with bFGF receptors (Yeh & Osathanondh, 
1993; Ben-Haroush et al, 2005).  The expression of bFGF in primordial follicles is 
down-regulated upon activation and transition to the primary stage (Quennell et al, 
2004), suggesting function before this stage.  However, it was determined as bFGF 
expression declines in oocytes, it is up-regulated in the surrounding granulosa and 
theca cells of primary follicles (Yamamoto et al, 1997), suggesting a bi-phasic role 
for bFGF as the follicle matures.  
Although there are more growth factors involved in early ovarian development and 
germ cell differentiation, the factors described here are the most well described in 
terms of function and human expression (summarised in Table 1.2). 
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Table 1.2 Summary of Growth Factor Regulation 
Summary of fetal ovarian phenotype from murine models (or function where noted) of key growth factors 
Growth Factor Localisation Phenotype Model Reference 
Kit-ligand GC Loss of GCs and infertility 
Steel mutant mice (homozygous 
mutation at S1 locus) 
( McCoshen & McCallion, 
1975) 
WNT4 SM 
Disruption of sex determination and 
loss of oocytes 
Homozygous null mice 
(Heikkila et al, 2005) 
Retinoic Acid SM 
No phenotype (although Stra8 and 
Cyp26b1 both important for 
regulation of meiosis) 
Homozygous null mice 
(Kumar et al, 2011) 
Activin GC 
Function -GC proliferation, survival 
and initiation of primordial follicle 
formation 
Human fetal ovarian culture 
(Coutts et al, 2008; Childs & 
Anderson, 2009) 
Follistatin SM Loss of GCs and subfertility FST288-only homozygous null mice (Kimura et al, 2010) 
BMP2 GC Embryonic lethality – reduced PGCs Homozygous null mice (Ying & Zhao, 2001) 
BMP4 GC Embryonic lethality – no PGCs Homozygous null mice (Lawson et al, 1999) 
BMP7 GC Function in GC proliferation Homozygous null mice (Ross et al, 2007a) 
BMP8 GC Embryonic lethality – reduced PGCs Bmp8b homozygous null mice (Ying et al, 2000) 
BMP15 GC Subfertility due to ovulation defect Homozygous null mice (Yan et al, 2001) 
GDF9 GC 
Infertile- defect in cumulous 
expansion 
Homozygous null mice 





GC loss at primordial stage 
TrkB Homozygous null mice 
 
(Spears et al, 2003) 
bFGF SM 
Function- activation of follicles past 
primordial stage 
Mouse and bovine ovarian culture 
(Nilsson et al, 2001) 
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1.8 Transcription Factors 
Transcription factors work in concert with growth factors to regulate developmental 
processes in the fetal ovary.  Growth factors regulate cell function via ligand-receptor 
signalling followed by an intracellular cascade, which often modulates transcription 
factor/s in order to exert function.  In turn, transcription factors affect cell function 
via direct up- or down-regulation of target genes.  Transcription factors known to 
regulate fetal ovarian development are described in detail below (Figure 1.7). 
 
1.8.1        OCT4 
OCT4 is a transcription factor from the POU domain f mily, and is expressed by 
germ cells in both human and mouse, as early as PGC specification and migration 
(Rosner et al, 1990; Scholer et al, 1990; Pesce t al, 1998a).  OCT4 expression is 
also found later in gestation, in oocytes undergoin primordial follicle formation; 
however, its expression is repressed in between these events, with down-regulation 
occurring around meiosis (Pesce et al, 1998a; Pesce t al, 1998b; Rajpert-De Meyts 
et al, 2004).  It is postulated OCT4 repression may be the result of antagonism by 
meiotic-specific factors including retinoic acid or its downstream targets 
(Schoorlemmer et al, 1994; Dann et al, 2008).  It is further hypothesised that Oct4 
acts in fetal germ cells as a transcriptional repressor, and may be down-regulated at 
this time to allow for heighten transcription in the oocytes during the initiation of 
meiosis (Pesce t al, 1998b). 
OCT4 is well characterised for its role in maintaining pluripotency in embryonic 
stem cells (ES cells) (Nichols et al, 1998) (Pesce & Scholer, 2000).  As ESCs have 
many phenotypic similarities to the PGC population, t is understandable that OCT4 
regulation is also important in germ cells in vivo (Pesce et al, 1998a; Pesce & 
Scholer, 2000); however, there are distinct differences between these two cell types 
and the role of OCT4 in each.  In ES cells, OCT4 is characterised for its role in 
maintenance of pluripotency (Pan et al, 2002).  However, the PGC- specific deletion 
of Oct4, utilising CRE/loxP targeting of tissue non-specific alkaline phosphatase 
((TNAP) PGC specific marker before e10.5 (Lomeli et al, 2000)) in a murine model, 
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leads to PGC apoptosis (Kehler et al, 2004), demonstrating Oct4 regulates survival in 
PGCs rather than differentiation.  The exact functions of OCT4 later in gestation and 
in the human fetal ovary remain unknown.  It has, however been demonstrated that 
disruption of OCT4 is associated with gonadal tumours, highlighting actions in the 
maintenance of gonadal function in the human (Looijenga et al, 2003; Rajpert-De 
Meyts et al, 2004).  
1.8.2        NANOG 
NANOG, like OCT4, is a pluripotency-associated factor in ES cells, and is expressed 
by PGCs in both human and mouse (Matsui et al, 1991; Chambers et al, 2003; Mitsui 
et al, 2003; Hart et al, 2004; Yamaguchi et al, 2005).  However unlike OCT4, 
NANOG is not expressed past the initiation of meiosis (Wang et al, 2003a; 
Yamaguchi et al, 2005; Kerr et al, 2008).  PGC specific deletion of Nanog, (utilising 
TNAP CRE/loxP cross as described for Oct4, in addition to a second line utilising an 
estrogen receptor-CRE ) resulted in loss of PGC founder cells, with the remaining 
PGCs dying during migration (Yamaguchi et al, 2009).  These results demonstrate 
Nanog is necessary for regulation of PGC survival prior to and during migration, and 
similarly to Oct4, Nanog does not regulate differentiation as demonstrated in ES 
cells.   
It is postulated Nanog’s function in survival of germ cells may be due in part to its 
regulation of TIA1 cytotoxic granule-associated RNA binding protein-like 1(Tial1), 
a regulator of apoptosis (Taupin et al, 1995; Beck et al, 1998), oogonia are absent in 
mice lacking Tial1 (Beck et al, 1998).  Nanog may also function via regulation of the 
Ids (as discuss previously for Bmp4), as Nanog deficient mice demonstrate a down-
regulation of Id1 (Yamaguchi et al, 2009), which is known to regulate transcription 
in ES cells (Kim et al, 2008).  Finally, although the germ cell-specific Nanog-/- 
murine model (Yamaguchi et al, 2009) demonstrated no disruption of migration, 
recent studies in zebrafish suggest Nanog may regulate PGC expression of Cxcr4, 
which aids in guiding PGCs to the genital ridge (Sanchez-Sanchez et al, 2010), 
suggesting a role in migration as well as survival.  However, it remains to be seen if 
Nanog regulates CXCR4 in the mouse or human. 
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Figure 1.7 Transcription factors important for ovarian development 
Several transcriptional regulators are known to be involved in early human ovarian development leading up to primordial follicle formation and 
beyond, including Pou5f1 (OCT4), GATA4, SF1, NANOG, SOHLH1-2, FOXO3A, NOBOX, FIGLA, LHX8 and FOXL2.  Expression patterns of 
each are demonstrated above via a continued line through the gestational period.  OCT4 is repressed during meiosis and thus is depicted as a 
dashed line during this period.  Figure adapted from (Jagarlamudi & Rajkovic, 2011). 
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1.8.3          Newborn ovary homeobox (NOBOX) 
NOBOX is an oocyte-specific homeodomain transcription factor, which is expressed 
by both the mouse and human in germ cell nests and in oocytes within primordial 
follicles (Suzumori et al, 2002; Huntriss et al, 2006).  In the mouse, homozygous 
deletion of Nobox, results in germ cell nests which fail to breakdown properly, and 
rather than forming primordial follicles at birth, entire syncytia undergo atresia 
(Rajkovic et al, 2004; Lechowska et al, 2011).  Nobox-/-  ovaries appear to have an 
occasional primordial follicle, but these oocytes nver grow beyond 20 µm and do 
not recruit the required granulosa cell compliment necessary for later activation 
(Rajkovic et al, 2004; Lechowska et al, 2011).  Complete repression of Gdf9, 
Bmp15, and Oct4 are noted in Nobox-/- homozygous null mutants, demonstrating 
Nobox regulates expression of these genes and possibly others in order to orchestrate 
its function in ovarian development (Rajkovic et al, 2004; Choi & Rajkovic, 2005; 
Choi et al, 2010a).  Although direct functional analysis has not been performed in the 
human, NOBOX is up-regulated during primordial follicle formation (Fowler et al, 
2009), and mutations in NOBOX has also been identified in patients with POI (Qin et 
al, 2007). 
1.8.4             LIM homeobox 8 (LHX8) 
LIM homeobox 8 (Lhx8) is a LIM homeodomain protein xpressed by oocytes in 
germ cell nests and primordial follicles in the fetal mouse ovary from e13.5 onwards 
(Pangas et al, 2006).  Similar to Nobox-/- ovaries, homozygous deletion of Lhx8 
results in infertility, with loss of oocytes around initiation of primordial follicle 
formation (Pangas et al, 2006; Choi et al, 2008a).  Examination at postnatal day 
(pnd) 0 and pnd7 demonstrated there was no differenc  in oocyte number in Lhx8-/- 
ovaries compared to wild-type ovaries at birth; although there were significantly 
fewer primordial follicles, with the majority of oocytes lost in  Lhx8-/- ovaries before 
pnd7 (Choi et al, 2008a).  Expression of Gdf9, Oct4, and Nobox is abolished in Lhx8-
/- ovaries (Choi et al, 2008a), which leads to the suggestion that Lhx8 might exert 
some of its effects via direct regulation of Nobox (Pangas et al, 2006). However, 
further transcriptome analysis of Nobox-/- and Lhx8-/- ovaries determined that 
although several factors were similarly missexpressed, there were distinct regulatory 
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targets that were not shared between the factors (Choi et al, 2008a).  One factor 
distinctly down-regulated in Lhx8-/- ovaries was Kit and its ligand Kitl, which may 
explain the more severe phenotype when compared to Nob x-/- ovaries.  However, it 
is yet to be seen if LHX8 is important in human primordial follicle formation and 
oocyte survival, as the LHX8 mutations identified thus far  in human patients have 
not been associated with a reproductive phenotype (Qin et al, 2008). 
1.8.5 GATA4 
Gata4 is a zinc finger transcription factor involved in sex determination in the 
gonads, and is normally expressed in the somatic cells of the fetal ovary 
(Heikinheimo et al, 1997; Viger et al, 1998; Tevosian et al, 2002).  In the mouse 
Gata4 is expressed from e11.5 onwards, with homozygous ablation resulting in 
embryonic lethality (Kuo et al, 1997; Tevosian et al, 2002).  It was determined that 
Gata4 interacts with another somatic factor, Friend of GATA2 (Fog2), to promote 
the female pathway during sex determination (Tevosian et al, 2002).  Homozygous 
deletion of Fog2 also ends in embryonic lethality (Molkentin et al, 1997), but this 
can be partially rescued by expression of Fog2 in the myocardium, which allows 
fetuses to develop to ~e17.5 (Tevosian et al, 2000).  This murine line, in addition to a 
model utilising a Gata4 knock-in allele which prevents interaction between Gata4 
and Fog2 (Crisponi et al, 2001), were utilised to examine Gata4/Fox2 regulation of 
fetal ovarian development (Manuylov et al, 2008).  Both murine lines led to 
disruption of ovarian development in a similar fashion, with PGC depletion, 
suggesting interaction with Gata4 is the sole cause for the phenotype seen in Fog2 
disrupted ovaries (Tevosian et al, 2002; Manuylov et al, 2008).  In addition, 
Follistatin and Foxl2 are down-regulated and Inha and Dkk1 are up-regulated in both 
mutant lines suggesting these are likely targets of Gata4/Fog2 action (Manuylov et
al, 2008).    
In the human GATA4 mRNA and protein are localised to the granulosa cells of the 
fetal ovary, expression of which decreases with gestation (Vaskivuo et al, 2001).  
This pattern of expression has led to the hypothesis GATA4 is likely to function in 
the human fetal ovary both in sex determination, as well as a protective factor in the 
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granulosa cells of follicles.   However, further investigation is necessary to determine 
function of GATA4 in the human. 
1.8.6 Steroidogenic factor 1 (SF1) 
SF1 (NR5A1) is an orphan nuclear receptor expressed by both granulosa and 
mesenchymal stromal cells of the human and murine ovary (Ikeda et al, 1994; 
Tajima et al, 2003).  Sf1 expression is noted as early as e9.5 in the fetal mouse ovary 
and is essential for fetal gonad development and sex determination  (Parker & 
Schimmer, 1997).  It is thought Sf1 may regulate these processes via its known 
targets including Amh (Shen et al, 1994), Cyp11a1 and 3βhsd (Parker & Schimmer, 
1994; LeersSucheta et al, 1997).   Sf1’s role in gonad development was determined 
via systemic homozygous deletion, which resulted in a lack of gonads and adrenal 
glands in both male and female offspring (Ingraham et al, 1994; Luo et al, 1994; 
Sadovsky et al, 1995). 
However, in order to dissect ovarian-specific function, Sf1 was disrupted via 
CRE/loxP mutatgenesis utilising the Amhr-2/CRE line (limiting deletion to cells of 
granulosa origin) (Jeyasuria et al, 2004; Pelusi et al, 2008).  Granulosa-specific 
disruption of Sf1 led to a decrease in primordial follicle number and  defect in 
ovulation, rendering the females infertile.  However, follicles of all stages were 
present demonstrating Sf1 plays a role in ovarian development after primordial 
follicle formation (Jeyasuria et al, 2004; Pelusi et al, 2008).  It was also noted that 
several proliferative factors (p27 and cyclin D2), aromatase and Amh were down-
regulated in Sf1conditional ovaries suggesting these factors are downstream of Sf1 
and may be responsible for the defects in follicle number and/or ovulation.   
However further investigation is necessary to fully determine Sf1’s role during fetal 
ovarian development, as the Amhr-2/CRE conditional model disrupted only 
granulosa Sf1, with continued expression in interstitial/ heca cells which may mask 
overall Sf1 ovarian function (Jeyasuria et al, 2004; Pelusi et al, 2008).   
In addition, the role of SF1 in the human fetal ovary is unclear.  Although several 
cases of SF1 disruption have been reported in regards to disruption of male sex 
differentiation (Coutant et al, 2007; Reuter et al, 2007; Koehler et al, 2008), only one 
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case of female disruption of SF1 has been reported, with no change in ovarian 
function (Biason-Lauber & Schoenle, 2000).  However, it has been hypothesised a 
similar orphan nuclear receptor, liver receptor homolog-1 (LRH-1/NR5A2), may also 
be able to regulate SF1 targets, and thus masks SF1’ function in ovarian biology 
(Weck & Mayo, 2006).  
1.8.7  SOHLH1 and 2 
Spermatogenesis and oogenesis specific basic helix-loop-helix 1 and 2  (Sohlh1 and 
2) are basic helix-loop-helix (bHLH) transcription factors, which are expressed in 
germ cell syncitia and oocytes within primordial follicles in the female, as well as in 
spermatagonia in the male (Ballow et al, 2006; Pangas et al, 2006).  Sohlh1 was 
initially identified along with Nobox in an array identifying genes expressed 
preferentially in oocytes (Rajkovic et al, 2001), with Sohlh2 subsequently identified 
as a bHLH factor sharing high homology with Sohlh1 (Ballow et al, 2006) .   
The murine model of homozygous ablation of S hlh1 has a similar phenotype to 
Nobox-/- ovaries, losing all follicles by 3 weeks postnatal ge (Choi et al, 2008b; 
Toyoda et al, 2009).  This phenotype is the result of a defect in primordial follicle 
development rather than formation, as follicles do not progress to the primary stage 
as a result of disrupted proliferation of pre-granulosa cells (Pangas et al, 2006).  As a 
result follicles are lost, which is accompanied by down-regulation of Gdf9, Bmp15, 
Lhx8, Kit and Nobox (Pangas et al, 2006).  Gene expression patterns and phenotype 
were notably similar to that of Nobox-/- ovaries, which led to the hypothesis that 
Sohlh1 regulates Nobox, as Nobox is affected in Sohlh1-/- ovaries but no change of 
Sohlh1 was determined in Nobox-/- ovaries (Pangas et al, 2006).  Similar comparison 
of phenotypes was performed in other models leading to the hypothesis that Sohlh1 
also regulates Lhx8 and Figla to varying degrees (Pangas et al, 2006; Choi et al, 
2008a). 
Sohlh2 homozygous null ovaries also demonstrate a loss of follicles postnatally; 
however the phenotype is less severe than seen in either Sohlh1-/- or Nobox-/- ovaries, 
with a few follicles progressing to a stage with multi-layered granulosa cells (Choi et 
al, 2008b; Toyoda et al, 2009).  Sohlh2-/- ovaries also demonstrate similar down-
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regulation of follicle-associated genes to that seen in Sohlh1-/- ovaries, which is not 
surprising as Sohlh1 and 2 are able to form heterodimers, and thus may exert their 
functions in cooperation (Choi et al, 2008b; Toyoda et al, 2009). 
Data regarding SOHLH1 or 2 in the human fetal ovary are limited.  Data from 
azoospermic patients demonstrates the SOHLH1 human orthologue does play a role 
in germ cell function (Choi et al, 2010b).  In addition, up-regulation of SOHLH1 in 
mid-gestational fetal ovaries has been determined (Fowler et al, 2009).  Therefore 
the role of SOHLH1 and 2 in the human fetal ovary with regards to primordial 
follicle formation and development, along with possible mutations in POI patients 
remain of interest. 
1.8.8 Factor in the germline alpha (FIGLA)  
FIGLA is also a basic helix-loop-helix (bHLH) transcription factor, restricted to the 
germ cells within the ovary in the mouse and human (Liang et al, 1997; Soyal et al, 
2000; Huntriss et al, 2002; Bayne et al, 2004).  Figla was originally characterised as 
a regulatory factor in the adult ovary via its interaction with the zona pelucida (ZP) 
proteins (Liang et al, 1997; Dean, 2002), which function later in ovarian biology in 
regulation of plasma membrane formation and fertilisation (Bleil & Wassarman, 
1980).  However, a murine model of systemic ablation of Figla created to investigate 
this role further demonstrated the resulting homozyg us females were unable to form 
primordial follicles after birth resulting in oocytes loss and infertility (Soyal et al, 
2000) suggesting an important role for Figla in both fetal and adult ovarian biology.   
Further investigation determined Figla expression peaks at initiation of nest 
breakdown and follicle formation (Soyal et al, 2000; Joshi et al, 2007).  This increase 
in expression co-insides with the up-regulation of b th Oct4 and NACHT domain, 
leucine-rich-repeat domain, and pyrin domain-containing protein 5 (Nalp5), which 
Figla is hypothesised to regulate (Soyal et al, 2000; Joshi et al, 2007).  As previously 
discussed, Oct4 is highly involved in early PGC development, and is also thought to 
regulate primordial follicle formation.  Function of Nalp5 in the fetal ovary has yet to 
be determined, although it expressed specifically by oocytes and is up-regulated with 
initiation of primordial follicle formation in the mouse (Joshi et al, 2007) and human 
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(Fowler et al, 2009).  Studies in other tissues suggest Nalp5 may regulate caspase-3 
activation and apoptosis, which is consistent with the hypothesis Figla functions to 
regulate germ cell nest breakdown (Lo et al, 2008).  In addition to up-regulation of 
oocytes specific factors, Figla appears to repress testis specific factors and thus may 
also play a protective role during early ovarian development (Joshi et al, 2007; Hu et 
al, 2010).   
Up-regulation of FIGLA prior to primordial follicle formation was also noted in the 
human fetal ovary (Huntriss et al, 2002; Bayne et al, 2004).  FIGLA is thought to 
have a similar function in the human fetal ovary, as demonstrated in the mouse, as it 
is able to regulate the ZP genes in a similar fashion (Bayne et al, 2004; Fowler et al, 
2009) to that noted in the mouse, and there are reports of POI patients with mutations 
in FIGLA (Zhao et al, 2008). 
1.8.9 Forkhead box O3a (FOXO3A) 
Foxo3a is a forkhead transcription factor, which is expressed primarily by oocytes 
within primordial follicles, with further expression in granulosa cells surrounding 
activated follicles (Liu et al, 2007).  A murine model homozygous null for Foxo3 
was generated as it was hypothesised the Foxo family of transcription factors were 
involved in development (Castrillon et al, 2003).  The resulting animals had several 
minor physiological abnormalities including anaemia and decreased rate of glucose 
uptake; however the main phenotypic difference with systemic deletion of Foxo3a 
was a rapid reduction in fertility in female mice, which were completely sterile by 15 
weeks of age (Castrillon et al, 2003).  Further examination of Foxo3a-/- females 
determined no change in ovarian physiology compared to wildtype mice at pnd3, but 
determined a rapid decline in oocyte number after primordial follicle formation, the 
result of premature activation of follicles (Castrillon et al, 2003).   
However, as both germ cell and somatic cells express Foxo3, a tamoxifen-inducible, 
germ cell-specific Vasa-CRE was utilised to further study Foxo3 function 
specifically in oocytes (John et al, 2008).  This conditional model developed a 
similar phenotype to that of the Foxo3a-/- ovaries, with global activation of follicles 
after tamoxifen treatment.  It was further demonstrated that Foxo3a is activated by 
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the PTEN-PI3K-AKT signalling pathway (as it is in other systems (Tran et al, 
2003)), as a similar Vasa-CRE conditional deletion of PTEN demonstrated the same 
phenotype of Foxo3a conditional deletion (John et al, 2008).  An additional murine 
model was designed to further confirm Foxo3a function in oocytes via constitutively 
activating Foxo3a under control of the Zp3 promoter which is expressed after the 
primary stage of folliculogenesis (Liu et al, 2007).   Constitutively active Foxo3a 
results in loss of all follicles at the primary and secondary stage and oocytes display 
impaired growth (Liu et al, 2007).  These data determined Foxo3a regulates 
signalling allowing for primordial follicle arrest, and is likely downstream of PTEN-
PI3K-AKT signalling as well as Kit (as previously discussed) (Castrillon et al, 2003; 
Hosaka et al, 2004; Liu et al, 2007; John et al, 2008).  However, study of the human 
ortholog of FOXO3a in patients with POI has yet to identify a similar function 
(Watkins et al, 2006; Gallardo et al, 2008; Vinci et al, 2008) and little is known 
about its expression in the human fetal ovary. 
 
1.8.10 Forkhead box L2 (FOXL2) 
Foxl2 is important during sex determination, in therepression of male specific 
factors (Uhlenhaut et al, 2009).  FOXL2 is expressed by the pre-granulosa and 
granulosa cells in the fetal and adult ovary respectiv ly in both the human and mouse 
(Crisponi et al, 2001; Cocquet et al, 2003; Duffin et al, 2009).  Transcript expression 
of Foxl2 is increased in mid-gestation in the mouse around the initiation of sex 
determination, consistent with its established functio  at this time (Cocquet e al, 
2003; Duffin et al, 2009).  Further, functional analysis was performed utilising 
female mice homozygous null for Foxl2, which are infertile as a result of impaired 
pre-granulosa cell differentiation and basal lamina formation, thereby preventing 
primordial follicle formation (Schmidt et al, 2004; Uda et al, 2004).  This disruption 
also leads to a reduction in Activin βa and Amh expression (Schmidt et al, 2004; Uda 
et al, 2004).     
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Conditional deletion of Foxl2 utilising a tamoxifen inducible CRE affecting both 
granulosa and theca cells (R26CreERT2)  in the adult mouse ovary resulted in 
immediate differentiation of these cells to Sertoli and Leydig-like cells, and 
increased expression of testis markers including Sox9 and steroidogenic acute 
regulatory gene (StAR) (Pisarska et al, 2004; Uhlenhaut et al, 2009).  This data 
further demonstrates Foxl2 acts to repress the malepathway even after initial sex 
determination and promotes differentiation of granulosa cells necessary for 
primordial follicle formation.  
Interestingly, FOXL2 is one of the few factors of the germ cell niche originally 
identified in the human, with mutation identified in humans patients with 
blepharophimosis ptosis epicanthus inversus syndrome (BPES I and II), which 
includes ovarian failure or subfertility (Crisponi et al, 2001; Prueitt & Zinn, 2001; 
Cocquet et al, 2002b; Cocquet et al, 2003).  Non-BPES mutations of FOXL2 have 
also been reported with ovarian dysfunction (Harris et al, 2002).  Both FOXL2 
localisation and gene expression patterns in the human fetal ovary are comparable to 
that seen in the mouse, with initiation of FOXL2 expression before 8 weeks gestation 
and up-regulated at 14-15 weeks gestation (Duffin et al, 2009).  However, FOXL2 
function in the human fetal ovary has yet to be confirmed. 
This is a summary of the established transcription factors (Table 1.3) identified as 
regulators in the fetal ovary and female germ cell d velopment.
Chapter 1                                                                                             Literature Review 
51 
Table 1.3 Summary of Transcription Factor Regulation 
Summary of fetal ovarian phenotype from murine models (or function where noted) of key transcription factors 
Transcription Factor Localisation Mouse Phenotype Mouse Model Reference 
Oct4 GC PGC loss - infertility PGC-specific CRE/Lox (Kehler et al, 2004) 





(Manuylov et al, 2008) 
Sf1 SM PGC loss - infertility 
FTz-F1 disruption which 
codes for Sf1 protein 
(Luo et al, 1994) 
Nanog GC PGC loss - infertility PGC-specific CRE/Lox (Yamaguchi et al, 2009) 
Sohlh1 and Sohlh2 GC Primordial to primary block –sterile 
Homozygous null (Pangas et al, 2006; 
Choi et al, 2008b) 
Foxo3a GC Global activation of follicles –sterile  Homozygous null (Castrillon et al, 2003) 
Nobox GC Primordial to primary block –sterile Homozygous null (Rajkovic et al, 2004) 
Figla GC Primordial follicle block - infertility Homozygous null (Soyal et al, 2000) 
Lhx8 GC Primordial to primary block –sterile Homozygous null (Choi et al, 2008a) 
Foxl2 SM Loss of follicles due to somatic fault –sterile Homozygous null (Uda et al, 2004) 
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1.8.11 Germ cell niche and other factors 
Growth factors (illustrated in Tables 1.2 and Table 1.4) extracellular matrix proteins, 
and hormones, allow for crosstalk between the germ cells and neighbouring cells in 
the human fetal ovary, which in turn initiates intracellular signalling and modulation 
of transcription factors (Table 1.3) in order to regulate ovarian biology and germ cell 
development.   
The paracrine, juxtacrine and autocrine support provided via these factors creates the 
microenvironment necessary for germ cell development and function and is termed 
the ‘germ cell niche’ (McLaren, 1991; De Felici, 2000).  This term refers to the 
signalling milieu that is necessary to sustain the germ cell progression allowing for 
normal fertility in adulthood.  However, the full cohort of growth and transcription 
factors involved in ovarian development remain unknow .  Primordial follicle 
formation is important for future fertility, thereby making the determination of the 
factors within the germ cell niche and their interactions essential. 
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Table 1.4 Other factors that may be involved in fetal ovarian development 
Summary of fetal ovarian phenotype from murine models (or function where noted) of other factors possibly involved in fetal ovarian development 
Factor  Hypothesised function Model Reference 
Notch Regulates follicle formation Mouse organ culture (Trombly et al, 2009a) 
Nalp5 







 trimester human fetal ovary 
(Joshi et al, 2007) 
(Fowler et al, 2009) 
Wt1 Regulates gonad formation 
Homozygous null mice (Kreidberg et al, 
1993) 
Zglp1 Regulates GC survival ZGLP-1 (lacZ) null mice (Li et al, 2007) 
Lhx9 Regulates PGC survival Homozygous null mice (Birk et al, 2000) 
Pod1 Regulates of gonad structure Homozygous null mice (Cui et al, 2004) 
Aromatase Regulates follicle formation Homozygous null mice (Britt et al, 2004) 
AMH 
Regulates primordial follicle 
activation 
AMH levels in humans relates to follicle number 
Mouse organ culture 
(de Vet et al, 2002; 
Durlinger et al, 2002) 
Aryl-hydrocarbon 
receptor 
Regulates primordial follicle 
number 
Homozygous null mice (Benedict et al, 2000; 
Robles et al, 2000) 
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1.9 Possible regulators of early ovarian developmen t 
Several questions remain regarding the established factors of the germ cell niche and 
whether other unidentified factors are involved during fetal ovarian development.  
Several factors are known to regulate similar mechanisms in other tissues 
(proliferation, differentiation, apoptosis, etc), and interact with established ovarian 
regulators.  In addition, these factors are known to be vital to adult ovarian function.  
However, their roles during fetal ovarian development and interaction with the germ 
cell niche are unknown.  The following sections will describe these regulatory factors 
postulated to be involved during fetal ovarian function. 
 
1.9.1 Prostaglandin E2 
The prostaglandins (PGs) are lipid mediators classic lly characterised as regulators 
of inflammation, immunity, and vascular homeostasis (Murakami et al, 1993). Their 
signalling is known to promote angiogenesis, inhibit apoptosis, and increase 
proliferation and migration (Sales & Jabbour, 2003a), with regulation determined in 
various species ranging from invertebrates to humans de oting their roles are 
generally evolutionarily conserved (Cha et al, 2006).  PGs came into the limelight in 
the clinical world in the early 1970’s, with  non-steroidal anti-inflammatory drugs 
(NSAIDs) which reduce inflammation symptoms including swelling, pain and fever 
by inhibiting PG synthesis  (Vane, 1971).  
PGs are synthesised by the conversion of arachadonic acid by cyclooxygenase 
enzymes (COX1 and COX2).  In a physiological sense, COX1 is traditionally 
thought of to be the ubiquitously expressed “maintenance” enzyme, whereas COX2 
is important for cytokine mediated specific events.  This is supported by constitutive 
expression of COX1 in several organs (kidney, lung, stomach, colon) and the 
inability to stimulate COX1 levels in vitro (Kargman et al, 1996), whereas COX2 
expression is not constitutively expressed in most tis ues but can be rapidly induced 
by cytokine or growth factor expression (Cha et l, 2006).    
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The COX enzymes produce prostaglandin H2  (PGH2), which is further converted to 
prostaglandin D2, E2, F2α, thromboxane (TXA2 or TXB2) or prostacyclin (PGI2) by 
specific terminal prostanoid synthase enzymes, suchas prostaglandin E synthase 
(PTGES) (As shown in Figure 1.8).  In addition, although the mechanism remains 
unclear, genetically modified murine models have demonstrated the COX enzymes 
may preferentially synthesize specific prostaglandins (as further described below).  It 
is also notable that the PGs and COX2 are able to signal in both an autocrine and 
paracrine fashion that results in a positive-self-sustaining feedback loop (Sales & 
Jabbour, 2003b). 
 
Figure 1.8 Arachadonic acid to prostaglandin pathway 
As fully described in the text, PGE2 is synthesised from a stepwise enzymatic pathway 
initiating with breakdown of phospholipids and resulting in several prostaglandins (D2, F2α, 
and E2), thromboxane (TXA2 and TXB2) and prostacyclin PGI2).  
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Even before PGs were identified, several scientific groups had determined there was 
a lipid mediator in semen (now known to be PGs) that causes contraction of the 
uterine smooth muscle and reduced blood pressure (Cha et al, 2006).  For this reason, 
the PGs were isolated and characterised as regulators of reproductive inflammatory 
events, including parturition, ovulation, menstruation and endometriosis, as well as 
fertilisation, implantation and decidualisation (Behrman, 1979; Oates et al, 1988a; 
Oates et al, 1988b; Baird et al, 1996; Sales & Jabbour, 2003b).   
Studies using animal models have further defined thse roles, with homozygous 
ablation of COX1 in female mice resulting in prolonged gestation and parturition, 
with normal ovulation and fetal development (Langenbach et al, 1995).  The 
reproductive phenotype could also be rescued with administration of PGF2α (Gross et 
al, 1998), suggesting this may be the dominate PG product of COX1.  In contrast, 
COX2 homozygous null females result in a more severe reproductive phenotype, 
including failure to ovulate, fertilise, implant, and decidualise (Dinchuk et al, 1995; 
Lim et al, 1997).  However, the ovarian phenotype was rescued with the 
administration of PGE2  (Lim et al, 1997).  Despite both precursor enzymes 
catalysing the same reaction and some level of redundancy confirmed (Wang & Roy, 
2004), it is apparent from these models that the COX enzymes may catalyse different 
amounts of each prostaglandin leading to different downstream outcomes.  
Unfortunately, overall effects of complete ablation of the COX enzymes cannot be 
investigated as double-knockout mice die shortly after birth due to patent ductus 
arteriosus (Loftin et al, 2001). 
However, specific COX-/- models have identified PGE2 and PGF2α as the two main 
PGs responsible for of the above reproductive phenotypes, and therefore the most 
involved in reproductive function.  Further investigation led to the ablation of the 
PGF2α receptor, which resulted in a mouse model that loses parturition function, 
whereas ablation of one of the PGE2 receptors results in disruption of ovulation 
(Hizaki et al, 1999; Kennedy et al, 1999; Tilley et al, 1999; Narumiya & FitzGerald, 
2001).  From this evidence it is apparent that PGE2 may be the more important PG in 
ovarian function. 
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PGE2 functions in the adult ovary in initiation of ovulation and fertilisation of the 
oocyte (Ojeda et al, 1982; Hizaki et al, 1999), doing so via four G-coupled protein 
receptors (GPCRs), EP1-4.  Each of these signals vi a d fferent downstream 
pathway; EP1 signals via Gq to up-regulate intracellular calcium; EP2 and EP4 are 
‘stimulatory’ receptors and signal via Gαs to increase cyclic adenosine 
monophosphate (cAMP), with EP4 also able to act via he PI3/AKT pathway; and 
EP3 is regarded as ‘inhibitory’ and signals via Gi to decrease cAMP (Alfranca et al, 
2006) (Figure 1.9).  This variance in downstream signalling, coupled with varying 
localisation to different cell types, allows a single prostanoid to exert multiple 




Figure 1.9 Specific downstream signalling of the four EP receptors 
PGE2 is able to signal via 4 G-coupled protein receptors (EP1-4), each of which signals 
via a distinct downstream intracellular cascade.  EP1 signals via Gq to increase 
intracellular calcium, EP2 and EP4  via Gs to induce adenylate cyclase activity (with EP4 
also inducing the PI3K/AKT pathway), and EP3 via Gi inhibits adenylate cyclase activity 
and induces Stat signalling.  Figure adapted from (Alfranca et al, 2006). 
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In addition to classical ligand receptor action, there is also evidence that the EP 
receptors can be internalised to the nucleus to directly regulate gene transcription 
(Bhattacharya et al, 1998; Bhattacharya et al, 1999; Desai et al, 2000).  Of the EP 
receptors, EP2 is thought to be the most involved in ovarian function, determined by 
the ovulatory defects and failure of fertilisation in Ep2 homozygous null mice, 
whereas inactivation of the remaining Ep receptors lead to no major reproductive 
dysfunction (Hizaki et al, 1999; Kennedy et al, 1999; Tilley et al, 1999).  It was 
determined that gonadotropins increase both Cox2 and Ep2 levels in the adult ovary 
leading to cumulus expansion (Hizaki et al, 1999), which is sustained by the positive 
feedback capabilities of the PGE2 system.  It is likely the Ep2
-/- phenotype may be a 
result of inhibition of this signalling pathway. 
Apart from reproductive function, PGE2 mediates development of other organs, most 
critically closure of the ductus arteriosus, which allows for postnatal circulation, and 
is the main cause of fatality in COX1/2-/- doubly ablated mice (Nguyen et al, 1997; 
Loftin et al, 2001).  PGE2 regulation of fetal angiogenesis is also well characterised 
(Majima et al, 1997), and is likely to be mediated by the angiogenic factors up-
regulated by PGE2 including bFGF and vascular endothelial growth factor (VEGF)  
(Cheng et al, 1998).  Additionally, PGE2 is postulated to be required for blastocyst 
development (Dey et al, 1980; Davis et al, 1983), as inhibition of the COX enzymes 
during pregnancy results in degradation of murine blastocysts (Cha et al, 2006).  This 
key role in development is also noted in the inhibition of PGE2 in the zebrafish, 
where it regulates cell migration necessary for gastrulation (Cha et al, 2006).  
With roles in both the adult ovary and development of other organ systems, PGE2 is 
an attractive candidate for possible regulation of fetal ovarian development. PGE2 has 
also been shown to interact with established germ cell niche factors.  PGE2 is known 
to be up-regulated during human placental development, when the hypoxic 
environment activates Activin A (Petraglia et al, 1993; Jenkin et al, 2001; 
Supramaniam et al, 2004), it is also demonstrated to regulate BMP2, 4, and 7 in 
osteoid cells (Virdi et al, 1998; Takiguchi et al, 1999; Paralkar et al, 2002), and 
induces BDNF expression in astrocytes (Toyomoto et al, 2004; Hutchinson et al, 
2009)   In addition, an recent exploratory gene expr ssion assay revealed PGE2 as a 
Chapter 1                                                                                             Literature Review 
59 
potent regulator of the neurotrophins in female reproductive tissues (Jabbour, 
unpublished).  However, none of these interactions/relationships have been 
confirmed in the human fetal ovarian environment. 
 
1.9.2 The IL6-type cytokines 
The IL6-type cytokines are secreted, pro/anti-inflammatory cytokines which 
demonstrate overlapping function and may, like PGE2, be involved in fetal ovarian 
development.  The IL6-type cytokine family is composed of several cytokines which 
signal via receptor complexes consisting of shared components, and includes IL6, 
IL11, leukaemia inhibitory factor (LIF), oncostatin-M (OSM), cardiotropin-1 and 
ciliary neurotrophic factor (CNTF) (Heinrich et al, 1998).   The IL-6 type cytokines 
signal via receptor complexes made up of hetero- or homo- dimers or trimers, with a 
common receptor component gp130 in each receptor complex (Figure 1.10).  As 
reviewed in detail (Heinrich et al, 1998); each receptor complex contains one or 
more shared signal transducing components, and somec plexes also include an α-
receptor subunit, which although not required for int acellular signalling is necessary 
for specific ligand binding.  LIF and OSM share thesame signalling complex 
consisting of a heterodimer of LIF receptor (LIFR) and gp130 (Gearing & Bruce, 
1992).  OSM is also able to signal via a heterodimer of a newly characterised OSM 
receptor (OSMR) and gp130 (Ichihara et al, 1997).  Comparable to LIF and OSM, 
CNTF also utilises the LIFR/gp130 heterodimer, but also requires a specific CNTF 
receptor (CNTFR) α subunit for signalling (Gearing & Bruce, 1992; Davis et al, 
1993).  Finally, IL6 ligand utilises an α-receptor subunit, IL6 receptor in combination 
with a homodimer of gp130 (IL6R) (Taga et al, 1989).   Several studies have 
demonstrated a high degree of redundancy in IL6-type cytokine function as a result 
of shared receptor components and similar intracellular signalling (Koshimizu et al, 









Figure 1.10 IL6-type cytokine signalling 
As described fully in the text, the IL6 type cytokines signal via formation of hetero- or 
homo- dimers or trimers of various shared receptor components to intracellularly signal 
via the Jak/STAT pathway in order to modulate gene expression.  This signalling can be 
inhibited via SOCS3, which is also a downstream target of IL6-type signalling and thus 
part of a negative feedback loop.  Figure adapted from (Suzuki et al, 2009). 
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The IL6-type cytokine receptor complexes signal via activation of the Janus kinases 
(Jaks) and the signal transducer and activator of transcription (STAT) transcription 
factor (Jak/STAT) pathway (Lutticken et al, 1994; Stahl et al, 1994).  The activation 
of this signalling pathway via various phyosphorylation events is able regulate target 
gene expression via phosphoylated dimerisation of STATs which is required for 
DNA binding (Shual et al, 1993).  However, Jak/STAT regulation is known to be 
transient and thus effective mediators of the system, specifically suppressor of 
cytokine signalling 3 (SOCS3), have been identified (Nicholson et al, 2000; Schmitz 
et al, 2000).  STAT dimers are able to up-regulate various transcripts, including the 
SOCS inhibitory factors themselves (Heinrich et al, 1998), which in turn act as 
negative feedback inhibitors by acting on activated IL6 receptors or Jaks to inhibit 
further signalling.  Both IL6 and LIF signalling are known to induce SOCS3 
expression, suggesting these factors are able to promote their own negative feedback 
loop, limiting signalling and allowing for acute regulation (Endo et al, 1997).  This 
acute regulation allows the IL6-type cytokines to regulate specific events in various 
tissues, including the ovary.  In the adult ovary, IL6-type cytokines are involved in 
various processes including cumulus expansion and oocyte competence (Liu et al, 
2009).  
As with Oct4 and Nanog, the IL-6 type cytokine family was originally highlighted as 
a potential regulator of germ cell development based upon various in vitro 
experiments using stem cells, embryonic germ (EG) cells, and PGCs (Williams et al, 
1988; Defelici & Dolci, 1991; Matsui et al, 1991; Resnick et al, 1992; Cheng et al, 
1994; Koshimizu et al, 1996).  LIF ligand in particular has been well characterised in 
the maintenance of ES cells and PGCs in culture in combination with KITL and 
bFGF (Matsui et al, 1991; Resnick et al, 1992), thus demonstrating regulation of 
proliferation and survival.  Further studies demonstrated LIF function could be 
replicated by addition of IL6, CNTF or OSM to the culture media, demonstrating 
compensatory action (Cheng et al, 1994; Koshimizu et al, 1996).  Further, culture of 
mouse PGCs demonstrated reduction in apoptosis with LIF treatment (Pesce et al, 
1993a), and that the common signalling component gp130 is able to regulate 
initiation of meiosis (Chuma & Nakatsuji, 2001).  Based upon this accumulation of 
Chapter 1                                                                                             Literature Review 
62 
in vitro data, it was hypothesised the IL6-type cytokines had a role in germ cell 
function in vivo, specifically during early development and maturation. 
However, as discussed for both Oct4 and Nanog, regulatory roles demonstrated in ES 
cells and/or PGCs in vitro often differ from their physiological roles in vivo.  To date, 
several genetically engineered murine models have been generated in attempts to 
recapitulate the regulation of IL6-type cytokines sen in vitro in the fetal gonad 
(Stewart et al, 1992; Escary et al, 1993; Ware et al, 1995; Yoshida et al, 1996; 
Molyneaux et al, 2003a) with little success.  Systemic deletion of LIF was the first 
model to be investigated, which did result in infertility in female offspring, but it was 
identified this was the result of an ovulatory defect rather than an effect on germ cell 
differentiation (Stewart et al, 1992).  As the IL6-type cytokines are known to have 
overlapping function, several models focused on shared signalling components, in 
order to prevent compensation by other IL6 cytokines which might mask function 
(Ware et al, 1995; Yoshida et al, 1996; Takeda et al, 1997).   However, homozygous 
deletion of the shared receptor components gp130 or LIFR or the common 
downstream target STAT3 resulted in a lethal phenotype, either embryonically or 
shortly after birth (Ware t al, 1995; Yoshida et al, 1996; Takeda et al, 1997), 
preventing any elucidation of systemic blockage of IL6-type cytokine signalling.  A 
gp130 germ cell specific knockout was also generated utilising the TNAP-CRE, as 
previously described for Oct4 and Nanog (Molyneaux et al, 2003a).  This line 
resulted in no change in ovarian phenotype during fetal and early postnatal life 
(although there was an ovulation defect in adult female and a reduction in PGCs in 
male pups (Molyneaux et al, 2003a).   
 
Although several attempts have been made to elucidate IL6-type cytokine function in 
vivo, their role during fetal gonad development has not been established.  In addition 
little is known about the IL6-type cytokines and their receptors in the human fetal 
ovary, despite strong evidence for these factors as egulators of differentiation and 
proliferation in vitro.  For these reasons, the IL6-type cytokines were hypothesised to 
function as part of the germ cell niche during ovarian development. 
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1.9.3 The Prokineticins 
A final group of regulators were also hypothesised to regulate fetal ovarian 
development; the prokineticins (PROK) 1 and 2, which are recently described 
proteins known to regulate angiogenesis and inflammtion (Catalano et al, 2010; 
Monnier & Samson, 2010).  The name prokineticin reflects how the proteins were 
originally characterised, as potent regulators of smooth muscle contractility in the 
gastrointestinal tract (Li et al, 2001) (eg. pro- kinetic).  The PROKs have similar 
function to vascular endothelial growth factor (VEGF) in promotion of angiogenesis, 
and PROK1 was initially termed endocrine gland VEGF (EG-VEGF) (LeCouter et 
al, 2001).  In addition, PROK1 was also named venom protein A (VPRA) and 
mamba intestinal toxin1 (MIT1), as the PROK1 orthologue was initially identified as 
a non-toxic protein derived from the venom of the back mamba snake (Dendroaspis 
polylepis) (Joubert, 1980; Schweitz et al, 1990).  PROK2 was also identified in a 
different species by a different name; Bv8, derived from the skin secretions of the 
yellow-bellied toad (Bombina variegata) (Mollay et al, 1999).  Despite various 
aliases and nomenclatures, the human orthologous of the PROKs were identified and 
termed PROK1 and PROK2, as they will be referred to in this report.   
The PROKs signal via two prokineticin receptors (PROKR1 and PROKR2) (Masuda 
et al, 2002) which share 87% homology (Soga et l, 2002).  Both PROK ligands are 
able to signal interchangeably via the two GPCRs; however, PROK2 has a slightly 
higher affinity for both receptors (Lin et al, 2002; Soga et al, 2002).  The PROKRs 
then signal via either Gi or Gq signalling, which in turn increases intracellular 
calcium concentration and provokes rapid activation of p44/p42 MAP kinase 
signalling as well as activation of STAT signalling (Lin et al, 2002; Masuda et al, 
2002; Soga et al, 2002).   
Although initially characterised in endothelial cells, PROK receptors and ligands are 
expressed in various cell types throughout the body. PROK1 is expressed in B and T 
cells (Dorsch et al, 2005) and PROK2 in bone marrow, blood cells, immune cells, 
and neuronal tissue (LeCouter et al, 2004).  In these systems PROKs are shown to 
promote proliferation, differentiation and survival (Melchiorri et al, 2001; LeCouter 
et al, 2004).  Additionally, both ligands are highly expressed in the steroidogenic 
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reproductive tissues, such as the gonads (Wechselberg r et al, 1999; Ferrara et al, 
2003; Kisliouk et al, 2003; LeCouter et al, 2003; Samson et al, 2004), the placenta 
(LeCouter et al, 2001; Hoffmann et al, 2006) the endometrium (Evans et al, 2008; 
Evans et al, 2009) and the adrenal glands (Lin et al, 2002).  Although relatively little 
systemic data is available for these recently characte ised proteins, each ligand has 
been well characterised in a distinct organ system.  PROK1, as alluded to previously, 
is extensively described in its role in smooth muscle contractility, with evidence for 
regulation of most of the GI tract in various species (Li et al, 2001; Hoogerwerf, 
2006; Wade et al, 2010).  However this role is not shared with PROK2, which 
demonstrates that, although similar, the two ligands share distinct roles in different 
systems (Bassil et al, 2005).  PROK1 and 2 are able to induce proliferation and 
differentiation in the central nervous system (CNS) (Ngan et al, 2007; Ngan et al, 
2008; Ruiz-Ferrer et al, 2011), but only PROK2 is able to regulate more spcific 
CNS processes such as circadian rhythm, pain sensatio , ppetite, locomotor activity 
and thermoregulation (Cheng et al, 2002; Negri et al, 2002; Cheng et al, 2005; 
Prosser et al, 2007; Jethwa et al, 2008; Ren et al, 2011). 
Despite the elucidation of PROK function in other organ systems, little is known 
their roles in the gonads, despite being localised n the interstitial cells of both the 
testis and ovary (Wechselberger et al, 1999; Ferrara et al, 2003; Kisliouk et al, 2003; 
LeCouter et al, 2003; Samson et al, 2004).  Homozygous ablation of Prok2 or 
Prokr2 using rodent models resulted in the atrophy of the reproductive system (male 
or female) similar to the phenotype seen in human Kllmann syndrome (Dode et al, 
2006; Matsumoto et al, 2006; Pitteloud et al, 2007); however it was determined this 
was likely due to Prok2/Prokr2 effects on gonadoropin-releasing hormone (GnRH) 
expression, rather than direct regulation in the gonads (Matsumoto et al, 2006; 
Pitteloud et al, 2007).  Further evidence of this regulation was found in women who 
suffer reversible hypothalamic amenorrhea (predisposition to GnRH 
deficiency/disruption after exposed to stressors), which found several of these 
women had mutations in PROKR2 (Caronia et l, 2011).  Although not yet defined, 
it has been postulated PROK1 does have a direct role in the ovary and is localised to 
the theca cells in adult tissues (Ferrara et l, 2003; Kisliouk et al, 2003).  This 
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hypothesis is based upon the observation that PROK1 transcript expression increases 
with development of the corpus luteum (Ferrara et l, 2003; Fraser et al, 2005).  
However, further mechanistic investigation and localisation of the PROK receptors 
has yet to be performed.   
However, two recent transcriptome studies have demonstrated the PROKs are 
expressed and may play a role in the fetal ovary.  One array demonstrated increased 
expression of Prok1 in the fetal ovary comparative to the fetal testis (Houmard et al, 
2009).  The other detected novel expression of PROK2 in the human fetal ovary 
which increased with gestation leading to primordial follicle formation, suggesting a 
possible role for the ligand in ovarian development (Fowler et al, 2009).  Further, 
there is evidence from other reproductive tissues, that the PROKs may regulate 
signalling components of the other candidate regulators (PGE2 and the IL6-type 
cytokines) (Denison et al, 2008; Evans et al, 2008; Evans et al, 2009; Cook et al, 
2010). 
In addition to the hypothesis that the PROKs may be active in regulating the human 
fetal ovary, it is also postulated the PROKs may play a role in fetal testis 
development, as several studies have highlighted increased expression of PROK2 
and PROKR2 in the fetal testis compared to both the fetal ovary, and other tissues, 
including the brain where PROK2 and PROKR2 are known to be highly active 
(Wechselberger et al, 1999; LeCouter et al, 2003; Samson et al, 2004).  These 
studies also highlighted a potential role for PROK regulation of steroidogenesis, 
which is integral to sex differentiation and further t stis development.  With this data 
in mind, the expression of PROKs in the human fetal ov ry and testis were further 
characterised, to explore both PROK regulation during fetal gonad development, but 
also differential regulation between the sexes. 
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1.10 Aims of PhD 
Human fetal ovarian development is critical, as primordial follicle development at 
this stage underpins adult fertility in later life.  The fetal ovary and germ cells within 
are regulated by the germ cell niche, which regulates progression from PGC 
specification to primordial follicle formation.  Despite the importance of the germ 
cell niche, few of its contributing factors have been identified, leaving the regulation 
of early ovarian development poorly understood.  It is likely the germ cell niche is 
more similar to a web than a single cascade, allowing for positive and negative 
feedback loops/checks and balances in the system to prevent disruption.  Therefore, 
the question remains: What factors make up the germ c ll niche, and how do these 
factors interact to regulate fetal ovarian development?   
In order to further answer this question, several factors implicated in regulation of 
reproductive function later in life, which were known to interact with established 
factors of the germ cell niche were identified; PGE2, the IL-6 type cytokines, and the 
PROKs.  It was postulated that these regulatory factors (or families of factors), were 
involved in fetal ovarian development and primordial follicle formation. 
The specific aims of this research were to: 
1. Examine expression and localisation of signalling PGE2 components across 
human gestation (8-20 weeks), and further investigate tr nscriptional and 
functional effects of PGE2 treatment ex vivo in human fetal ovarian samples.  
 
2. Further determine the relationship between PGE2 signalling and germ cell 
development in vivo, utilizing a fetal rat model of COX inhibition via 
paracetamol exposure. 
 
3. Explore the roles of the IL6-type cytokines in the human fetal ovary to further 
clarify in vivo roles during germ cell development, and to further clarify if 
regulation seen in ESC culture in vitro is relevant to PGCs and oocytes in vivo.  
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4. Characterise PROK expression and localisation in the human fetal ovary, and 
further investigate function via the creation of a germ cell line stably expressing 
PROKR1, to determine signalling pathways regulated by PROK1-PROKR1 
interaction. 
 
Secondary to the focus on the ovarian germ cell niche s interest in how ovarian and 
testicular development differ, and how the same regulatory factors have differing 
roles in the two systems.  As the PROKs are differentially expressed in the testis and 
the ovary in both the human and the mouse, it was hypot esised that PROKs might 
have differing regulation in each system, and thus were also investigated in the fetal 
testis: 
 
5. Compare PROK expression and localisation in the human fetal testis to that 
demonstrated in the human fetal ovary, and further identify sex-specific 
function by culturing interstitial cells isolated from human fetal testes.







Chapter 2  
General Materials and Methods
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Chapter 2. General Materials and Methods 
 
2.1 Human Dissection and Tissue Collection  
Human fetuses (8-20 wks) were obtained as previously described in (Coutts et al, 
2008).  Informed consent was given, and the study approved by the Lothian Research 
Ethics Committee (LRC08/S1101/1).  Surgical terminations were also obtained after 
administration of misoprostol (200mg per vaginam) via vacuum aspiration.  General 
aesthetic was used during the procedure.   
It is recognised misoprostol treatment may interfer with parts of this study that 
focus on prostaglandin interaction in fetal tissue.  However, as tissue collected 
responded to PGE2 treatment, it is unlikely that the gonads are greatly affected by 
maternal misoprostol treatment (see Chapter 3). 
All fetuses were gestationally aged based on ultrasound scan. This gives an 
‘obstetric’ gestation based on last menstrual period rather than post-conception 
dating.  After the specimens were obtained this gestation was confirmed utilising 
either crown-rump length in first trimester specimens or foot length in second 
trimester specimens. 
After obtaining samples, tissue was transported to the laboratory for further 
dissection.  Micro-dissection to remove the gonads wa performed in sterile 
conditions and further tissue taken for SRY polymeras  chain reaction (PCR) as 
explained below (Section 2.3) in order to sex first t imester fetal gonads.  Gonads to 
be used for RNA/protein analysis or tissue culture were carefully separated from all 
extraneous material including the mesonephros using sterile needles (BD). 
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2.2 Rat Treatment, Dissection and Tissue Collection  
Female Wister rats were maintained according to UK Home Office guidelines and 
fed soy-free breeding diet (RM3 (E) soya free, SDS).  Rats were kept in controlled 
lighting housing (on at 0700h, off at 1900h) at a temperature of 19-21º C with 
LITASPEN standard bedding (SPPS).  Timed matings were established by visible 
vaginal plug and deemed embryonic day (e) 0.5.  At e13.5 of gestation, dams were 
fed via gavage 350 mg/kg paracetamol (Sigma) diluted in corn oil (Mazola).  A 
dosage of 350 mg/kg paracetamol was utilised as previous studies had determined 
this concentration was high enough to affect rodent f tuses without causing maternal 
morbity (including liver necrosis) (Kristensen t al, 2011).  A higher dosage than that 
which a pregnant woman would use was utilised as rats h ve both an increased basal 
metabolic rate (~7x that of the human) and drug clearance rate 
(acetaminophen/paracetamol ~8.6x that of the human) comparative to humans 
(Choiu et al, 1998).  Gavage delivery of paracetamol was utilised to mimic oral 
delivery of paracetamol in humans, with one large bolus rather than multiple doses to 
reduce stress to the animals which may have obscured eff cts of the drug itself. 
Control dams received corn oil via gavage only.  This was repeated every morning 
for 7 days (e20.5), followed by culling of the dams via cervical dislocation at e21.5.  
Pups were recovered and weighed before being culled via ecapitation.  Ovaries 
were removed via micro-dissection and one was snap frozen at -80° C for further 
analysis via enzyme linked immunosorbent assay (ELISA), while the other was fixed 
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2.3 SRY Genotyping 
PCR amplification of the sex-determination gene (SRY) was performed to determine 
the sex of human first trimester specimens, as gender cannot be visually determined 
(Friel et al, 2002).  The sample of specimen retained for DNA extraction was added 
to 100 µl of 25 mM NaOH/0.2 mM EDTA.  The solution was heated at 95° C for 20 
min and then neutralised in 100 µl of 40 mM Tris.HCl on ice. 
The samples are vortexed for 1 min and 5 µl of the sample added to the reaction mix 
(Table 2.1).  Remaining sample can be stored at -20°C. 
Table 2.1 SRY RT-PCR Reaction Mix 
Reagent Amount Used Manufacturer 
ImmoMix Red 12.5 µl Bioline 
25 µM SRY Forward Primer 0.5 µl Eurogentech 
25 µM SRY Reverse Primer 0.5 µl Eurogentech 
H2O 6.5 µl Ambion 
 
The reaction mix was run on a thermocycler (PTC-100, MJ Research Inc) as in Table 
2.2.  Each sample was run with a 100 bp ladder (Promega) via electrophoresis on a 
1% agarose gel (Sigma) containing Gel Red (Biotium) for visualisation.  A product 
of 300 bp confirms the specimen as male, absence of the band is determined as 
female.  Known positive and negative controls were utilised to ensure reaction 
success. 
Table 2.2 SRY PCR Thermocycler Programme 
Step Temperature Time 
1 95°C 10 min 
2 95°C 30 sec 
3 58°C 30 sec 
4 72°C 45 sec 
Repeat steps 2-4 for 35 cycles 
5 72°C 10 min 
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2.4 cDNA synthesis and RT-PCR 
Snap frozen samples (-80º C) were homogenised and RNA extracted using the 
RNeasy Micro Kit (Qiagen) with on-column DNase digestion according to 
manufacturer’s instructions.  Reverse transcription was performed using the 
Superscript VILO kit (Invitrogen) according the manufacturer’s instructions, 0.5 µg 
of RNA was used in each reaction.  Negative control samples (RT-) lacking 
transcription enzyme were also synthesised to identify contamination in further 
experiments. 
Target-specific PCR was performed to determine presence or absence of specific 
transcripts using 1 µl of the RT+ or RT- cDNA reaction in a reaction volume of 25 µl 
(Table 2.3).  Products were run on agarose gels (1-2.5%, Sigma) with a 100 bp ladder 
(Promega) using electrophoresis.  Primer pairs can be found in Table 2.4. 
 
Table 2.3 RT-PCR Reaction Mix 
Reagent Amount Used Manufacturer 
ImmoMix Red 12.5 µl Bioline 
25 µM Forward Primer 0.5 µl Eurogentech 
25 µM Reverse Primer 0.5 µl Eurogentech 
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Table 2.4 PCR Primer Pairs 
Gene 
Target 
Forward Primer Reverse Primer 
Product 
Size 
3β-HSD GCGGCTAATGGGTGGAATCTA CTGGCAGAAAGGAATGGGCC 101 bp 
AMH ACATCAGGCCCAGCTCTATCAC TGTTTGTGCAGGACAGACCC 151 bp 
BDNF AACAATAAGGACGCAGACTT TGCAGTCTTTTTGTCTGCCG 222 bp 
CNTF CAGGGCCTGAACAAGAACAT CTAAGAGCCTGGCCAACAAA 151 bp 
COX-1 TGTTCGGTGTCCAGTTCCAATA ACCTTGAAGGAGTCAGGCATGAG 95 bp 
COX-2 CCTTCCTCCTGTGCCTGATG ACAATCTCATTTGAATCAGGAAGCT 82 bp 
CYP11A1 CCAGACCTGTTCCGTCTGTT GAAGTTCTGGGTGTATATGTCAGC 99 bp 
DAZL GAAGGCAAAATCATGCCAAACAC CTTCTGCACATCCACGTCATTA 186 bp 
DESMIN GGAGATTGCCACCTACCG GGTCTGGATGGGGAGATTG 67 bp 
DKK1 GCGGGAATAAGTACCAGACCAT GGGACTAGCGCAGTACTCATCAGT 92 bp 
EP1 AGATGGTGGGCCAGCTTGT GCCACCAACACCAGCATTG 73 bp 
EP2 GACCGCTTACCTGCAGCTGTAC TGAAGTTGCAGGCGAGCA 71 bp 
EP3 GACGGCCATTCAGCTTATGG TTGAAGATCATTTTCAACATCATTATCA 87 bp 
EP4 ACGCCGCCTACTCCTACATG AGAGGACGGTGGCGAGAAT 64 bp 
GAPDH GACATCAAGAAGGTGGTGAAGC GTCCACCACCCTGTTGCTGTAG 212 bp 
GP130 CTGAATGGGCAACACACAAGTT CCAGACTTCAATGTTGACAAAATACA 107 bp 
ID3 CTCTTCAGGCCACAAGTTCAC GTGTCCTGACACCTCCAGAAC 192 bp 
IL6 GCCGCCCCACACAGACA CCGTCGAGGATGTACCGAAT 71 bp 
IL6R AGCTCAGATATCGGGCTGAA GGACTCCTGGATTCTGTCCA 202 bp 
INHBA GGCAAGTTGCTGGATTATAGTG CCACATACCCGTTCTCCCCGAC 272bp 
LIF TGGTGGAGCTGTACCGCATA TGGTCCCGGGTGATGTTG 64 bp 
LIFR TCAAAGGGGCCTGATACTTG CTGCTTTGTGCTGAGGATCA 178 bp 
MCL1 ATCTCTCGGTACCTTCGGGAGC GCTGAAAACATGGATCATCACTCG 221 bp 
NTF5 QUANTITECT PRIMAR Assay Hs_NTF5_1_SG (QIAGEN) 96 bp 
OCT4 ACATCAAAGCTCTGCAGAAAGAAC CTGAATACCTTCCCAAATAGAACCC 126 bp 
OSM ACAGAGGACGCTGCTCAGTC AGGAGTCTGCTGGTGTCCTG 150 bp 
OSMR TTGACAACCCGGAAGAAAAG TGAATCAGCATCGAGGAGTG 157 bp 
PROK1 GTGCCACCCCGGCAG AGCAAGGACAGGTGTGGTGC 65 bp 
PROKR1 TCTTACAATGGCGGTAAGTCCA CTCTTCGGTGGCAGGCAT 69 bp 
PROK2 TTGGGCGGAGGATGCA AAATGAAGTCCGTAAACAGGCC 65 bp 
PROKR2 GCTCTGTGCCTCCGTCAACT CCAGCAAGGCATTGGTGG 65 bp 
PTGES GAAGAAGGCCTTTGCCAAC GGGTTAGGACCCAGAAAGGA 168 bp 
RPL32 CATCTCCTTCTCGGCATCA AACCCTGTTGTCAATGCCTC 100 bp 
SMAD2 TTTCAGTTCCGCCTCCAATCGC CGTGAATGGCAAGATGGACG 208 bp 
SMAD3 TGAGGCTGTCTACCAGTTGACC CTAAGACACACTGGAACAGCGG 199 bp 
StAR GGCATCCTTAGCAACCAAGA ACTTTGTCCCCATTGTCCTG 62 bp 
VASA AAGAGAGGCGGCTATCGAGATGGA CGTTCACTTCCACTGCCACTTCTG 238 bp 
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2.5 Quantitative RT- PCR 
Quantitative real time PCR (qRT-PCR) was performed to etermine mRNA 
transcript levels using Applied Biosystems 7500Fast or 7900Fast instruments 
(specified in each chapter).  Standard curves for all targets were performed as 
described (Coutts et al, 2008) using either late second trimester fetal ovrian or 
endometrial cDNA to ensure proper reaction efficieny was achieved for each target.   
All measurements were performed in duplicate 10 µl reactions. 
For relative comparison, PowerSYBR Green Master Mix(ABI) was utilised and 
targets were analysed alongside a ubiquitously expressed ‘housekeeping’ gene 
(GAPDH or RPL32) and calculated as relative expression.  Each reaction was 
performed in a single well of a 96-well reaction plate (Applied Biosystems) as 
described in Table 2.5. 
Table 2.5 Sybr Green Reaction Mix 
Reagent Amount Used Manufacturer 
Sybr Green 5 µl Invitrogen 
25 µM Forward Primer 0.2 µl Eurogentech 
25 µM Reverse Primer 0.2 µl Eurogentech 
H2O 3.6 µl Ambion 
Sample (diluted 1/10 in H2O) 1 µl -- 
 
Some primers were designed and donated by the Henry Jabbour lab for Taqman 
multiplexing comparison using Express qPCR Super Mix with Premixed ROX 
(Invitrogen) (targets used in this manner are listed in Table 2.8).  Similarly, some 
primers were designed and donated by the Philippa Saunders lab and utilised for 
multiplexing comparision using the Universal Probe Library (Roche).  These primers 
alongside specifically designed probes were utilised with internal-well comparison 
marker 18s (ribosomal RNA control, Applied Biosystems).  Each target was 
calculated and presented as relative expression to this internal control in a reaction 
mixes are as described in Table 2.6 and 2.7. 
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Table 2.6 Taqman Reaction Mix  
Reagent Amount Used Manufacturer 
Super Mix 6.3 µl Invitrogen 
25 µM Forward Primer 0.2 µl Eurogentech 
25 µM Reverse Primer 0.2 µl Eurogentech 
5 µM Probe  0.5 µl Eurogentech 
18s  0.2 µl Applied Biosystems 
H2O 4.6 Ambion 
Sample (diluted 1/10 in H2O) 1 µl -- 
   
Table 2.7 Universal Probe Taqman Reaction Mix  
Reagent Amount Used Manufacturer 
Super Mix 7.5 µl Invitrogen 
200 nM Forward Primer 0.15 µl Eurogentech 
200 nM Reverse Primer 0.15 µl Eurogentech 
100 nM Universal Probe  0.15 µl Roche 
18s   0.1125 µl Applied Biosystems 
H2O 5.4375 µl Ambion 
Sample (diluted 1/10 in H2O) 1.5 µl -- 
 
Table 2.8 PCR Probes 
Gene Target Probe 
CYP11A1 Universal Probe Library (Roche) – Probe 11 
DESMIN Universal Probe Library (Roche) - Probe 55 
DKK1 TACCAGCCGTACCCGTGCGCAG 
PROKR1 TGCAGACCTGGACCTCAAGACAATTGG  
PROK2 CACTTGCCCATGTCTGCCAGGCT 
PROKR2 CCTGCGCACCGTCTCCCTCTACG 
StAR Universal Probe Library (Roche) – Probe 11 
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Data analysis was performed using GraphPad Prism version 5 (GraphPad Software 
Inc).  One-way ANOVA and t-tests were performed with post-testing as described 
for each chapter. 
2.6 Tissue Fixation, Processing, and Slide Prep 
Tissue was fixed in Bouins solution (Clintec) for 2-3 hours and then transferred to 
70% ethanol (VWR) for immunohistochemistry. 
Fixed tissue was processed in an automated Leica TP1050 processor and embedded 
in paraffin wax.  Paraffin blocks were cut via microtome into 5 µm thick sections and 
floated in a warm water bath to promote smooth tissue transfer. Sections were 
mounted on electrostatically charged glass slides (pink slides for human tissue, 
Thermo-scientific; white slides for animal tissue, L ica).  The slides were kept at 
50°C overnight in a slide oven to ensure tissue adhered to the slide surface.  
2.7 Haematoxylin and Eosin Staining 
2.7.1 Dewaxing and Rehydration 
Samples from each specimen were taken every 10th slide to determine tissue quality 
and orientation.  Slides were dewaxed and rehydrate through a series of alcohol 
gradients.  The slides are first put in xylene (VWR) twice for 5 min, then moved to 
absolute alcohol twice for 20 sec, 90% alcohol for 20 sec, 80% alcohol for 20 sec, 
70% alcohol for 20 sec, and finally in tap water.   
2.7.2 Counterstaining 
Slides were immersed in haematoxylin (Leica), a blue n clear counterstain, for 30-60 
sec.  Slides were washed in water to remove excess stain and immersed in acid 
alcohol (section 2.13) to remove non-specific cytoplasmic staining.  Slides were 
rinsed again in water to remove the acid alcohol and further immersed in Scott’s tap 
water (section 2.13) for 30 sec to allow the haematoxylin to develop.  Slides were 
then immersed in Eosin, (BD) a red cytoplasmic stain, for 1 min, and rinsed in tap 
water. 
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2.7.3 Dehydration and Mounting 
After counterstaining the slides were dehydrated in preparation for mounting.  This is 
done by immersing the slides in 70% ethanol for 20 sec, 85% ethanol for 20 sec, 
95% ethanol for 20 sec, and finally 100% ethanol twice for 20 sec each.  The slides 
were then immersed in xylene twice for 5 min. 
After dehydration the slides are mounted using glass coverslips (VWR) and Pertex 
(Histolab), mounting solvent based glue.  Air pockets were pushed away from the 
tissue section with pressure applied by forceps, and the slides left to dry.  The slides 
were analysed as described below and stored in dry sto age at room temperature. 
 
2.8 Immunohistochemistry 
Immunohistochemistry was used to for localisation and visualisation of target 
proteins in tissues of interest. 
 
2.8.1 Dewaxing and Rehydration 
Dewaxing and rehydration were performed as described a ove, moving the slides to 
antigen retrieval after the first series of alcohol immersions. 
 
2.8.2 Antigen Retrieval 
In order to ensure detection of proteins that may have been masked during the 
fixation process, the tissue is exposed to high temperature and pH change (Shi et al, 
1993).  Antigen retrieval was performed in 0.01 M citrate buffer with a pH of 6.0 in a 
standard domestic pressure cooker.  The slides were add d to 2000 ml of boiling 
citrate buffer (section 2.13) and the pressure cooker sealed for 5 min.  The pressure 
cooker was then taken off the heat source and the pressure released.  The slides were 
left to stand for 20 min, after which they were cooled with water. 
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2.8.3 Non-Specific Blocking 
To prevent non-specific detection by the primary or secondary antibody, the slides 
are blocked using peroxide blocking solution (section 2.13) rocking for 30 min (all 
rocking is performed at 20-40 rpm).  The slides are then washed in tris buffered 
saline (TBS) twice for five min. 
After peroxidase blocking, the slides are blocked for endogenous biotin, which is 
known to be prevalent in human tissue.  This is done via a strepavidin/biotin 
blocking kit (Vector).  The strepavidin solution is applied neat to the tissue for 15 
min incubation in a humidity chamber, and then the slides are washed in TBS twice 
for five min.  The biotin solution is applied as previously described for the 
strepavidin solution and the slides washed after incubation. 
To further prevent non-specific binding of the secondary antibody, the slides are 
incubated for 30 min in a blocking buffer consisting of normal serum (NS)(Biosera) 
diluted in TBS (1:4) containing 5% bovine serum albumin (NS/TBS/BSA) in a 
humidity chamber.  Normal goat serum (NGS) was used nless the primary antibody 
was raised in goat, in which case normal rabbit serum was used in the blocking 
buffer. 
2.8.4 Primary Antibody 
The blocking serum (NS/TBS/BSA) was then replaced with primary antibody diluted 
in blocking serum to an optimised concentration.  Concentration was determined for 
each antibody by titering the dilution of the antibody on standard tissue to find the 
maximum level of detection lacking non-specific background staining.  The primary 
antibody is left on the tissue overnight at 4° C.  The table below (Table 2.9) describes 
the antibodies used and optimum concentrations for fetal tissue.   
Appropriate negative and positive controls were included as appropriate.  Negative 
controls were done in two ways (as outlined in each chapter); adding no primary 
antibody to the serum for the overnight incubation, r adding antibody that was 
incubated with peptide to block binding and reveal any non-specific binding that may 
have occurred. 
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Secondary  Manufacturer 
BrdU 1:1000 Sheep Rabbit Anti-Sheep Fitzgerald 
COX1 1:50 Goat Rabbit Anti-Goat Santa Cruz 
COX2 1:50 Goat Rabbit Anti-Goat Santa Cruz 
CC3 1:75 Rabbit Rabbit Anti-Goat Cell Signaling 
EP1 1:700 Rabbit Goat Anti-Rabbit Cayman 
EP2 1:100 Rabbit Goat Anti-Rabbit Cayman 
EP3 1:2000 Rabbit Goat Anti-Rabbit Cayman 
EP4 1:250 Rabbit Goat Anti-Rabbit Cayman 
GP130 1:1000 Rabbit Goat Anti-Rabbit Santa Cruz 
LIFR 1:100 Rabbit Goat Anti-Rabbit Santa Cruz 
PHH3 1:3000 Rabbit Goat Anti-Rabbit Upstate 
PROK1 1:250 Rabbit Goat Anti-Rabbit Phoenix 
PROKR1 1:250 Rabbit Goat Anti-Rabbit Caltag 
PROKR1 1:100 Rabbit Polymer Sigma 
PROK2 1:50 Goat Rabbit Anti-Goat Santa Cruz 
PROKR2 1:50 Rabbit Goat Anti-Rabbit MBL 
PROKR2 1:250 Rabbit Goat Anti-Rabbit Lifespan 
PTGES 1:50 Rabbit Goat Anti-Rabbit Cayman 
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2.8.5 Secondary Antibody 
After washing off the primary antibody in TBS twice for five min, biotinylated 
secondary antibody (diluted 1:500 in blocking serum) was applied to the tissue and 
incubated in a humidity chamber for 30 min.  The secondary antibodies are raised 
against a species-specific sequence on the primary antibody.  Therefore the type of 
secondary used depends on both the primary antibody an  the NS used previously.  
Table 2.8 outlines which secondary was used with eac  antibody, and Table 2.9 
describes the secondary antibodies. 
For antibodies that were not readily detectable with standard secondary antibodies, a 
signal amplification polymer was used (Immpress reagent, Vector).  This polymer 
was used undiluted on slides in place of a secondary antibody and strepavidin (see 
Tabel 2.10), followed by standard detection.   
Table 2.10 Secondary Antibodies 
Antibody Manufacturer 
Goat Anti-Rabbit Vector 
Goat Anti-Rat Vector 
Rabbit Anti-Goat Dako 
Rabbit Anti-Sheep Vector 
 
2.8.6 Visualization of Antibody 
The secondary antibody was removed by rocking in TBS twice for five min.  
Streptavidin-horseradish peroxidase (HRP) (Vector) was diluted 1:1000 in TBS and 
applied to the slides for a 30 min incubation in the humidity chamber before being 
removed using TBS. 
Some antibodies with low detectability levels were incubated with Streptavidin-ABC 
(Vector) in place of HRP (as outlined in each chapter).  The complex was incubated 
for 30 min in an Eppendorf tube before usage as per manufacturer’s instructions.  
The Streptavidin-ABC was dropped onto slides and incubated for 30 min as in the 
above protocol for HRP. 
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Antibody localisation was determined using 3,3-diaminobenzidine (liquid DAB+, 
DAKO).  DAB chromagen was diluted in its buffer, according to the manufacturers’ 
instructions.  Sections were then incubated with DAB until staining was optimally 
detected (determined via use of light microscope).  This process usually took ~60 
sec, but possibly up to 5 min in some cases.  The reaction was stopped by immersing 
the sections in water.  
2.8.7 Counterstaining, Dehydration, and Slide Mount ing 
After antigen detection, the slides were counterstained using haematoxylin (no eosin) 
and mounted as described previously. 
2.9 Fluorescent Immunohistochemistry 
Fluorescent immunohistochemistry allows for more spcific protein localisation 
within a tissue.  It also allows antigens to be co-localised within the target tissue, so 
comparisons can be made.  The general protocol for fluorescent 
immunohistochemistry is similar to that of DAB Immunohistochemistry (section 2.7) 
with some exceptions as described below. 
2.9.1 Washes and Blocking Serum 
All washes between treatments were performed in phos ate-buffered saline (PBS) 
instead of TBS for fluorescent immunohistochemistry.  This also affects the blocking 
serum as it is changed to NS/PBS/BSA. 
2.9.2 Primary Antibody 
Concentration of primary antibody was adjusted as fluorescent detection is more 
sensitive.  See the table for the dilutions used for flu rescent immunohistochemistry. 
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Dilution Species Raised  Secondary  Manufacturer 
3β-HSD 1:5000 Rabbit Goat Anti-Rabbit Gift from Prof. 
Ian Mason 
EP2  1:4000 Rabbit Goat Anti-Rabbit Cayman 
EP4 1:2000 Rabbit Goat Anti-Rabbit Cayman 
OCT4 1:150 Goat Rabbit Anti-Goat Santa Cruz 
PROKR1 1:2000 Rabbit Polymer Sigma 
PROKR2 1:500 Rabbit Goat Anti-Rabbit Lifespan 
SMA 1:500 Mouse Goat Anti-Mouse Sigma 
VASA 1:300 Rabbit Goat Anti-Rabbit Abcam 
 
2.9.3 Secondary Antibody 
The secondary antibodies used for fluorescence wereperoxidase-conjugated (Table 
2.12) rather than biotinylated as they were retrieved in a slightly different way.   
Peroxidase antibodies were used at 1:500 and were dilut d in NS/PBS/BSA.  
Table 2.12 Secondary Antibodies 
Antibody Manufacturer 
Goat Anti-Rabbit Vector 
Goat Anti-Mouse Vector 
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2.9.4 Visualisation of Antibody 
Rather than using Strepavidin detection, fluorescent immunohistochemistry utilises 
tyramide detection (TSA-Plus cyanine 3 system, Perkin Elmer).  After the peroxidase 
secondary was washed off, a tyramide enhancement was applied diluted 1:50 in its 
own buffer as described by the manufacturer.  The slid s were then incubated in a 
dark humidity chamber for 10 min.  The tyramide was removed with PBS in an 
opaque container to prevent any bleaching of the fluorescence.  
2.9.5 Counterstain 
The counterstain used for fluorescence varied depending on the colour of detection 
used for the primary antibodies (Table 2.13).  They w re diluted 1:1000 in PBS and 
applied to the slides for a10 min incubation in a dark humidity chamber.   
 
Table 2.13 Secondary Antibodies 
Counterstain Manufacturer 
Propidium Iodide  (Red) Sigma 
Sytox Green  (Green) Invitrogen 
Dapi (Turquoise) Sigma 
 
 
2.9.6 Dehydration and Mounting 
Fluorescent immunohistochemical slides do not need to be dehydrated.  Instead they 
are mounted using Permaflur (Lab Vision Corp), a mounting medium for 
fluorescence.  The slides are then stored at 4°C in the dark. 
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2.10 Co-localisation by Fluorescent Immunohistochem istry 
In order to visualise two antigens in the same tissue the previous protocol (section 
2.8) was followed by additional citrate retrieval in a microwave oven for 2 min 
boiling followed by the slides resting in the warm buffer for 20 min.  Following the 
citrate retrieval, the above section (2.8) was repeated starting from the 
streptavidin/biotin blocking stage.  Slides were kept in the dark as much as possible 
to preserve fluorescence, and the strongest primary antibody (one used at the highest 
dilution) was used first. 
2.11 Microscopy 
2.11.1 Light microscopy 
Cellular sites of expression of target proteins were determined and slides 
photographed using a Provis AX70 (Olympus) microscope fitted with a camera 
(AxioCam HRc, Zeiss).  Scale bars were generated using measurement slides and 
Adobe Photoshop CS5.  This program was also used to compile photographic figures 
seen in the text. 
2.11.2 Fluorescent microscopy 
Slides were visualised using a Zeiss 510 META confocal microscope.  Scale bars 
were embedded using the Zeiss software and images compiled into figures using 
Photoshop CS5. 
2.11.3 Stereology / image analysis 
Image analysis was performed on histological sections t  quantify differences 
between treatment groups in various experiments.  Several forms of image analysis 
were utilised as described below with the assistance of an Imager.A1 microscope 
(Zeiss) fitted with a Qicam Fast 1394 camera (Qimaging) and a ProScan II (Prior) 
image tiling device.  Image-Pro Plus software (Media Cybernetics) was used to 
quantify images and calibrations were regularly checked. 
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Positive cells per area 
For germ cell, apoptosis, and proliferative counts cells were stained for appropriate 
markers and the number of positive cells directly quantified.  The area of the organ 
or tubule was determined.  The positive cell count was then divided by the area to get 
an index of positive cells per area (Figure 2.1). 
 
Figure 2.1  Screen shot of germ cells per area count 
Fetal rat ovaries were analysed using Image-Pro Plus software, that allowed for positively 
stained celsl to be quantified (red circles) and the area of the ovary to be measured 




Ovarian volumes were determined for e21.5 fetal rat ov ries by H&E staining every 
10th slide of the serial sectioned ovary.  A start and e point of the ovary was then 
determined and area taken from every slide containing ovarian tissue.  These areas 
were then averaged and multiplied by the number of slides between the start and end 
of the ovary to determine volume. 
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Germ cell nuclear diameter 
Quantification of nuclear diameter was performed as a measure of germ cell 
maturity.  This measure was taken by tri-secting the nucleus of a cell and the 
subsequent measurement of each diameter.  In order t  g t an accurate measurement 
of the variation of nuclear diameters in each specim n, multiple germ cells and slides 
were quantified as outlined in the following chapters. 
2.12 Protein Extraction and Quantification 
Proteins were extracted from primary tissue or cells with 50 µl RIPA buffer for 
primary tissue or 350 µl for cells (Section 2.13).  Cellular samples were then snap 
frozen (-80 ºC) for future use if not immediately needed.  Before use, samples were 
homogenised with an electronic pestle (Sigma) with disposable tips (Sigma).  This 
ensured maximum lysis of extracts.   
2.12.1 Bradford Assay 
Protein extracts were quantified by Bradford assay to determine concentration for 
further use.  This was performed with the DC Protein Assay Kit (Bio-Rad) according 
to manufacturer’s instructions, utilising a 96-well microplate (Corning).  After 15 
min incubation plates were scanned on a Multiskan EX microplate reader 
(Labsystems) at 590 nm.  Specimens were then compared to a BSA standard curve 
run on the same microplate to determine protein concentration. 
2.12.2 Western Blot 
Protein samples were diluted in dH2O to 30 mg in 13 µl.  Thereafter, 5 µl of 4x SDS 
loading buffer and 2 µl of reducing agent (2-Mercaptoethanol, Sigma Aldrich) were 
added to each sample before denaturing at 85° C for5 min on a Thermomixer 
(Eppendorf).  Samples were cooled on ice and spun down (Eppendorf 5415D 
centrifuge) before loading into a 12% tris-HEPES-SDS Precise Protein gel (Thermo 
Scientific) alongside SeeBlue Plus2 protein standard (Invitrogen).  Gels were run in a 
protein electrophoresis system (Bio-Rad) with running buffer (tris-HEPES SDS 
Buffer, Thermo Scientific) at 125v utilising a Powerpac (Bio-Rad) for 45-60 min or 
until the loading dye had run to the bottom of the gel.
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Gels were then removed and washed in dH2O for 10 min, then washed in transfer 
buffer (fast semi-dry buffer, Thermo Scientific) for 10 min.  PVDF membrane 
(Millipore) was cut to the appropriate size for thegel and prepared for transfer by 
washing 1 min in methanol, 1 min in dH2O, and 5 min in transfer buffer.  Filter paper 
was prepared by soaking in transfer buffer.  The gel and membrane were loaded with 
the filter paper into a semi-dry blotter as per manuf cturer’s instructions and run at 
25v for 7-9 min depending on protein size. 
The membrane was collected after transfer and washed in dH2O, before being 
blocked in blocking buffer (1:1 PBS tween: Li-cor blocking buffer (Odyssey)).  
Primary antibodies were diluted in blocking buffer and the membrane was left to 
incubate at 4 °C overnight. 
Membranes were washed in PBS tween the following morning for 15 min, then twice 
for 5 min, before being incubated with fluorescently labelled secondary antibodies 
diluted in blocking buffer for 1 hr at room temperature in the dark.  Membranes were 
then washed x4 for 5 min in PBS tween, again in the dark, before detection on the Li-
Cor Infrared Imaging System (Odyssey). 
2.13 Cell / tissue culture  
2.13.1 Stable transfection of PROKR1 T-Cam2 cells 
In order to fully examine PROK1 signalling via PROKR1, the T-Cam2 germ cell line 
was stably transfected with the PROKR1 receptor.  The creation of the PROKR1 
construct was performed by Dr. Pamela Brown as follows:  
The PROKR1 gene was subcloned from an Ishikawa vector (Evans et al, 2008) into a 
pLENTI6-derived destination vector containing a prolactin (PRL) peptide to ensure 
the receptor was expressed.  A sequence for Blasticidin resistance was also part of 
the construct and used for later selection.  
Cells were transfected alongside a similar construct containing GFP, as a positive 
control for transfection.  
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Linearisation 
Both constructs (GFP and PROKR1) were linearised using the restriction enzyme 
NaeI (New England Bio) as per manufacturer’s instructions before transfection, in 
order to increase the number of cells integrating the plasmid in their DNA.  Cells 
were also transfected with the plasmid uncut (super-coiled), as this increased the 
number of plasmids to enter the cells initially.  A 2 µl sample of the linearised 
plasmid and supercoiled plasmid were run on a gel to verify the linearised sample 
was fully cut before transfection. 
Ethanol Precipitation and Quantification of DNA 
 Digested plasmid was then purified and concentrated using ethanol precipitation.  
This was performed by adding 100 µl dH2O to the plasmid, followed by 20 µl 
Sodium Acetate (Sigma) (3M, pH 5.2) and 3 volumes of pure ethanol (660 µl).  This 
was mixed and incubated at -20º C for 20 min to speed up precipitation of DNA.  
The sample was then centrifuged at full speed for 10 min at 4 ºC and the supernatant 
carefully removed.  Then 500 µl 70% ethanol was added to remove salt and further 
spun at 4 ºC for 5 min.  The supernatant was removed and the tube left open for the 
remaining ethanol to evaporate.  The pellet was re-suspended in 20 µl TE and left at 
4 ºC overnight.  Plasmids were quantified using a Nanodrop spectrophotometer 
(Thermo Scientific). 
Transfection 
Cells were plated in 150mm diameter cell culture plates (Corning) 2 days prior to 
transfection to ensure maximum transfection efficien y.  15 µg of DNA from each 
plasmid was incubated with 60 µl TransIT –LT1 transfection reagent (Mirus) for 20 
min in an Eppendorf tube.  The solution containing the plasmid was then dropped 
onto the plates with newly added media and mixed by gentle rocking. 
The T-Cam2 cells were left overnight with the transfection solution in the media.  
The next morning medium was changed on the plates and a selection medium was 
applied, consisting of normal T-Cam2 medium with 10 µg/ml Blastacidin 
(Invivogen).  This killed off any cells that had not been transfected, or in which the 
plasmid was not correctly integrated.  This selection medium was used for 12 days 
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post transfection and the medium was changed every 2 days to ensure dead cells 
were removed promptly (prevented transfected cells from being adversely affected 
by dying cells).   
PROKR1 T-Cam2 cells were then trypsinised as in normal passaging (section 
2.10.11), and kept in a 25 cm2 flasks. Standard maintenance medium as described in 
section 2.13 was then used (with only 2 µg/ml Blasticidin).  At this stage linearised 
transfections were abandoned as transfection was low if at all successful.  All 
experiments were done using the supercoiled plasmid for PROKR1.  Cells were 
frozen periodically for stock in 1.5 ml Bambanke frezing medium (Lymphotec).  
Heightened expression of PROKR1 was confirmed via qRT-PCR and Western blot 
analysis. 
2.13.2  Stable cell culture maintenance 
T-Cam2 wild-type and PROKR1 transfected cells were k pt in T-Cam2 medium as 
described below (Section 2.14) at 37 °C with 5% CO2.  The cells were maintained in 
162cm2 flasks and passaged every 3-4 days using 0.5% Trypsin/EDTA (Gibco).  
Trypsin was added for 5 min and cells were put back in the incubator to accelerate 
their detachment.  Cells were then split 1:4 in the case of wild-type or 1:3 in the case 
of PROKR1 cells. 
Ishikawa cells stably transfected with the PROKR1 gene (Evans et al, 2008) were 
used as a positive control.  They were maintained i the media described in Section 
2.14 in the same culture conditions as the T-Cam2 cells.  They were split every 3-4 
days at a ratio of 1:5. 
2.13.3 Organ culture 
For organ culture analysis of fetal gonads, tissue was micro-dissected as described 
above (Section 2.1).  First trimester gonads were halved, with one piece of each 
gonad going into the treatment group and the other into control (Table 2.13).  Second 
trimester gonads were dissected into small pieces which were randomised and put 
into treatment groups.  Small pieces of tissue were tak n from each specimen as a 
‘time 0’ control to determine tissue quality before b ing put into culture. 
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Droplets of 30 µl of organ culture media (as described in section 2.14) were placed 
on the lid of a 10cm2 square dish (Corning).  Each piece of gonad was delicat y 
placed into the droplets using needles.  The bottom of the dishes was filled with 10ml 
dPBS (Gibco) to keep tissue hydrated.  The lid was then quickly turned and placed 
on top of the bottom of the dish, suspending the organ pieces in the media.  This 
technique was devised to mimic in vivo surface tension and prevent necrotic effects 
of direct exposure to culture plates and/or filters, and has been utilised successfully 
for fetal gonad culture in several organisms, thus potentially proving a better model 
for human fetal culture possibly resulting in better issue quality post-culture (Zhang 
et al, 2008; Szczepny et al, 2009).   
Tissue was removed from the media droplets after the appropriate amount of time 
(Table 2.14) and snap frozen (-80 °C) or fixed for further analysis. 
Table 2.14 Organ culture treatments 
Treatment Manufacturer Amount Tissue/Purpose Culture Time 
PGE2 Sigma 100nM Ovary/Histology 8 or 24 hours (as specified) 
PROK1 Peprotech 40nM Ovary and Testis/Culture 24 hours 
2.13.4 Testicular interstitial cell culture 
Fetal testes were removed from early second trimester fetal specimens and 
extraneous material removed via micro-dissection.  The testes were then transferred 
into a glass dimple slide containing 100 µl Collagenase IV (Sigma) (1mg/ml in 
HBSS (Sigma)) and teased apart using needles until pieces were small enough to 
pipette.  Tissue was then transferred into a 1.5 ml tube (Eppendorf) and the slide 
washed 4 times with 100 µl Collagenase each time adding wash to the tube (making 
the total volume 500 µl). 
The sample was incubated at 37 ºC for 5 min, mixing at 650 rpm (Thermomixer, 
Eppendorf).  The sample was mixed via pipetting to ensure a one-cell suspension and 
incubated for a further 5 min.  DNase I (Sigma) (10µl of 10mg/ml in HBSS) was 
added to the suspension to reduce viscosity and samples were then incubated for a 
further 5 min with this addition. 
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To remove the Collagenase, the cells were centrifuged at 800g for 5 min.  The 
supernatant was discarded and the sample re-suspended in 1 ml HBSS.  This wash 
process was repeated for a second time, and a small portion of cells removed for a 
‘time 0’ control.  Cells were then washed in testis culture medium (Section 2.13) 
spun down a final time, and re-suspended in 1 ml medium.  Cells were run through a 
70 µm cell strainer to ensure a single-cell suspension, and plated into 2 wells of a 6-
well plate (500 µl each well) that had been coated with 0.1% sterile gelatine (Sigma). 
Cells were allowed to adhere to the plate surface overnight.  Medium was changed in 
the morning, with one well getting 40 nM PROK treatment and the other receiving 
the dH2O vector control.  Cells were left to incubate for 24 hours, and then lysed in 
RLT buffer for mRNA analysis.   
2.14 Commonly Used Solutions 
Acid Alcohol 
Acid alcohol is prepared using 70% ethanol with 1% concentrated HCl. 
Blocking Serum 
Normal serum (Biosera) was diluted 1:4 in TBS or PBS as appropriate with 5% 
bovine serum albumen (BSA) (Sigma). 
Citrate Buffer 
42.02g Citric acid monohydrate was diluted in 900 ml distilled water, and brought to 
pH 6.0 using NaOH. 
Freezing Medium 
Storage of cell lines was performed by freezing cells down in Bambanker freezing 
media (Lymphotec). 
Ishikawa Medium 
PROKR1 transfected Ishikawa cells were cultured in Dulbecco’s Modified Eagles 
Medium (DMEM) with Glutamax (Gibco), supplemented with 10% heat inactivated 
fetal bovine serum (FBS) (Gibco), 200 µg/ ml G418 (Invivogen). 
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Ishikawa Starving Medium 
PROKR1 transfected Ishikawa cells were starved in DMEM Glutamax, with no 
supplementation. 
Peroxide Blocking Solution 
3% by volume hydrogen peroxide (Fisher Scientific) (30mls of 30%) added to 
methanol (270 mls) (Fisher Scientific). 
NP40 / RIPA Lysis Buffer 
Lysis buffer was prepared with 150 mM NaCl (Sigma), 50 mM Tris.HCl, pH7.5 
(Sigma), 1% NP40 and 0.25% sodium deoxycholate brought to pH 7.4 with HCl.  A 
protein inhibitor mini tablet (Roche) and 20 µl sodium vanadate (New England 
Biolabs) per 10 ml of solution was added immediately before use. 
Organ Culture Media 
Fetal testis and ovary samples were cultured whole or in pieces (1mm2) in αMEM 
(Gibco), supplemented with 3% BSA, 1% 100x Non-Essential Amino Acids 
(NEAA) (Gibco), 1% 200mM L-glutamine, 1% Penicillian-strepromycin (Lonza), 
1% Sodium pyruvate (Gibco), and 0.002% ITS (Lonza).  Media was filter sterilised 
before use. 
Phosphate-Buffered Saline (PBS) 
PBS used for fluorescent immunohistochemistry and western blotting was prepared 
by adding 1 PBS tablet (Sigma) consisting of 0.01M phosphate buffer, 0.0027 M 
potassium choloride, and 0.137 M NaCl with a pH of 7.4 to 200 ml distilled water. 
Scott’s tap water 
Scott’s tap water was prepared by adding 10 g Potassium hydrogen carbonate and 
100 g Magnesium sulphate to 5000 ml tap water. 
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T-Cam2 Medium 
T-Cam2 cells were cultured in RPMI medium, supplemented with 10% heat 
inactivated FBS and 1% 100x L-glutamine. Blasticidin (2 µg/ml) was added to 
PROKR1 transfected T-Cams only. 
T-Cam2 Starving Medium 
T-Cam2 cells were starved in RPMI medium, supplemented with 2mM L-glutamine. 
Testicular Interstitial Culture Medium 
Interstitial cell cultures derived from fetal testis ssue, were maintained in phenol-
red free DMEM, supplemented with 10% FBS, 1x NEAA2mM L-glutamine, 1% 
Penicillian-strepromycin, 1% amphotericin (Sigma), and 1% D-(+)-Glucose (45% 
solution; Sigma).  In addition, 10 IU of hCG was adde  to each ml of medium to 
ensure normal steroidogenesis was promoted.  Medium was filter-sterelised before 
use. 
Tris-Buffered Saline (TBS) 
TBS used for DAB immunohistochemistry was prepared by adding 121.1g Tris base 
(Sigma) and 170g NaCl to 2000 ml distilled water, and brought to pH 7.4 with HCl. 
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Chapter 3. Prostaglandin E2 in fetal ovarian develo pment 
3.1 Introduction 
PGE2 is a potent mediator of cellular migration, proliferation, and vascularisation 
(Diazflores et al, 1994; Wang & DuBois, 2006).  Within female reproduction, PGE2 plays 
well-recognised and important roles in tissues such as the ovary, endometrium, 
myometrium, and cervix (Oates t al, 1988b; Oates et al, 1988a; Sales & Jabbour, 
2003a). PGE2 is a well-characterised regulator of ovulation and fertilisation but its role in 
early ovarian development or function has not been investigated.  Despite this lack of 
information, it is known that PGE2 and other prostaglandins such as PGD2 can induce 
expression of the neurotrophins, known regulators of early ovarian development 
(Anderson et al, 2002b; Spears et al, 2003; Kerr et al, 2009; Childs et al, 2010a), in 
astrocyte cultures (Toyomoto et al, 2004).  In addition to Toyomoto’s work, recent 
studies conducted by colleagues at the University of Edinburgh have also identified PGE2 
as a mediator of the neurotrophins in the human femal  reproductive tract (Jabbour, 
unpublished).  This link suggests PGE2 may play an up-stream role in the pathway 
controlling human ovarian development and possibly primordial follicle formation. 
PGE2 is derived step-wise from arachadonic acid by the cyclooxygenase enzymes 
(COX1 and 2), and the PGE2 specific synthase, PTGES (Figure 3.1) (Funk, 2001).  
COX1 and 2 play differing roles in the production of d wnstream prostanoids, as 
COX1 is constitutively expressed in many cell types, whereas COX2 is an inducible 
enzyme synthesised in response to cytokine action (Sales & Jabbour, 2003b).  
PTGES, unlike the COX enzymes, is a specific terminal prostanoid synthesis enzyme 
which controls conversion of PGH2, a prostanoid intermediate, to PGE2 (Forsberg et 
al, 2000).  After synthesis, PGE2 signals through one of four GPCRs (EP1-4) to elicit 
its targeted response (Narumiya et al, 1999).  The EP receptors are able to regulate 
differing downstream intracellular cascades (Section 1.10; (Alfranca et al, 2006)), 
allowing PGE2, to mediate various functions in the same tissue (Coleman et al, 1994).  
Additionally, as PGE2 is a lipid mediator with a short half-life, causing its action to be 
restricted to cells close to sites of PG secretion, his allows for paracrine or autocrine 
regulation, and thus cell specific control, as compared to hormones which can act 
systemically (Negishi et al, 1995). 




Figure 3.1 Prostaglandin E2 synthesis and signalling pathway. 
PGE2 is synthesised from arachidonic acid by the action of the cyclo-oxygenase enzymes 
(COX1 or 2) to produce the intermediate PGH2.  This intermediate is further converted by 
specific terminal enzymes such as PTGES (in the case of PGE2) to form prostanoids 
including PGD2, PGE2 and PGF2α.   After synthesis PGE2 is able to signal via four G-
coupled protein receptors (EP1-4).  Synthesis enzymes are noted in red, lipids in blue 
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In order to fully explore what role PGE2 might play in early ovarian development, the 
expression of its precursor enzymes (COX1, COX2, and PTGES) as well as its 
receptors (EP1-4) were characterised.    These enzyme and receptor targets were 
examined across the first and second trimester, with bo h transcript levels and protein 
localisation identified.  Receptors which were deemd to have discreet germ cell 
localisation were further inspected to determine if their expression was limited to a 
specific subset of oogonia.  In addition, human fetal ovarian tissue was cultured with 
PGE2 and analysed for alteration in expression of germ cell markers and known 
regulatory factors.  Subsequent cultures were performed to identify histological 
changes to further identify a function for PGE2 in the developing ovary.   
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3.2 Materials and Methods 
Tissue collection 
Human fetal tissue used in the following experiments was obtained and dissected as 
described previously (Section 2.1), with subsequent SRY genotyping to determine 
sex of first trimester specimens (Section 2.3). 
RNA extraction and cDNA synthesis 
Sample tissue was then processed to extract RNA and subsequently cDNA 
synthesised for genomic analysis as previously discussed (Section 2.4). 
Quantitative RT-PCR 
In order to determine if mRNA transcripts encoding PGE2 precursor enzymes 
(COX1, COX2, and PTGES) and receptors (EP1-4) varied across gestation, qRT-
PCR was performed using the ABI 7500Fast system and either SYBR Green or 
Taqman analysis as described in Section 2.5. 
Quantitative RT-PCR analysis of human fetal cultures was also performed using the 
ABI 7900HTFast system and SYBR Green analysis to deermine any changes in 
germ cell marker expression (OCT4, VASA, DAZL) and known ovarian regulators 
(BDNF, NTF5, MCL-1, INHBA, SMAD2, SMAD3); details of this protocol are also 
outlined in Section 2.5. 
Immunohistochemistry 
Human fetal ovarian samples were used to localise PGE2 precursor enzymes (COX1, 
COX2, and PTGES) and receptors (EP1-EP4) to determin  cell-specific sites of 
PGE2 synthesis and action.  Varying germ cell maturity markers were also utilised to 
determine if specific receptors were developmentally related (VASA, OCT-4).  
Finally, immunohistochemistry was also utilised to determine changes in apoptosis 
(CC3) and proliferation (BrdU).  Protocols for these localisations can be found in 
Section 2.8. 
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Human fetal ovarian culture 
Second trimester fetal ovaries (n= 6, 15-17 weeks gstation) were cultured as small 
explants on culture inserts as described previously (Martins da Silva et al, 2004).  
Tissue was cultured using organ culture media as described in Section 2.13.  Tissue 
was split into 3 treatment groups: no treatment, 3 µg/ml indomethacin (Sigma) with 
vehicle (ethanol), or 3 µg/ml indomethacin with 100nM PGE2.  Indomethacin was 
utilised to reduce endogenous PG production which may have masked effects of the 
exogenous PGE2 treatment.  Tissue cultured for transcript expression analysis was 
cultured for 8 hours, subsequently snap-frozen (-80 °C) followed by RNA extraction 
as described in Section 2.4.  These cultures were performed by Dr. Rosey Bayne.   
A second series of experiments were performed for histological analysis (n=5, 15-17 
weeks gestation). Tissue was cultured in hanging drops with treatment as above for 
24 hours with BrdU and subsequently fixed in Bouins solution and processed as in 
Section 2.5. 
Stereology/Image Analysis 
Histological changes after PGE2 treatment in the human fetal ovary were determined 
via image analysis using various markers as described in section 2.10.9. 
Measurements of proliferation were performed using 5 slides from each sample at 
least 10 sections apart (50 microns).  Positive cells (BrdU) were counted and ovarian 
area taken (necrotic tissue as the result of the culturing process was not taken in to 
account in this analysis, and the amount of necrotic tissue was not seen to vary 
between treatment groups). This method was deemed to be more than necessary for 
accurate quantification, with subsequent apoptotic counts (CC3) performed on 3 
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Statistical Analysis 
Quantitative RT-PCR data were analysed with GraphPad Prism version 4 statistical 
software (GraphPad Software Inc).  Gestational comparision data were analysed 
using one-way ANOVA, data were then either analysed as escribed or log-
transformed for further analysis.  Log-transformation was performed in instances 
where data sets did not fit a Gaussian distribution.  The Kolmogorov-Smirnov 
normality test was used for this purpose.    
Data were then analysed utilising the Newman-Keuls Multiple Comparison post-test 
to determine significant changes between gestational values.  This post-test was 
chosen as has more strength than a Tukey post-test and the risk of type I error does 
not occur with only three groups (as in our study).  Some data was also analysed 
using a post-test for linear trend, this test was performed when data were in a natural 
order (ie across gestation). 
Gene expression changes identified using qRT-PCR after PGE2 treatment of human 
fetal ovaries were also analysed using GraphPad Prism as above.  Data were 
analysed using paired t-tests on log-transformed data comparing PGE2 treated tissue 
to indomethacin-only treated tissue (as the appropriate control). 
Stereology/image analysis data were analysed using the above statistical software, 
with Student’s t-test to determine difference between treatment groups.




3.3.1 Precursor enzymes of PGE2 are up-regulated at  initiation 
of primordial follicle formation 
To determine the presence and pattern of expression of mRNA transcripts encoding 
PGE2 precursor enzymes during human fetal ovarian development, qRT-PCR was 
performed for COX1, COX2 and PTGES across a range of gestations.  Ovarian 
specimens were grouped into three gestational stages o broadly reflect the key 
developmental events of early to mid-gestation ovarian development, namely the 
proliferation of undifferentiated PGCs (8-11 weeks ge tation), the formation of germ 
cell nests and entry of the first germ cells into meiosis (13-16 weeks), and on-going 
meiotic entry and the onset of primordial follicle formation (17-20 weeks). 
Transcripts encoding all precursor enzymes were detcted in the human fetal ovary, 
as shown in Figure 3.2.  Expression of transcripts encoding COX2 increased across 
gestation, being expressed at low levels at 8-11 weeks gestation (0.5±0.2 x10-7, 
relative to the housekeeping gene GAPDH), increasing at 13-16 weeks gestation 
(3.9±1.0 x10-7 relative to GAPDH) and again at 17-20 weeks gestation (5.4±2.2 x10-7 
relative to GAPDH, linear trend p=0.02, n=5-7 per group, Figure 3.2B).  
Additionally, the PGE2 specific enzyme PTGES was significantly decreased at early 
second trimester compared with both first and late second trimester (2.3±0.2 and 
1.8±0.2 compared to 0.8±0.1 x10-1 relative to GAPDH, p= 0.002 and 0.008 
respectively, Figure 3.2C).  However, no change was seen in the transcripts encoding 
the constitutively expressed precursor enzyme COX1 (p= 0.79, Figure 3.2A).  These 
data reveal transcripts encoding the PGE2 precursor enzymes COX2 and PTGES are 
up-regulated in late second trimester coincident with initiation of primordial follicle 
formation.  In addition, PTGES, which specifically s nthesises PGE2 , displays a bi-
phasic pattern as it is heightened in first trimester as well as late second trimester.   
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Figure 3.2 Genes encoding the PGE2 precursor enzymes are up-
regulated at initiation of primordial follicle formation. 
Expression of the three enzymes necessary to synthesise PGE2, was analysed by qRT-
PCR across gestation and split into age groups concordant with gestational events; 
PGC proliferation in 8-11 weeks (1st T), meiosis and germ cell nest formation in 13-
16 weeks (Early 2nd T), and primordial follicle formation in 17-20 weeks (Late 2nd T; 
n= 5-7 samples for each gestation).  (A) Expression of COX1 did not change during 
early ovarian development.  (B)  COX2 expression was significantly up-regulated at 
late 2nd trimester (*=p<0.05 determined by test for linear trend).  (C)  Transcript levels 
for PTGES were significantly increased at both 1st and late 2nd trimester, compared 
with expression at early 2nd trimester gestation (**=p<0.01).  All data are expressed as 
a relative expression, normalised to the housekeeping gene GAPDH. 
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3.3.2  EPs required for PGE 2 signalling are expressed and 
developmentally regulated in the fetal ovary 
 
Further examination was performed to determine the expression of transcripts 
encoding the four GPCRs necessary for PGE2 signalling using the gestational range 
outlined above.  EP1, 2, and 4 displayed similar expr ssion patterns (Figure 3.3 A, C, 
D), increasing transcript expression with increasing gestational age.  However, only 
EP4 showed a significant change across gestation. Expression of EP4 was low at 8-
11 weeks gestation (0.5±0.3 x10-3 relative to GAPDH), increased at 13-16 weeks 
(1.1±0.3 x10-3 relative to GAPDH) and again at 17-20 weeks gestation (1.6±0.3 x10-3 
relative to GAPDH, linear trend p= 0.3, Figure 3.3D).  EP1 and EP2 displayed a 
similar trend, however this did not reach significan e (p=0.16 and 0.35 respectively).  
EP3 did not show a similar trend to the other receptors, displaying high variability in 
early 2nd trimester, with no significant changes in transcript expression across 
gestation (p=0.49, Figure 3.3B).  Outwith expression pattern, it is also notable that 
EP3 and EP4 are expressed at higher levels than that of EP1 and EP2.  These data 
suggest EP3 and EP4 may play a more predominant role during human fetal ovarian 
development, and that the role of EP4 increases with development leading to 
primordial follicle formation. 




Figure 3.3 PGE2 receptor mRNA expression across gestation 
Expression of the four receptors (EP1-4) necessary for PGE2 signalling, was analysed 
by qRT-PCR across gestation and split into age groups concordant with gestational 
events; PGC proliferation in 8-11 weeks (1st T), meiosis and germ cell nest formation 
in 13-16 weeks (Early 2nd T), and primordial follicle formation in 17-20 weeks (Late 
2nd T; n= 4-6 samples for each gestation).  Expression of (A) EP1 (B) EP2 and (C) 
EP3 did not change during early ovarian development. (D) Transcript levels for EP4 
are significantly up-regulated across gestation (*=p<0.05, determined by test for linear 
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3.3.3  Developmentally-regulated precursor enzymes are germ 
cell specific 
 
To determine the site of PGE2 production, immunohistochemistry was performed 
using human fetal ovarian tissue to detect the precursor enzymes required for PGE2 
synthesis.    COX1 protein was localised to the pre-granulosa cells closely associated 
with germ cells within the germ cell nests.  No expression was seen in the germ cells 
or the interstitial cells within stromal cell streams (Figure 3.4A-B).  Conversely, 
COX2 was not seen in pre-granulosa cells or stromal cell streams; rather being 
expressed in a germ cell-specific manner with varying intensity of expression seen in 
specific germ cells and distinct staining of primordial follicles (Figure 3.4C-D).  
PTGES, the PGE2 specific enzyme, was also germ cell-specific with consistent 
expression throughout the germ cells (Figure 3.4E-F).  The expression patterns noted 
for the PGE2 precursor enzymes determines that PGs in the ovary can be derived 
from the breakdown of arachadonic acid by COX1 in the pre-granulosa cells or by 
COX2 in the germ cells, but that final conversion into functional PGE2 occurs 
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Figure 3.4 Immunohistochemical detection of the PGE2 precursor 
enzymes in the human fetal ovary. 
Prostaglandin synthesis enzymes were localised in second trimester human fetal 
ovarian tissue tissue using 3,3′-diaminobenzidine tetrahydrochloride staining (brown). 
(A-B) COX1 is pre-granulosa cell specific, staining somatic cells within the germ cell 
nests. (C-D) COX2 is germ cell specific, with no staining detected in stromal cell 
streams or pre-granulosa cells.  Additionally, intensity of COX2 staining varied 
between neighbouring germ cells.  (E-F) PTGES was also localised to germ cell nests 
but expression was consistent across germ cells.  Scale bars equal 50 microns (A, C, 
and E) and 10 microns (B, D, and F).  Images are a composite of several stained 
tissues, with each antibody utilised on at least three separate tissues from specimens of 
varied ages to confirm localisation and identified any differences in expression across 
gesetation. 
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3.3.4  PGE2 receptor expression is primarily localised to the 
germ cells in the human fetal ovary 
 
In order to determine the cell-specific sites of PGE2 action in the human fetal ovary, 
immunolocalisation was performed to detect each of t e four EP receptors.  EP2 and 
EP4 displayed similar sites of expression, with the germ cells appearing to be the 
sole location for both receptors (Figure 3.5C, D, G, and H).  However, EP2 and EP4 
localisation was discrete, with EP2 staining only expr ssed in the more central germ 
cells (ie the most mature) with distinct staining of primordial follicles, whereas EP4 
staining was primarily localised to the immature germ cell population near the 
periphery of the ovary.  EP3 displayed expression in both pre-granulosa cells and 
germ cells within germ cell nests, as well as strong expression in the epithelial layer 
of the ovary (Figure 3.5 E-F).  EP1 expression was notably weaker than that of the 
other EP receptors, with expression in cells lining blood vessels and the blood cells 
within, but no notable expression in surrounding ovarian tissue (Figure 3.5A-B).  
These data demonstrate that three of the EP receptors are capable of directly 
regulating the germ cells, and germ cells appear to be the sole site of expression of 
EP2 and EP4.  Additionally, these data also highlight the possibility that EP2 and 
EP4 may play a role in distinct subsets of germ cells.










Figure 3.5  Immunohistochemical detection of the PGE2 receptors in 
the human fetal ovary. 
The PGE2 receptors EP1-4 were localised in second trimester ova ian tissue using 3,3′-
diaminobenzidine tetrahydrochloride staining (brown).  (A-B) EP1 was limited to the blood vessels 
(BV) with no staining of germ cells (GC).  (C-D)  EP2 was localised to a discreet population of GC 
and primordial follicles (PF) with no staining seen near the periphery of the ovary, in somatic cells 
(SC) or pre-granulosa (PG) populations. (E-F) EP3 was the most ubiquitously expressed PGE2 
receptor with clear staining throughout the GCs and PGs, with additional staining in the epithelial 
layer (EP).  (G-H) EP4 was localised to the GCs, and ppeared to display more expression near the 
periphery of the ovary and less in the medulla.  Scale bars equal 100 microns (E, G, and C), 50 
microns (A and F) and 10 microns (B,D, and H).Images are a composite of at least three separate 
tissues from specimens of varied ages. 
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3.3.5 EP2 and EP4 rarely co-localise in the human f etal ovary 
To further determine site-specific roles of EP2 andEP4, co-localisation was 
performed in second trimester ovarian tissue.  Both EP2 and EP4 were expressed as 
previously demonstrated in Figure 3.5; EP2 was expressed discreetly in the centre of 
the ovary, whereas EP4 expression was more widespread but concentrated at the 
periphery (Figure 3.6).  Low magnification images suggest little co-localisation of 
the two receptors (Figure 3.6A); however, higher magnification shows that the 
receptors are expressed in the same cells near the middle of the ovary (Figure 3.6B).  
Expression of the receptors on co-localised cells wa often not interspersed, rather 
one side of the cell expressed EP2 and the other EP4.  These images demonstrate that 
although EP2 and EP4 receptors are primarily expressed in differing germ cell 
populations, their sites of action are not mutually-exclusive.  Additionally, they often 



















Figure 3.6 Co-localisation of EP2 and EP4 in the human fetal ovary. 
The germ cell-specific receptors EP2 and EP4 were examined in 17 week gestation 
human fetal ovarian tissue.  (A) EP2 (red) and EP4 (green) were expressed in the germ 
cells (GC) of the human fetal ovary with rare co-localisation (yellow).  (B) Cells in 
which both receptors were co-expressed showed polarloc lisation of the two receptors 
with EP2 on one side and EP4 on the other (arrow).  Dapi counterstain (blue) was 
utilised and scale bars equal 20 microns.  Images are representative of staining 
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3.3.6 EP2 expression is limited to more mature oogo nia and 
oocytes within primordial follicles 
As EP2 expression appeared to be restricted to maturing germ cells, co-localisation 
with the immature germ cell (PGC) marker OCT4 was performed, alongside co-
localisation with a mature germ cell marker VASA (Anderson, 2007).   No co-
localisation of EP2 and OCT4 was determined in the human fetal ovary (Figure 3.7).  
OCT4 was seen to stain the immature PGCs on the periphery of the ovary, whereas 
EP2 was localised to the centre of the ovary (Figure 3.7A).  There was some 
interspersion of OCT4 positive cells nearer to the centre of the ovary but none of 
these cells expressed EP2 (Figure 3.7B).   
VASA expression was shown in most germ cells in the human fetal ovary, bar the 
PGC layer near the epithelium of the ovary (Figure 3.8A).  EP2 was also lacking in 
these PGCs, but EP2 expression was restricted to an even more mature population 
than that of VASA, with a distinct band of VASA positive germ cells nearer the 
periphery that were EP2 negative.  In addition, in the centre of the ovary, primordial 
follicles could be identified which contained oocytes positive for both VASA and 
EP2.  These data demonstrate the PGE2 receptor EP2 is exclusively located on the 














Figure 3.7 EP2 is not expressed by PGCs in the human fetal ovary 
 
EP2 (red) and the immature germ cell marker OCT4 (green) were dual expressed in 
19 week human fetal ovarian tissue. (A) OCT4 was restricted to a band of PGCs near 
the epithelium of the ovary, whereas EP2 expression was concentrated in the more 
mature germ cells.  (B) Some OCT4 positive cells were more centrally localised, but 
no co-localisation of EP2 was seen in these immature cells (noted by neighbouring 
cells (arrows) exclusively expressing one marker).  Dapi (blue) was used for 
counterstain and scale bars equal 20 microns.  Images are representative of staining 










Figure 3.8 EP2 co-localises with VASA in mature oocytes. 
 
EP2 (red) and the mature germ cell marker VASA (green) were dual expressed in 18 
week human fetal ovarian tissue.  (A) VASA expression is germ cell specific but does not 
stain immature PGCs on the periphery of the ovary.  EP2 shows a similar expression 
pattern but is restricted to even more mature germ cells, as displayed by the more central 
localisation of expression.  (B)  Co-localisation of the VASA and EP2 (orange/yellow) in 
the centre of the ovary demonstrates both proteins are located in mature germ cell nests 
as well as oocytes within primordial follicles (PF).  Dapi (blue) was used for counterstain 
and scale bars equal 20 microns.  Images are representative of staining performed on 
three separate second trimester tissues. 
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3.3.7 EP4 is not restricted to primordial germ cell s 
 
Co-localisation with EP2 and EP4 demonstrated that the wo PGE2 receptors 
displayed differing patterns of expression in the human fetal ovary.  After 
confirmation that the EP2 receptor was restricted to maturing oocytes and oocytes 
within primordial follicles, immunolocalisation was used to further clarify whether 
EP4 was solely expressed by immature PGCs in the human fetal ovary.  The 
immature marker OCT4 was again utilised for this purpose.  PGCs were identified 
co-expressing both OCT4 (nuclear) and EP4 (membranous) (Figure 3.9A-B); 
however, co-localisation also revealed EP4 is not germ cell specific, which became 
more apparent in later gestational tissue, rather EP4 is also expressed by somatic 
cells and epithelium at the periphery of the ovary (Figure 3.9B).  Expression of EP4 
was primarily restricted to the edge of the human fetal ovary with less expression 
seen centrally.  These data demonstrate EP4 is not germ cell specific, and is also 
expressed by interstitial and epithelial cells at the edge of the ovary. 





Figure 3.9 EP4 is not germ cell specific but is more concentrated 
near the periphery of the ovary. 
 
EP4 (red) and the immature PGC marker OCT4 (green) were dual expressed in 19 week 
human fetal ovarian tissue.  (A)  EP4 is not germ cell-specific and is expressed by the 
somatic and epithelial cells at the edge of the fetal ovary.  (B)  EP4 is expressed by some 
fetal germ cells as co-localisation between OCT4 (nuclear) and EP4 (cytoplasmic) is 
displayed (white arrows).  Dapi (blue) was used for counterstain and scale bars equal 20 
microns.  Images are representative of staining performed on three separate second 
trimester tissues. 
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3.3.8 Determination of PGE 2 function in the human fetal ovary 
To determine a possible function for PGE2 in the human fetal ovary, early second 
trimester human fetal ovarian cultures were performed in the presence of PGE2 for 8 
hours (n=6), with subsequent qRT-PCR analysis to deermine modulation of germ 
cell genes or known ovarian regulators.  Culture tissue was split into three treatment 
groups; untreated control, indomethacin control (indomethacin was utilised in culture 
to prevent endogenous PG production, allowing effects of exogenous PG treatment 
to be investigated), and indomethacin plus PGE2 treatment. 
No change in expression was determined in any of the germ cell markers investigated 
when comparing indomethacin control against PGE2 treated tissue (OCT4 (p=0.62), 
VASA (p=0.87) or DAZL (p=0.63), Figure 3.10A-C).  As predicted in the previously 
discussed array (Jabbour, unpublished) the neurotrophin, BDNF was up-regulated by 
PGE2 (0.8±0.3 vs 1.3±0.6 relative to GAPDH, p=0.004, Figure 3.10D).  However, 
another neurotrophin NTF5 (which codes for NT4) was not affected by PGE2 
treatment (p=0.22, Figure 4.9E).  Another known regulator of ovarian development, 
INHBA (which encodes for the protein Activin A), was also investigated and shown 
to significantly increase in response to PGE2 treatment (2.0±0.2 vs 4.2±1.1 x10
-3 
relative to GAPDH, p=0.04, Figure 3.10G).  In contrast, the two Activin signalling 
factors SMAD2 and SMAD3 were not changed (p=0.26 and 0.25 respectively; Figure 
3.10H and I).  In addition, the anti-apoptotic factor MCL-1 was also up-regulated 
with PGE2 treatment (3.8±0.2 vs 4.4±0.5 x10
-2 relative to GAPDH, p=0.04, Figure 
3.10F). 
These data demonstrate PGE2 is capable of regulating expression of BDNF and 
INHBA, which are known regulators of ovarian development.  PGE2 also up-
regulated MCL-1, an anti-apoptotic factor.  However, PGE2 does not modulate germ 
cell marker expression, the neurotrophin NTF5, or the downstream signalling 
components of Activin. 
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Figure 3.10 qRT-PCR analysis of genomic changes with PGE2 treatment in the human fetal ovary. 
Human fetal ovarian explants were cultured with no treatment (untreated), in the presence of 3µg/ml indomethacin (Indo), or indomethacin and 
100nM PGE2 (Indo+PGE2).  No change was seen in the germ cell markers investigated; (A) OCT4, (B) VASA, or (C) DAZL.  (D) The neurotrophin 
BDNF was significantly up-regulated with PGE2 treatment, but another neurotrophin, NTF5 was not changed.  (F) The anti-apoptotic factor MCL-1 
was also seen to increase with PGE2 treatment, as was the TGF-β superfamily member, (G) INHBA.  However, neither of the inhibin/activin 
downstream signalling molecules were altered with PGE2 treatment (SMAD2 and 3 (H and I)).  All data are expressed as relative expression, 
normalised to the housekeeping gene GAPDH.  These cultures were performed by Dr. Rosey Bayne.




3.3.9 PGE2 treatment does not lead to gross changes in 
apoptosis or proliferation 
 
To further characterise the functional effects of PGE2 treatment, cultures were 
repeated in a similar fashion with an extended treatm nt period of 24 hours and 
examined for histological changes via the immunohist chemical markers 5-bromo-
2'-deoxyuridine (BrdU) which marks proliferation, and cleaved caspase-3 (CC3) 
which marks apoptosis (n=5).  No changes were determin d in proliferation (Figure 
3.11A and B) of somatic (p=0.81) or germ cells (p=0.98) in the human fetal ovary.  
Similarly, no changes were seen in the number of cells undergoing programmed cell 
death (somatic cell apoptosis (p=0.87) and germ cell apoptosis (p=0.60), Figure 
3.11C and D).  These data demonstrate that treatment with 100 nM PGE2 for 24 
hours does not lead to any gross changes in ovarian cell turnover. 
 
 




Figure 3.11 No change in proliferation or apoptosis is detected after 
24 hour treatment with 100nM PGE2 
Second trimester fetal ovarian tissue (15-17 weeks, n=5), was treated with 3µg/ml 
indomethacin (INDO), or indomethacin and 100nM PGE2 (INDO+PGE2) for 24 hours.  
Proliferation was observed via positive 5-bromo-2'-deoxyuridine (BrdU) staining and was 
not seen to change in either the (A) germ cell or (B) somatic cell populations.  Apoptosis 
was also assessed via the marker cleaved caspase-3 (CC3) and did not change in (C) 
germ cells or (D) somatic cells.  These data are expressed as positively stained cells per 
micron of tissue.





Fetal ovarian development and germ cell maturation are vital for adult fertility.  
PGE2 has been well-characterised as a potent regulator of ovarian function in the 
adult (Oates et al, 1988a; Oates et al, 1988b), but few data exist relating to its 
function during ovarian development.  Additionally, PGE2 has been identified as a 
regulator of the neurotrophins in tissue outwith the ovary (Toyomoto et al, 2004; 
Jabbour, unpublished).  The neurotrophins are known regulators of early ovarian 
development leading to the hypothesis that PGE2 may also play a functional role in 
the ovary at this time.  The data presented here confirm that all precursor enzymes 
necessary for PGE2 production (COX1, COX2, and PTGES) are expressed in the 
human fetal ovary, as are the receptors required for PGE2 signalling (EP1-4).  
Furthermore, the expression of several of these components is restricted to the germ 
cells, denoting PGE2 is synthesised in the germ cells and can target the germ cells 
directly in the developing human ovary. Treatment of human fetal ovary with PGE2 
in vitro demonstrated increase in expression of germ-cell expressed genes previously 
identified as important regulators of early ovarian development, providing evidence 
that PGE2 may play an important role in developmental signalli g in the human fetal 
ovary. 
Expression of two of the precursor enzymes (COX2 and PTGES) required for PGE2 
synthesis was developmentally-regulated.  COX2 expression was increased linearly 
across gestation, with highest expression in late second trimester concomitant with 
the initiation of primordial follicle formation.  PTGES showed a significant drop in 
expression in early second trimester compared with expression in first and late 
second trimester, possibly indicating biphasic PGE2 production in the fetal ovary.  
Protein of both developmentally-regulated enzymes wa found to be exclusively 
expressed by the fetal germ cells at all gestations (data not shown), revealing germ 
cells to be the sole site of PGE2 synthesis in the human fetal ovary.  Unlike the other 
enzymes involved in PGE2 production, COX1 was consistently expressed across 
gestation and was localised to the somatic cells at the periphery of the human fetal 
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ovary.   This enhanced role for COX2 over COX1 in ovarian function is supported 
by rodents deficient for each of the enzymes; COX1-/- females show no disruption of 
adult ovarian function, whereas COX2-/- females suffer multiple reproductive 
disruptions including ovulation, fertilisation and implantation  (Dinchuk et al, 1995; 
Lim et al, 1997).  It is also noted that protein expression of COX2 seemed to be 
heightened in specific germ cells within germ cell n sts, together with its heighted 
expression in late second trimester.  This may suggest that COX2 is involved in 
survival or degradation of specific germ cells leading up to primordial follicle 
formation.   
Expression of the PGE2 receptors was varied in the human fetal ovary.  EP1, 2, and 3 
showed no significant change in transcript expression across gestation, whereas EP4 
displayed a significant increase similar to that of COX2.  This pattern was consistent 
with protein expression, where EP4 was heightened i later gestations at the 
periphery of the ovary.  This increase in protein expr ssion was not exclusive to the 
germ cells as first postulated, but rather EP4 is also expressed by somatic, epithelial 
and germ cells near the periphery of the ovary.  The increase seen in EP4 and its 
location may indicate a role in maintenance of the immature PGC population.  In 
contrast, EP2 was expressed in a more mature subset of oocytes, with little overlap in 
expression between EP2 and EP4 determined.  EP2 was solely expressed by mature 
germ cells, also positive for VASA, in germ cell nests and oocytes within primordial 
follicles; this may denote a specific signalling role for EP2 in mature germ cells.  
EP3 was expressed by germ cells and pre-granulosa cell  within germ cell nests. 
Conversely, EP1 displayed limited expression in the human fetal ovary, with weak 
staining in blood vessels revealing it is not likely to be involved in fetal ovarian/germ 
cell development.  Based upon these findings it is l kely that PGE2 action in the 
human fetal ovary is via EP2, 3, or 4.  Distinct expression of each of these receptors 
provides evidence for multiple roles for PGE2 as it interacts with the differing 
receptors during ovarian development and germ cell maturation.  Of the EP 
receptors, EP2 is the only one to be shown to be ess ntial in adult ovarian function, 
as loss of EP2 function in a murine model resulted in impaired ovulation (Hizaki et 
al, 1999; Kennedy et al, 1999; Tilley et al, 1999).  However, it is probable that PGE2 
Chapter 3                                                                                             Prostaglandin E2 
122 
 
action in the fetal ovary is orchestrated via multiple receptors to exert differing 
effects on distinct subsets of germ cells.  With PGE2 synthesised in germ cells, 
receptor localisation demonstrates this PGE2 function can be via autocrine (germ 
cell) or paracrine (somatic cell) action.  
It is possible the developmental changes in mRNA expr ssion of the enzymes and 
receptors are a result of changes in the tissue composition as the fetal ovary develops, 
rather than increased expression as a result of increased PGE2 signalling.  As 
discussed in the introduction, in the human fetal ov ry the germ cells proliferate 
greatly between first and second trimester, increasing their proportion compared to 
the somatic environment.  This may account for some f the increase in expression 
seen in COX2, PTGES and EP4.  However, if this were the only cause for increases 
determined, expression of PTGES should also increase.  In addition, as expression of 
the germ-cell specific receptor EP2 is not increased in a significant fashion and 
conversely the somatic-specific enzyme COX1 is not significantly decreased with 
gestation, it does not appear that the significant hanges in expression levels can be 
solely due to changes in ovarian composition.    
Subsequent culture analysis partially illuminates PGE2 function during early 
development.  As the PGE2 receptors were expressed primarily by germ cells in the 
human fetal ovary, tissue was assessed for any changes i  expression of germ cell 
markers (OCT4, VASA, and DAZL), whose expression is also associated with 
differing stages of germ cell development (Anderson et al, 2007).  No significant 
changes were seen that might suggest a change in germ cell development, which 
provides further evidence for an upstream effect on germ cell growth factors rather 
than a direct action on germ cells survival.  However, it is possible the short 
timecourse of 8 hours was not long enough to determine developmental effects. 
As speculated, the neurotrophin BDNF was up-regulated by PGE2 treatment.  
However, another neurotrophin NTF5 was not affected by PGE2 treatment.  The 
receptor for these neurotrophins, the TrkB receptor, has been well characterized as an 
important mediator of development in the mammalian ovary (Dissen et al, 1995; 
Spears et al, 2003; Paredes et al, 2004; Childs et al, 2010a).  Both BDNF and NT4 
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are expressed primarily in the somatic cells in the developing human ovary (Coutts et 
al, 2008; Childs et al, 2010a); however, BDNF expression is also present in the germ 
cells at later gestations.  Given that PGE2 receptors are primarily expressed by the 
germ cells, it is possible this difference in regulation is due to BDNF mRNA up-
regulation specifically in the germ cells, which may explain the lack of effect on 
NTF5. 
Supporting this germ cell specific effect hypothesis, is the up-regulation of MCL-1 
and INHBA, which are also expressed solely by the larger, moe mature germ cells, 
including oocytes within primordial follicles (Hartley et al, 2002; Martins da Silva et 
al, 2004).  INHBA is another known regulator of human fetal ovarian development, 
which exhibits increased transcript levels in late second trimester (Martins da Silva et 
al, 2004) and may regulate germ cell development via regulation of kit ligand/c-KIT 
expression (Coutts et al, 2008; Childs et al, 2010a).  As PGE2 is able to up-regulate 
INHBA expression, it is possible it plays an up-stream role in this regulation.  MCL-
1, an anti-apoptotic factor (Kozopas et al, 1993), was also up-regulated by PGE2 
treatment.  This up-regulation may be a direct action or possibly secondary to the up-
regulation of INHBA, as MCL-1 can be regulated by Activin in other systems 
(Fukuchi et al, 2001).  In contrast, other downstream targets of Activin action, 
SMAD2 and 3, were not affected by PGE2 treatment, but as with NTF5, these factors 
are located in the somatic cell population. 
In order to further determine the functional effects of these expression changes, the 
PGE2 cultures were repeated with an extended culture period of 24 hours.  No 
changes were determined in the rate of proliferation or apoptosis in either somatic or 
germ cell populations.  This observation and the inability of PGE2 to modulate 
expression of germ cell genes suggest that PGE2 may not have a direct role in germ 
cell survival, rather regulating other factors in ovarian development, although the 
lack of functional changes in histology may also be du  to the short duration of the 
culture (24 hours).  Further investigation, using either an in vivo model, such as the 
mouse, or an extended in vitro culture system capable of sustaining tissue survival 
for extended periods of time would be beneficial for determining PGE2 function. 
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In conclusion, the necessary components for PGE2 signalling are present in the fetal 
ovary, and treatment with PGE2 can increase transcript levels for germ-cell specific 
factors known to be important for oocyte survival and maturation.  These data 
provide novel evidence for PGE2 as a regulator of early human ovarian signalling 
and thereby germ cell development.  Future research should establish the direct 
function PGE2 may play during germ cell development. 









Effects of maternal paracetamol 
usage on fetal ovarian 
development
Chapter 4                                                                                             Paracetamol 
126 
 
Chapter 4. Effects of maternal paracetamol usage on  fetal 
ovarian development 
4.1 Introduction 
Studies in the human fetal ovary determined a possible function for PGE2 in 
regulation of oocyte survival and proliferation, but were unable to determine its 
mechanism of action; therefore, it was determined a longer duration, in vivo model 
of PG disruption would be beneficial in order to investigate further PG function 
(specifically PGE2) during fetal ovarian development.  Maternal administration of 
paracetamol (acetaminophen) during pregnancy in a rodent model was utilised for 
this purpose, as treatment with PGE2 would likely induce early parturition (Kelly et 
al, 2009), administration of other PG inhibitors (indomethacin, NSAIDs, etc) causes 
maternal morbidity (Wilcox et al, 1997; Sigthorsson et al, 2000), and a model of 
maternal exposure to paracetamol is clinically relevant.      
More than 50% of women in the Western world use analgesics during pregnancy, 
with paracetamol being most widely used (Werler et al, 2005).  Paracetamol is 
similar to the NSAID family of analgesics, with both drug types functioning via the 
inhibition of the COX enzymes to prevent inflammatory signalling.  However 
paracetamol is a weak anti-inflammatory with poor anti-platelet activity compared to 
the NSAIDs (Lages & Weiss, 1989; Niemi et al, 2000).  This difference is likely due 
to differing mechanisms of action.  NSAIDs directly inhibit the COX enzymes both 
in the central nervous system (CNS) and peripheral systems (Ayoub et al, 2006).  
Conversely, paracetamol, despite being on the market for over 50 years, does not 
have a well-characterised mechanism of action, althoug  it has been established it 
interacts with the COX enzymes (Graham & Scott, 2005).  It was briefly 
hypothesised that paracetamol functioned via inhibition of a third, yet to be 
characterised COX enzyme (COX3) (Chandrasekharan et l, 2002) but this 
hypothesis has since been rejected (Dinchuk et al, 2003; Schwab et al, 2003) 
Schwab, 2003).  Recent evidence suggests the primary target of paracetamol action 
in the human is COX2, as it exhibits comparable COX2 inhibition to other NSAIDs 
and COX2-specific inhibitors, but is unable to suppress COX1 to therapeutic levels 
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comparable to the NSAIDs (Hinz et al, 2008).  There may also be other targets of 
paracetamol action, and its direct mechanism of inhib ting COX2 remains unknown. 
Specific COX2 inhibitors, including paracetamol, are commonly prescribed for 
chronic pain and/or inflammation management, as COX2 specific inhibitors do not 
induce gastrointesitinal bleeding, which is a side eff ct of long-term inhibition of 
COX1 in NSAIDs (Wilcox et al, 1997; Sigthorsson et al, 2000).  It is also thought 
COX2 inhibitors are less likely to cause renal complications when compared to 
traditional NSAIDs (Zhao et al, 2001; Whelton et al, 2002).   However, COX2 
inhibitors have been shown to heighten risk of cardiovascular complications with 
long term use (Bombardier, 2002; Bresalier et al, 2005).  
Despite this, paracetamol has been considered safe, with no reported feto-toxic 
effects when taken within the therapeutic range (Rathmell et al, 1997).  However, 
recent studies from Denmark have disputed the safety o  prenatal exposure to 
analgesics, suggesting that maternal usage of thesedrugs, including paracetamol, 
results in increased risk of cryptorchidism in male offspring (Kristensen et al, 2011).  
This was determined via a meta-study of maternal usge of analgesics; paracetamol 
and NSAIDs (non-steroidal anti-inflammatory drugs; a pirin and ibuprofen), noting 
duration of use and what point in gestation the treatment was taken.  This study 
determined use of analgesics was associated with congenital cryptorchidism in a 
dose-dependent manner, with increased risk in mothers who used analgesics during 
second trimester.  These data were further supported by a rodent model that 
demonstrated paracetamol produced anti-androgenic effects in offspring leading to 
impaired masculinisation (as demonstrated by reduced ano-genital distance; 









As previously discussed COX enzymes, which are targe ed by paracetamol and 
NSAIDs, synthesise PGs and other inflammatory mediators.  Outwith the Kristensen 
et al. study, historical literature from Gupta and colleagues has also demonstrated 
inhibition of the Cox enzymes and indeed direct inhibition of the Pgs is able to 
disrupt male development in rodents (Gupta & Goldman, 1986; Gupta, 1989).  
However, the effect of maternal analgesic usage on f male development has not been 
investigated. 
Current knowledge of PG involvement in gonad development is limited.  PGD2 is 
thought to be involved in early sex determination, a d based upon data gathered in 
the previous chapter, it is postulated that PGE2 plays a regulatory role during ovarian 
development.  Inhibition of PG synthesis by analgesics during pregnancy would 
affect these pathways and might lead to disruption of gonad development in 
offspring.  To test this hypothesis, as well as furthe  examine the function of PGE2 
during fetal ovarian development, the rat model used in the Danish study was 
duplicated (Kristensen et al, 2011).  This model utilises maternal gavage (oral 
administration) also allowing the study to remain cl i ally relevant to human 
administration of analgesics during pregnancy.  Resulting female pups were 
examined for gross morphological and gonadal differences compared to pups 
exposed to vehicle control (corn oil).  Further investigation of the male pups and 
testis development was also investigated by collaborators, but will not be discussed 
in this chapter. 




4.2 Materials and Methods 
 
Tissue collection and dissection 
Pregnant Wister rats were either treated with 350 mg/kg paracetamol in oil for 7 days 
of gestation or oil control alone, from day e13.5 to e20.5.  Fetal rat ovaries were 
collected at embryonic day (e)21.5 of gestation.  In a second series of studies, 
paracetamol treatment was the same but with exposure for only 3 days with ovaries 
collected at day e17.5. 5 litters of each treatment group were analysed in the 
following experiments (with at least 3 animals per litter analysed).  Full details are in 
Section 2.2. 
Gross morphological measurements 
Body mass and ano-genital distance (AGD) were measur d at dissection using a 
micro-balance (Sartorius Handy model #110) and digital callipers (Faithfull Tools).  
Body mass was measured before decapitation to detect possible systemic changes.  
AGD was measured from the start of the anus to the start of the phallus in both sexes 
as an index of masculinsation (Figure 4.1).  Scales nd calipers were re-calibrated 
before use.   
 
Figure 4.1 Ano-genital distance measurement 
Ano-genital distance (AGD) was measured as indicated above, with a clear difference 
between male and female animals.  AGD was utilised as an early indicator of disruption 
of masculinisation (Ostby & Gray, 2004) 




AGD was also adjusted for body mass, as AGD changes i  proportion to body size.  
The equation is as described below and the adjusted measurement referred to as ano-
genital index (AGI). 
AGI = AGD (mm) / body mass1/3 (grams) 
Immunohistochemistry 
In order to determine if rodent expression of Pge2 factors was similar to that of the 
human fetal ovary, Cox1, Cox2, Ptges, and Ep1-4 were localised in the rat ovary 
using the same concentrations of primary antibody as in the human.  Further to 
determine changes in germ cell number, both Tra-98 nd Vasa staining were utilised, 
with additional staining for proliferation marker phosphohistone-H3 (PHH3) and 
apoptosis marker cleaved caspase-3 (CC3) to identify any changes in ovarian cell 
turnover.  Details of immunohistochemical protocols can be found in Section 2.8. 
Stereology 
All stereology was performed using the equipment described in Section 2.11.3.  All 
counts were performed blind to prevent inadvertent bias. 
Ovarian volumes 
Fetal rat ovaries were serial sectioned, with 2 sections placed on each slide.  Every 
tenth slide was stained with hematoxylin and eosin (as in Section 2.7) and the 
ovarian area measured.  An average ovarian area and the number of slides containing 
complete ovarian sections was then used to extrapolate volume using the equation 
below and as depicted in Figure 4.2. 
ovarian volume   = 
average ovarian area x (number of slides containing ovary x 10 µm) 
(Each section is 5 µm, and each slide contains two sections making each slide 10 µm). 
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This calculation is based upon Calvalieri’s principle, which postulates the area of 2D 
sections multiplied by the distance from end to endof an object is an accurate 
calculation for volume of the object, regardless of hape.  This principle has been 
verified as an accurate way to discern tissue volume, as long as the sections 
examined are of equal interval (Mayhew & Olsen, 1991). 
  
 
Figure 4.2 Schematic of determination of ovarian volume. 
Fetal rat ovaries were serial sectioned.  Area of every tenth slide was determined using 
image analysis and the area averaged before multiplying by the depth of ovary as 
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 Germ cells per area 
The germ cell marker Tra-98 was used to mark germ cells in the fetal rat ovary, and 
stereology was performed to count number of germ cells using two slides per animal 
(one from the centre of the tissue as determined from ovarian area, and another at 
least fifty microns from the centre).  The number of germ cells quantified was then 
adjusted for ovarian area determined from the same section and presented as germ 
cells per micron2.  A figure depicting this analysis can be found in Section 2.11. 
 Germ cell nuclear diameter 
Germ cell nuclear diameter (GCND) can be used as an index of oogonia/oocyte 
maturation, with more mature germ cells having larger nuclear diameters.  Germ cell 
nuclear diameter was measured using the ‘nucleator’ function of the above software, 
which tri-sects the germ cell and each of 6 radii are measured.  These radii are then 
averaged to provide an accurate measurement of nuclear diameter of the cell.  Fifty 
germ cells per section were randomly measured in this fashion, and two sections (the 
same slides were utilised for both germ cell number quantification and GCND 
measurement) from each animal were quantified.  Some f the paracetamol treated 
animals did not have 50 germ cells in a section.  In these cases, all germ cells were 
measured. 
 Apoptosis 
Apoptosis was measured via the marker CC3, as in the previous chapter.  CC3 
positive cells were counted and adjusted for ovarian area and presented as apoptotic 
cells per micron2. 
 Proliferation 
Proliferation was measured via the marker PHH3, similarly to the protocol used in 
the previous chapter for BrdU .  PHH3 positive cells were counted and adjusted for 
ovarian area and presented as proliferating cells pr micron2. 
 




Gross and stereological measurements were analysed with GraphPad Prism version 4 
(GraphPad Software Inc).  Student’s unpaired t-test was utilised for determination of 
significant changes between treatment groups, following analysis of each 
measurement for normality utilising the Kolmogorov-Smirnov test.    
Data were analysed both on an individual basis and as litter average.  This was 
performed by averaging the individual animal data for each animal from the same 
litter/dam.  





Fetal rat ovaries were collected after paracetamol or control treatment for 7 days of 
pregnancy at e21.5 gestation, and the following analyses were performed.  Gross 
morphological data presented (body mass, AGD, and AGI) is based upon all female 
animals collected (n=7 litters for both treatment, consisting of 35 control pups and 36 
treated pups).  The subsequent stereological data ws only performed on a subset of 
female animals chosen randomly, from 5 litters from both control and treated groups 
examined and at least 3 animals from each litter analysed (n=16 control animals and 
16 treated animals).  Only 5 of the 7 litters obtained were chosen for further 
stereological analysis.  One litter from each of the control and treated groups was 
omitted for having either fewer than 3 female pups or having an abnormally small 
litter.  All data were analysed and presented both as individual animal data and litter 
mean data to reveal any possible ‘litter effects’ which can be caused if animals from 
one or more litter are above or below average, resulting in skewed data. 
 
4.3.1 Fetal body mass is not altered by paracetamol  exposure 
Body mass was taken before decapitation of all fetara s collected.  Although there 
was a non-significant trend for paracetamol rats to be heavier when analysed as 
individual animals (p=0.23, Figure 4.3A), this trend was not seen when animals were 
analysed by litter means (p=0.73, Figure 4.3B).  These data establish there are no 
major changes in pup body mass with maternal usage of paracetamol. 







Figure 4.3 Female pup body mass does not change after fetal 
paracetamol exposure. 
Body mass was taken for e21.5 fetal female rats treated with 350mg/kg paracetamol 
(paracetamol) for 7 days of gestation or vehicle control (control). (A) No change was 
determined in body weight between paracetmol exposed and control individuals.  (B)  
This is consistent when analysed as litter mean, with no significant difference seen 
between treatment groups. 
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4.3.2 Masculinisation as determined by AGD and AGI is not 
changed with maternal usage of paracetamol 
AGD is classically used as an early indicator of masculinisation during fetal 
development (Edwards, 2006).  As data from previous st dies suggest paracetamol 
exposure may affect early androgen signalling thus affecting male development, both 
AGD and AGI were examined.  Analysis of individual animal’s AGD resulted in a 
trend for increased AGD in paracetamol exposed animls as compared to control 
(p=0.06), suggesting treated animals may have increased androgenic signalling 
compared to control animals (Figure 4.4A).  However, this trend was lost when 
analysed using litter mean data (p=0.61, Figure 4.4B).  As a slight change was 
detected in body mass, AGI was also utilised and confirmed there was no change in 
masculinisation of the female pups on both the individual basis or by litter mean data 




Figure 4.4 Ano-genital distance is not affected in female pups 
exposed to paracetamol. 
AGD of e21.5 fetal female rats was measured in bothtreated (350mg/kg paracetamol 
for 7 days of gestation (paracetamol)) and control (c ntrol) animals.  (A) A trend for 
increased AGD was seen in paracetamol treated animals but was not deemed 
significant.  (B)  This trend was not seen when data was analysed using litter means 
suggesting individual animal varience may have been r sponsible for the trend seen 
when analysed as individual animals.  






Figure 4.5 Ano-genital index is not affected in female pups exposed 
to paracetamol. 
AGI of e21.5 fetal female rats was measured in bothtreated (350mg/kg paracetamol 
for 7 days of gestation (paracetamol)) and control (c ntrol) animals. (A) No change 
was seen in AGI when analysed using individual animl easurements or (B) using 
litter mean measurements.  
 




4.3.3  Ovaries from paracetamol treated pups are si gnificantly 
smaller than control ovaries 
 
Fetal rat ovaries at e21.5 are relatively small compared to fetal rat testes or human 
fetal ovaries, and are enclosed in a thin layer of tissue referred to as the ovarian 
capsule.  These two features restricted initial measurement of ovarian mass, as 
removal of the capsule increased risk of damage to the ovarian tissue underneath and 
acquiring an accurate measurement of such small tissue was difficult.  Therefore, 
ovaries were removed and fixed with capsule intact and further examination was 
performed on serial sections of tissue.  Initial investigation of the ovaries was 
performed using the germ cell markers Tra-98 and Vasa.  Visual evaluation of 
morphology indicated there might be differences in both size and number of germ 
cells in the ovaries of paracetamol exposed tissue compared to control tissue (Figure 
4.6).  Therefore further quantification was performed. 
Ovarian volume was measured via stereology to determin  potential differences in 
ovarian size between treatment groups.  Quantification determined the ovaries of 
paracetamol treated rats were smaller than control ovaries when analysed on both an 
individual (2.6±0.4 vs 4.2±0.3 x107   micron3, p=0.0017, Figure 4.7A) and litter mean 
basis (2.7±0.5 vs 4.3±0.3 x107 micron3, p=0.03, Figure 4.7B).  These data suggest 
paracetemol exposure in utero effects ovarian size.  This decrease in mass is not een 
in body weight, suggesting the difference may be du to a loss of cells within the 
ovary. 





Figure 4.6 Morphological comparison of paracetamol exposed 
ovaries to control ovaries. 
Serial sections from control (A and C) and paracetamol exposed (B and D) e21.5 fetal 
rat ovaries.  Immunolocalisation (brown) for cytoplasmic germ cell marker Vasa (A 
and B) and nuclear marker Tra-98 (C and D) demonstrating visual observations of 
smaller ovarian size as well as fewer germ cells in the paracetamol exposed ovaries.  












Figure 4.7 Ovarian volumes from e21.5 fetal rats. 
Fetal ovarian volumes were determined using stereological methods.  (A) Paracetamol 
treated pups (paracetamol) had significantly smaller ovaries than control animals 
(control) when analysed by individual animals (n=16 control and treated animals, 
**=p<0.01).  (B)  Paracetamol treated ovaries also retained significance when 
analysed as litter means (n=5 litters for both treated and control, *= p<0.05).   
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4.3.4 Fetal exposure to maternal paracetamol result s in a 
decreased number of germ cells  
As it was hypothesised the decrease in ovarian volume might be the result of a loss 
of a specific cell type within the ovary and based upon visual observation of 
decreased germ cell staining, germ cell number was qu ntified in control and 
paracetamol treated ovaries.  Germ cell counts wereadjusted for ovarian area as 
paracetamol ovaries were deemed to be significantly smaller, in order to reveal if 
germ cell number was independently altered with fetal paracetamol exposure.  
Paracetamol treated ovaries displayed a significant reduction in germ cells per 
micron2 of ovary in comparison to controls when analysed as individual animals 
(1.0±0.1 vs 1.8±0.2 x10-3, p=0.004, Figure 4.8A).  When analysed as litter mans the 
loss of germ cells remained consistently significant between paracetamol and control 
litters (1.0±0.1 vs 1.8±0.2 x10-3, p=0.01, Figure 4.8B).  These data suggest factor/s 
altered by paracetamol exposure lead to germ cell loss or possibly decreased 
proliferation in fetally exposed ovaries. 





Figure 4.8 Ovarian germ cell number is decreased with maternal 
usage of paracetamol. 
Germ cell number was determined using the nuclear grm cell marker Tra-98 via 
stereological methods and adjusted for ovarian size. (A) Ovaries from paracetamol 
treated pups (paracetamol) had significantly fewer germ cells per micron2 when 
compared to control ovaries (control) (n=16 for both groups, **=p<0.01).  (B) This 
reduction in germ cell number was also seen when germ c ll number was analysed 
using litter means (n=5 for both groups, *= p<0.05)   




4.3.5 Reason for reduction in germ cell number is n ot apparent 
at e21.5. 
In order to identify a possible mechanism for germ cell loss in paracetamol treated 
ovaries, the rate of apoptosis and proliferation in treated and control ovaries was 
assessed.  Rate of programmed cell death, as determined by the apoptotic marker 
CC3, was not significantly different between control and paracetamol exposed 
ovaries on an individual or litter basis (p= 0.54 and 0.21, Figure 4.9A and B 
respectively).  Additionally, no significant change was seen in proliferation when 
using the mitotic marker PHH3, on either an individual or a litter mean basis (p=0.22 
and 0.25, Figure 4.10A and B respectively).  These rat s are demonstrated as a 
percentage of positively stained (CC3 (Figure 4.9C-D) or PHH3 cells (Figure 4.10C-
D)) compared to total germ cell number (as collected from previous data).  These 
data determine that paracetamol exposure is not affecting normal ovarian cell 
turnover at e21.5, although the decrease in germ cell number may be a result of a 
developmental arrest. 





Figure 4.9 Germ cell reduction in paracetamol ovaries is not the 
result of increased apoptosis. 
Rates of germ cell apoptosis were determined using the apoptotic marker cleaved 
capsase-3 (CC3) via stereological methods and adjuste  for total number of germ 
cells, in order to demonstrate the proportion of CC3 positive germ cells per animal or 
litter.  (A) No change was seen in ovarian apoptosis with fetal paracetamol exposure 
when examining changes in individual animals (n=16 animals per treatment).  (B)  
This finding was confirmed using litter means, however there was a trend of increased 
apoptosis in paracetamol treated pups (n=5 litters p  treatment).  (C) Control and (D) 
paracetamol treated ovaries stained for CC3 (pink arrows).  Scale bars equal 50 
microns. 





Figure 4.10 Germ cell reduction in paracetamol ovaries is not the 
result of decreased proliferation. 
Proliferation rate was examined using the marker phos o-hisotone H3 (PHH3) via 
stereological methods and adjusted for total number of germ cells.  The number of 
PHH3 germ cells per area was then adjusted for total germ cell number to demonstrate 
the proportion of PHH3 positive germ cells per animal or litter.  (A)  A trend was seen 
for more proliferation in individual paracetamol exposed ovaries when compared to 
control animals but was not significant (n=16 ovaries per treatment).  (B)  This trend 
was also seen using litter mean but was also not significant (n=5 litter per treatment).  
(C) Control and (D) paracetamol treated ovaries stained for PHH3 (pink arrows).  
Scale bars equal 100 microns. 




4.3.6  Fetal paracetamol exposure delays germ cell progression 
and may affect germ cell synchronicity in the rat o vary 
 
GCND was examined as a measurement of germ cell maturity in both control and 
treated ovaries, in order to distinguish if paracetmol exposure had any effects on 
germ cell development.  When individual animal GCND means were calculated, 
germ cells from paracetamol animals were found to have significantly smaller 
GCND ie be less mature than those from control ovaries (7.4±0.1 vs 6.8±0.2microns, 
p=0.03, Figure 4.11A).  However, when GCNDs were analysed as a litter mean, 
significance was lost, although the trend remained (p=0.07, Figure 4.11B).  The rat 
ovary is comparatively synchronous at e21.5, composed f germ cell nests of roughly 
the same developmental stage; therefore, GCND data was further analysed to 
determine the proportion of cells at each diameter to detect subtle changes in 
maturation and changes in synchronicity.   
Analysis of the total population of germ cell measured for each treatment determined 
there was a significant difference in the distribution of development between control 
and paracetamol treated germ cells, with a larger population of smaller, immature 
germ cells in the paracetamol ovaries when compared with control (7.4±0.03 vs 
7.0±0.04 microns, n= 1385 and 1166, p=0.0001, Figure 4.11C).  In addition, 
paracetamol ovaries displayed a lack of synchronicity, ompared with control germ 
cells, of which ~80% remained within a variance of only 3 µm compared to a 4 µm 
variance in the same proportion of cells from paracet mol exposed ovaries.  
However, the paracetamol exposed germ cells were still able to reach the same 
maturity levels as seen in control germ cells (albeit fewer cells reached these stages), 
demonstrating a complete arrest of development was not occurring in paracetamol 
exposed ovaries, rather a developmental delay. 




Figure 4.11 Development of germ cells in paracetamol exposed 
ovaries is delayed and less synchronous when 
compared to control germ cells. 
Germ cell nuclear diameter (GCND) was determined using the nuclear germ cell 
marker Tra-98 via stereological methods.  (A)  A significant reduction in germ cell 
nuclear diameter can be seen upon comparison of individual animal GCND means (*= 
p<0.05, n=16 control and treated animals).  (B) This trend was consistent when 
comparing litter mean data, but was not significant (n=5 litters per group).  (C)  Total 
germ cell population from all animals was further analysed to determine subtle 
changes in maturation and changes in synchronicity (n=1385 control germ cells and 
1166 paracetamol exposed germ cells).    
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4.3.7 Paracetamol effects on fetal rats at e17.5 
Although we determined exposure to paracetamol over7 days in utero affects fetal 
rat ovaries when examined at e21.5, no clear mechanism for these effects was 
determined.  It was postulated the changes in ovarian size, germ cell number, and 
GCND may be the result of paracetamol effects earlir in gestation.  In order to 
examine possible changes in apoptosis or proliferaton prior to e21.5 pups were 
exposed to paracetamol as before, but were dissected at e17.5 after only 3 days of in 
utero exposure. 
Gross morphological examination upon dissection demonstrated control animals 
were significantly smaller than paracetamol pups (0.62 ± 0.03 vs 0.81 ± 0.01, 
p<0.0001, Figure 4.12A).  However, when analysed on a litter mean basis this 
reduction in body mass is no longer significant (p=0.15, Figure 4.12B).  AGD or 
AGI were not examined at e17.5 as little variance is seen at this age and no change 
had been determined at e21.5.  These data demonstrate there is no gross 
morphological difference between control or paracetmol exposed fetal female rats at 
e17.5. 
 
Figure 4.12 No difference in body mass of e17.5 fetal rats exposed to 
paracetamol 
Body mass was recorded from e17.5 fetal female rats treated with 350mg/kg 
paracetamol (paracetamol) for 4 days of gestation or vehicle control (control). (A) 
Paracetamol exposed female were significantly larger than control animals when 
analysed as individuals.  (B)  When analysed as litter mean data, there was no 
significant difference seen between treatment groups (*** p<0.0001). 
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4.3.8 No change in ovarian volume in e17.5 paraceta mol 
exposed fetal rats 
 
Ovarian volume was calculated as above for e21.5, to de ermine if a similar decrease 
in ovarian size could be detected at e17.5.  A trend for increased ovarian size was 
seen in paracetamol exposed animals but this was not significant (p=0.13, Figure 
4.13A).  Analysis of ovarian volumes utilizing litter mean data also demonstrated no 
significant difference between control and paracetamol exposed pups (p=0.36, Figure 
4.13B).  These data demonstrate the significant change in ovarian volume seen at 





Figure 4.13 No change in fetal ovarian volume at e17.5 
Fetal ovarian volumes were determined using stereological methods.  (A) No change 
in ovarian volume was determined with paracetamol exposure (paracetamol) on an 
individual animal basis compared to control animals (control, n=15 control and treated 
animals).  (B)  Analysis using litter mean data also demonstrates no change with 
paracetamol treatment (n=5 litters for both treated n  control).   
 





4.3.9 No change in germ cell number with paracetamo l exposure 
at e17.5 
 
Although no change in ovarian volume was determined at e17.5, germ cell number 
per micron2 was further evaluated at this age in order to determine any subtle 
changes in germ cell number.  No change in germ cell density was determined on 
either the individual (p=0.84, Figure 4.14A) or on a litter mean basis (p=0.82, Figure 
4.14B).  This further demonstrates the significant change seen at e21.5 must be a 




Figure 4.14 No change in germ cells per micron2 with paracetamol 
exposure at e17.5 
Germ cell number was determined using the nuclear grm cell marker VASA via 
stereological methods and adjusted for ovarian size. (A) Germ cell number in 
paracetamol treated pups (paracetamol) were not significantly different than that of 
control animals (control; n=15 for both groups).  (B)  No significant change was seen 
with paracetamol exposure when data was analysed using litter mean analysis (n=5). 





4.3.10 No demonstration of altered apoptotic or 
proliferative rates at e17.5 
No change in apoptosis or proliferation was seen at e21.5, which would indicate a 
cause for the demonstrated change in germ cell number.  In order to determine if this 
change in germ cell number was a result of earlier change in cell turnover, both 
apoptosis and proliferation rates were examined in e17.5 ovaries.  These rates were 
determined as previously described for e21.5, with CC3 or PHH3 positive cells per 
micron2 adjusted for total number of germ cells per micron2.  No change was seen in 
apoptotic rate on either an individual (p=0.87, Figure 4.15A) or litter mean basis 
(p=0.95, Figure 4.15B).  Additionally, no change was seen in proliferation rate on 
either an individual (p=0.21, Figure 4.16A) or litter mean basis (p=0.40, 4.16B).  
These results demonstrate there is no change in cell turnover at e17.5, suggesting 
either the change in cell turnover is acute between e17.5 and e21.5 or that the change 
in germ cell number may be due to loss via another mechanism. 







Figure 4.15 Germ cell reduction in paracetamol ovaries not the result 
of increased apoptosis at 17.5. 
Rates of germ cell apoptosis were determined using the apoptotic marker cleaved 
capsase-3 (CC3) via stereological methods and adjuste  for ovarian size.  The number 
of CC3 germ cells per area was then adjusted for total germ cell number to 
demonstrate the proportion of CC3 positive germ cells per animal or litter.  (A) No 
change was seen in ovarian apoptosis with fetal parcetamol exposure when 
examining changes in individual animals (n=15 animals per treatment).  (B)  This 
finding was confirmed using litter mean data (n=5 litters per treatment). 







Figure 4.16 Germ cell reduction in paracetamol ovaries is not the 
result of decreased proliferation. 
Proliferation rate was examined using the marker phos o-hisotone H3 (PHH3) via 
stereological methods and adjusted for ovarian size.  The number of PHH3 germ cells 
per area was then adjusted for total germ cell number to demonstrate the proportion of 
PHH3 positive germ cells per animal or litter.  (A)   trend was seen for less 
proliferation in individual paracetamol exposed ovaries when compared to control 
animals but was not significant (n=15 ovaries per tr atment).  (B)  This trend was lost 
when analysed as litter mean data (n=5 litter per treatment). 
 
Chapter 4                                                                                             Paracetamol 
154 
 
4.3.11  Prostaglandin synthesis in the fetal rat ov ary 
In an effort to further elucidate possible causes of paracetamol exposure effects, 
further investigation of Cox and downstream prostaglandin signalling was 
investigated in the fetal rat ovary.  The localisation of the Cox enzymes was 
identified in wild type e21.5 fetal rat ovaries.  In addition, as Pge2 was linked to germ 
cell survival in the human fetal ovary (as previously discussed in Chapter 3) (Bayne 
et al, 2009), Ptges, which is downstream of the Cox enzymes and responsible for 
Pge2 specific synthesis, was also investigated. 
Unlike the human, little Cox1 expression was seen in the fetal rat ovary (Figure 
4.17A-B), although expression can be seen in blood cells.  However, this expression 
is minimal, as shown by comparison with positive contr l tissue from the human 
endometrium (Figure 4.17C).  Conversely, Cox2 expression was very similar to that 
seen in the human fetal ovary, displaying germ cell-specific localisation with 
variability between germ cells within the same germ cell nests (Figure 4.17D-F).  
Ptges expression was also similar to that seen in humans, with the majority of protein 
localised to the germ cells of the fetal ovary (Figure 4.17G-I).  However, in the rat, 
unlike the human, expression is also seen in the pre-granulosa and somatic cells of 
the ovary.  Distinct absence of Ptges expression can be seen in the capsule tissue 
surrounding the ovary, suggesting Ptges immunolocalisation in the fetal ovary is 
specific.  These data demonstrate the primary site of Cox synthesis enzyme 
expression to be the germ cells in the fetal rat ovry, suggesting these are the targets 
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Figure 4.17 Cox and Ptges expression in the wild type fetal rat ovary 
The Cox enzymes and Ptges were immunolocalised in the e21.5 fetal rat ovary.  (A-B) Cox1 was mostly expr ssed in the blood cells (BC) of the fetal rat ovary with 
minimal expression in the germ cells (GC) compared to (C) glands in human endometrial tissue used as a positive control (EG).  (D-F) Cox2 expression was 
exclusive to the germ cells of the rat fetal ovary with somatic cells (SC) and pre-granulosa cells (PG) remaining immune-negative.  (G-I)   Ptges was localized to all 
fetal ovarian cells in the rat, including GCs, SCs, and PGs.  Scale bars equal 50 microns in all panels.  Images are representative of staining performed on three 
separate e21.5 ovaries.
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4.3.12 Pge2 receptor expression in the fetal rat ov ary 
 
To determine the targets of the Cox product Pge2, its four receptors (Ep1-4) were 
localised in the fetal rat ovary and compared to previous data from investigation in 
the human fetal ovary.  Ep1 expression was similar to that of expression in the 
human ovary, with little expression seen outside of the blood cells within vessels, 
although slight expression was seen in some germ cells (Figure 4.18A-B).  Ep2 
expression was also similar to that seen in the human fetal ovary and was localised 
specifically to rat fetal germ cells (Figure 4.18C-D).  Ep3 is also primarily expressed 
by fetal germ cells, although some Ep3 expression was seen in pre-granulosal cells, 
(Figure 4.18E-F).  Ep4, unlike the other Pge2 receptors, was localised to the nucleus 
of cells (Figure 4.18G-H), with primary localisation in somatic nuclei, but expression 
could also be seen in select germ and pre-granulosal cells.  This expression was 
different to that seen in the human study, where EP4 expression was membranous.  
These results determine Pge2 is capable of targeting various cell types in the rat fetal 
ovary, including the germ cells.
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Figure 4.18 Pge2 receptor expression in the rat fetal ovary 
Ep receptors were immunolocalised in the e21.5 fetal rat ovary to identify targets of Pge2 
action. (A-B) Ep1 was expressed minimally by the germ cells (GC) but was predominately 
expressed by blood cells (BC) in the fetal rat ovary.  (C-D) Ep2 expression was exclusive 
to the GC with no expression seen in somatic (SC) or pre-granulosa cells (PG).  (E-F)  
Ep3 was localised to both the GC and PG of the germ cell nests in the rat fetal ovary, with 
negative SC streams.  (G-H) Ep4 was localised to the nucleus of most cells in the ovary, 
predominately the SC, but also seen in the PG and some GC.  Scale bars equal 50 
microns.  Images are representative of staining performed on three separate e21.5 
ovaries.




Germ cell development during fetal life is essential for adult fertility in the female.  
Disruption of early ovarian development can lead to premature ovarian insufficiency 
(POI) or infertility.  Previous studies in the human fetal ovary identified PGE2 as a 
possible regulator of this early germ cell development (outlined in Chapter 3 (Bayne 
et al, 2009)) but were unable to identify PGE2 function due to the constraints of using 
human tissue.  The rodent model of maternal paracetamol exposure utilised in this 
study, circumvents these issues, and provides further evidence for a role for Pge2 in 
fetal ovarian development, as disruption of the Cox enzymes results in disruption of 
germ cell survival and maturation in female offspring.  This disruption was 
quantified using the germ cell marker Tra-98, which is a nuclear marker similar to 
germ cell nuclear antigen (GCNA; (Bagheri-Fam et al, 2011)) which we were unable 
to obtain commercially.  Tra-98 was utilised over other traditional germ cell markers 
because of its nuclear localisation, which allowed us to count both germ cell number 
as well as GCND using the same sections of ovary. 
The reduction in germ cell number is likely to be th cause for the significantly 
smaller ovarian volumes observed, as no change was observed in overall body size of 
the treated pups.  It was hypothesised this reduction in germ cell number might be 
the result of reduced proliferation or increased cell death.  However, after 
quantifying markers for both proliferation and apoptosis, neither were found to be 
significantly altered in paracetamol treated ovaries compared to vehicle treated 
controls.  It was further speculated that no change was seen in cell turnover at e21.5 
as the alteration in germ cell number was a result of changes occurring earlier in 
gestation; however this theory was not supported by ata collected from an earlier 
gestational group (e17.5).  Additionally, e17.5 litters demonstrated no change in 
ovarian size or germ cell number with paracetamol exposure, suggesting that late 
gestational treatment (e17.5-e21.5) immediately before parturition in the rat is 
possibly a period susceptible to developmental disruption, and effects seen in e21.5 
rats are due to change during this time.  This hypothesis is supported by human meta-
analysis data, indicated developmental effects of paracetamol and NSAIDs were 
heightened if exposure occurred during the second trimester in humans (Kristensen t 
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al, 2011), which is equivalent to late gestation in the rodent.  However, it is also 
possible germ cells are lost via another unknown mechanism (eg autophagy). 
It was further noted that remaining germ cells from paracetamol exposed pups at 
e21.5 had a reduced GCND, indicating the germ cellswere developmentally delayed 
compared to control germ cells.  However, the paracetamol treated germ cells did 
span the same diameters as compared to control germ cells ruling out complete arrest 
or specific loss of a subset of germ cells, but diameter was less synchronous in 
paracetamol exposed pups.  These data indicated Cox products may play a role not 
only in germ cell survival but also maturation and possibly synchronicity.  In further 
support of this theory, although not significant, both proliferation and apoptosis were 
heightened in paracetamol exposed germ cells at e21.5.  These changes in cell 
turnover are only possible in pre-meiotic germ cells thus further suggesting the 
paracetamol exposed germ cells are developmentally delayed. 
Based upon data collected from the human fetal ovary, it is postulated that inhibition 
of Pge2 synthesis is likely to be at least one of the factors underpinning the germ cell 
effects seen with paracetamol exposure.  To demonstrate Pge2 is capable of targeting 
the germ cells in the fetal rat ovary, the Cox enzymes; Pge2 specific enzyme, Ptges; 
and the Pge2 receptors were immunolocalised in the wild-type rat fetal ovary.  It is 
unlikely Cox1 plays a role in fetal ovarian development, as it was weakly expressed 
and is not greatly affected by paracetamol action (Hi z et al, 2008).  In contrast, 
Cox2 was highly expressed in the germ cells of the rat fetal ovary, with variable 
expression between germ cells.  This intense expression of Cox2 in specific germ 
cells may account for the partial loss of germ cells seen with paracetamol exposure, 
rather than a complete loss.  Additionally, the Pge2 specific synthesis enzyme Ptges 
is also expressed in germ cells; however, unlike in the human Ptges is also expressed 
in stromal and pre-granulosa cells of the rat fetal ov ry.  These results demonstrate 
that paracetamol is most likely to specifically affect Cox2 in the germ cells in the 
fetal ovary. 
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Secreted Pge2 can then signal via one of the four Ep receptors, which were found to 
have specific, diverging expression patterns in the rat fetal ovary, as in the human.  
Expression of Ep1-3 was similar to that of the human fetal ovary.  Conversely, Ep4 
expression was not similar to that seen in the human, with primary localisation seen 
in somatic cell streams with variable expression in germ and pre-granulosal cells, 
although all expression was nuclear in the rat, unlike the membranous expression 
expected from a classical GPCR.  This staining is not seen in negative control tissue, 
and likely to be specific.  Both EP4 and EP2 have be n reported to translocate 
intracellularly in some instances to act as transcriptional activators rather than 
membrane bound receptors, allowing development of a p sitive feedback loop 
(Figure 4.19) (Tjandrawinata & Hughes-Fulford, 1997; Inoue et al, 2000; Faour et al, 
2008; Steinert et al, 2009).  It is possible this localisation indicates Ep4 is acting 
directly to regulate transcription and in turn, increase Cox2 expression and Pge2 
synthesis.  In support of this theory, Ep4 is only selectively expressed in the nuclei of 
a subset of germ cells as is heighted expression of Cox2.  Although further evidence 
is needed for this mechanism, these results determin  direct regulation of fetal germ 
cells in the rat ovary by Pge2 is likely via Ep2, 3, or 4, with possible paracrine action 
mediated through Ep3 or 4, as Ep1 is minimally exprssed.  Although these data do 
not provide evidence for Pge2 inhibition as the sole mediating factor affecting germ 
cells in paracetamol treated ovaries, they do provide further support for the role of 
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Figure 4.19 Positive feedback loop exerted via EP2/4 receptors 
during PGE2 signalling. 
Positive feedback loop mechanism utilized by PGE2 via the two GPCRs EP2 and EP4.  
When inactivated, the cell expresses COX2 which in turn promotes secretion of PGE2 
and signaling via membrane bound GPCRs on neighboring cells.  In an activated stage, 
the PGE2 signals back to the cell via EP2 or 4 which then translocate inside the cell to 
promote sustained expression of the precursor enzyme COX2 via cAMP signaling 
maintaining a positive feedback system.  Abbreviations: cAMP, cyclic AMP; COX2, 
cyclooxygenase-2; EP2/4, prostaglandin E receptor 2/4GPCR, g-coupled protein 
receptor; PGE2, prostaglandin E2.  Figure adapted from (Inoue et al, 2000). 
 
Alternative factors possibly affected by paracetamol exposure have been 
suggested, including anti-androgenic signalling, as suggested in the previous 
studies of paracetamol exposure in male offspring (Gupta & Goldman, 1986; 
Gupta, 1989; Kristensen et al, 2011).  Although no change in AGD/AGI was 
observed in the female pups of this study, there remains to be evidence this 
measure is indicative of steroid signalling in female offspring.  However, male 
counterparts did show a significant fall in inter-tsticular testosterone, as well as a 
reduction in AGD/AGI, consistent with a reduction in fetal androgens (data not 
shown).  This fall in testosterone was also paired with a reduction in male germ 
cell number and an evident delay in maturation of germ cells with paracetamol 
exposure, similar to that seen in the female pups.  Studies in mouse, rat and 
human fetal ovaries have demonstrated enzymes and receptors necessary for 
steroid synthesis and signalling are expressed during early ovarian development 
preceding primordial follicle formation suggesting these pathways are active 
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(Weniger, 1993; Chen et al, 2007b; Chen et al, 2009; Fowler et al, 2011).  
Further, Chen et al. demonstrated progesterone/estrogenic signalling is capable of 
regulating both germ cell nest breakdown and primordial follicle formation in the 
mouse (Chen et al, 2007b).  Thus altered steroid signalling may lead to early nest 
breakdown which would result in germ cell loss.  However, there is little evidence 
for this as a possible mechanism as estrogen receptor null mice do not display any 
disruption of fetal ovarian development and establish a normal cohort of 
primordial follicles (Dupont et al, 2000; Couse t al, 2001).  In addition, a 
progesterone receptor-null model was also examined a d deemed to develop 
phenotypically normal ovaries (Lydon et al, 1995).  Alternatively, as in the male, 
testosterone might be the steroid altered by COX inhib tion.  Although little is 
known about testosterone’s role in the fetal ovary, it is known that the receptor by 
which it signals, androgen receptor (AR), is important for ovarian function.  This 
was determined in an AR knockout (ARKO) mouse model, which demonstrated 
premature ovarian insufficiency at 8 weeks of age, despite what was deemed a 
normal compliment of follicles after birth (Shiina et al, 2006).  It is clear from 
these results, testosterone does play a role in ovarian biology; however lack of 
functional data regarding its role during fetal ovarian development obscures 
further postulation of what functions might be disrupted by COX inhibition at this 
time. 
Another factor to be considered is maternal metabolism, with a possible metabolite 
of paracetamol or a change in liver response due to the additional metabolic effects 
of paracetamol resulting in downstream fetal effects. Paracetamol is almost entirely 
metabolised into other substances before being excreted (~98%), only one of these 
resulting metabolites, accounting for ~4% of total p racetamol metabolism, is known 
to be potentially toxic (Prescott, 1980).  This toxic metabolite is the highly reactive 
alkylating agent, benzoquinoneimine, which in normal rodent and human metabolism 
is swiftly inactivated by conjugation with glutathione in the liver (Prescott, 1980).  
However, in cases of paracetamol toxicity, the amount f benzoquinonemine exceeds 
the glutathionine produced, allowing for the excess metabolite to bind to liver cells 
causing acute necrosis (Mitchell t al, 1977).  As no liver necrosis was observed in 
the dams, it is thought this is not the cause of the fetal effects of paracetamol; 
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however, further studies investigating rate of paracet mol clearance would 
demonstrate if even minute paracetamol toxicity is occurring, as rate of clearance is 
slowed in animals experiencing paracetamol poisoning (Prescott & Wright, 1973). 
Additionally, paracetamol’s direct mechanism of action remains unknown, making it 
possible for an alternative unidentified signalling pathway (not a result of Cox 
inhibition) to be the cause of the developmental disruptions.  In order to rule out 
these two possibilities, in vitro culture of fetal rat ovaries using the same gestation l 
ages (e13.5-e20.5) were attempted with treatment of paracetamol and indomethacin 
(a COX specific inhibitor with known mechanism) (data not shown).  These cultures 
would provide evidence for an ovarian specific effect outwith maternal and fetal 
metabolism; and if effects seen with indomethacin mimicked that of paracetamol, 
that effects were a result of Cox inhibition.  However, these cultures were 
unsuccessful, as tissue recovered was highly distorted.  This distortion was likely due 
to being harvested close to sex determination and/or the length of culture, as tubular 
structures were identified in both sexes as well as a lack of proliferating germ cells.  
An additional attempt was made using gonads from slightly later in gestation (e15.5) 
with culture treatment for a shorter time period but this too resulted in widespread 
apoptosis in all treatment groups. 
In conclusion, although further study is required to determine if Pge2 disruption is 
the cause of germ cell loss and delay seen in e21.5paracetamol exposed fetal ovaries, 
this study has demonstrated there is an effect on fetal ovarian development with the 
use of the common analgesic paracetamol which inhibits the Cox enzymes upstream 
of Pge2 synthesis.  Additionally, components necessary for Pge2 signalling are 
present in the fetal rat ovary with most components xpressed in a similar 
localisation to that of the human fetal ovary, in which Pge2 signalling has been 
demonstrated to regulate factors involved in proliferation and survival.  Absence of 
this regulation might result in germ cell loss or developmental disruption, the two 
main effects seen in paracetamol exposed fetal ovaries.  
Overall, these data demonstrate fetal exposure to paracetamol affects fetal germ cell 
number, and may thereby affect the number of primordial follicles formed.  This 
would further affect the number of follicles available for ovulation and thus may lead 
Chapter 4                                                                                             Paracetamol 
164 
to POI in foetuses exposed to sustained paracetamol during in utero development.  
Further, investigation is necessary to determine if there are effects seen postnatally in 
paracetamol exposed female (and male) pups.  As paracet mol is one of the most 
common drugs to take during pregnancy in the human, this may have relevant 
clinical implications (Werler et al, 2005).  Additionally, incidence of POI, most of 
which is unexplained, remains high, this may further t  understanding of 
mechanisms predisposing women to early follicle loss (Coulam, 1986). 






IL6-type cytokines in the human  
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Chapter 5.    IL6-type cytokines in the human fetal  ovary  
5.1 Introduction 
The IL6-type cytokines, which include IL6, leukaemia inhibitory factor (LIF), 
oncostatin M (OSM), and ciliary neurotrophic factor (CNTF), are well characterized 
regulators of the immune response.  IL6-type cytokines also play key roles in the 
regulation of cell proliferation, differentiation and survival during embryonic 
development (Heinrich et al, 1998).  LIF has a well characterized role in the 
maintenance of pluripotency in mouse embryonic stem (ES) cells (Williams et al, 
1988), and consistent with this can (in the presence of basic fibroblast growth factor 
(bFGF) and KL) promote the conversion of PGCs into pluripotent ES cell-like 
Embryonic Germ (EG) cells (Matsui et al, 1991; Resnick et al, 1992).  LIF can also 
increase isolated mouse PGC numbers in vitro (Pesce et al, 1993b; Cheng et al, 
1994), as does OSM, CNTF, or IL6 (when cultured in the presence of the soluble 
isoform of its receptor) (Resnick et al, 1992; Cheng et al, 1994; Koshimizu et al, 
1996).  It has been suggested this results from an anti-apoptotic action of IL6-type 
cytokines on germ cells, rather than through the promotion of proliferation (Pesce et
al, 1993a).   LIF (and IL6 in conjunction with soluble receptor) also inhibits the 
spontaneous entry of mouse primordial germ cells into meiosis (Chuma & Nakatsuji, 
2001), and has been shown to promote the primordial to primary follicle transition in 
vitro (Nilsson et al, 2002).  
The IL6-type cytokines signal by forming dimers or trimers of various receptor 
components including two shared components glycoprotein-130 (gp130) and LIF 
receptor (LIFR) (reviewed in Heinrich et al, 1998 and depicted in Figure 5.1).  LIF 
and OSM signal via heterodimeric complexes of gp130 in combination with LIFR, 
and additionally, OSM can signal through an alternative receptor complex consisting 
of gp130 and an OSM specific receptor (OSMR).  CNTF utilizes a specific 
heterotrimeric complex of gp130, LIFR and a specific α-receptor subunit CNTF 
receptor (CNTFR).   IL6 also signals via a trimeric complex consisting of a gp130 
homodimer combined with its specific α-receptor subunit IL6 receptor (IL6R).  The 
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α-receptor subunits (IL6R and CNTFR), although necessary for formation of specific 
receptor complexes, do not themselves transduce signal, whereas gp130, LIFR, and 
OSMR trigger phosporylation of Janus (JAK) Kinases, in order to activate the 
Jak/STAT signalling cascade (Heinrich et al, 1998).  As a direct result of utilizing 
similar receptor complexes, the IL6-type cytokines have overlapping biological 
activity (Taga & Kishimoto, 1997), and this biological redundancy has hindered 
efforts to elucidate the function of specific ligands.  Thus in vivo results from 
genetically engineered animal models with target disruptions of IL6-type ligands and 
receptors have not recapitulated the effects of IL6-type cytokines on germ cells in 
vitro (Stewart et al, 1992; Escary et al, 1993; Ware et al, 1995; Yoshida et al, 1996; 
Molyneaux et al, 2003a). 
 
 
Figure 5.1 IL6-type cytokines signal via receptor complexes.  
 
IL6-type cytokine complexes are made of shared signal transducing components (light 
blue) and α-receptor subunits (black and grey) that are necessary for specific ligand 
binding. The OSM ligand can bind a receptor complex consisting of gp130 
homodimerised to LIFR or OSMR (reviewed in Heinrich et al, 1998). 
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Transcripts encoding LIF, gp130, and LIFR are expressed in the late fetal and adult 
human, and receptors are localized to oocytes (Abir et al, 2004).  However, the 
expression of these factors during the key developmental window encompassing 
PGC proliferation, the initiation of meiosis and the formation of primordial follicles 
in the human fetal ovary has not been previously report d.  We therefore examined 
the expression of LIF, IL6, OSM, and CNTF, as well as their receptor components in 
the human fetal ovary across increasing gestation from 8 to 20 weeks.  We also 
investigated the expression and localization of gp130 and LIFR proteins to determine 
the cellular target(s) of IL6-type signalling, as a basis for understanding the roles that 
these cytokines might play in vivo in the human. 
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5.2 Materials and Methods 
 
Tissue collection and dissection 
Human fetal tissue used in the following experiments was obtained and dissected as 
described previously (Section 2.1), with subsequent SRY genotyping to determine 
sex of first trimester specimens (Section 2.3). 
RNA extraction and cDNA synthesis 
Sample tissue was then processed to extract RNA and subsequently synthesis cDNA 
for genomic analysis as previously discussed (Section 2.4). 
Quantitative RT-PCR 
In order to determine if mRNA transcripts encoding IL6-type cytokine ligands (IL6, 
LIF, OSM and CNTF) and receptors (gp130, IL6R, LIFR, OSMR) varied across 
gestation, qRT-PCR was performed using the ABI 7500Fast system and both Sybr 
Green and Taqman analysis as described in Section 2.5. 
Statistical Analysis 
Quantitative RT-PCR data were analysed with GraphPad Prism version 4 statistical 
software (GraphPad Software Inc).  Gestational comparision data were analysed 
using one-way ANOVA, data were then either analysed as escribed or log-
transformed for further analysis.  Log-transformation was performed in instances 
where data sets did not fit a Gaussian distribution.  The Kolmogorov-Smirnov 
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Data were then analysed utilising the Newman-Keuls Multiple Comparison post-test 
to determine significant changes between gestational values.  This post-test was 
chosen as has more strength than a Tukey post-test and the risk of type I error does 
not occur with only three groups (as in our study).  Some data was also analysed 
using a post-test for linear trend, this test was performed when data looked to be in a 
natural order (increasing or decreasing across gestation). 
Immunohistochemistry 
In order to determine the cell-specific sites of IL6-type cytokine signalling, the 
common receptor components gp130 and LIFR were immunolocalised across 
gestation as outlined in Section 2.8. 




5.3.1 Genes encoding IL6 ligands are developmentall y-regulated  
To determine presence and pattern of expression of transcripts encoding IL6-type 
cytokines during human fetal ovarian development, we performed qRT-PCR for IL6, 
LIF, OSM, and CNTF across a range of gestations.  Ovarian specimens wre grouped 
into three gestational stages to broadly reflect the key developmental events of early 
to mid-gestation ovarian development, namely; the proliferation of undifferentiated 
PGCs (8-11 weeks gestation; first trimester), the formation of germ cell nests and 
entry of the first germ cells into meiosis (13-16 weeks; early second trimester) and 
on-going meiotic entry and the onset of primordial follicle formation (17-20 weeks; 
late second trimester). 
Transcripts encoding all four ligands investigated were detected in the human fetal 
ovary.  Expression of transcripts encoding IL6 increased by a modest but significant 
amount between first and early second trimester (1.6±0.3 x10-4 vs 3.0±0.4 x10-4 
relative to expression of the housekeeping gene GAPDH, p=0.03, n=5-6 per group) 
weeks gestation, but declined subsequently, such that expression at late second 
trimester (1.9±0.2 x10-4 relative to GAPDH) was significantly lower than early 
second trimester (but not significantly different from first trimester (p=0.04)) (Figure 
5.2A) .  OSM expression increased significantly with increasing gestation, starting at 
a borderline detectible level at first trimester (2.3±0.5 x10-5 relative to GAPDH), 
increasing at early second trimester (9.2±3.1 x10-5 relative to GAPDH), and again at 
late second trimester (1.9±0.8 x10-4 relative to GAPDH, linear trend p=0.04, Figure 
5.2B).  In contrast, the expression of LIF and CNTF did not change significantly 
across the gestational range examined (p=0.69 and 0.17 respectively, Figure 5.2C 
and D).  Transcript levels for CNTF were variable.  These data reveal transcripts 
encoding IL6 and OSM are developmentally-regulated but expression of LIF and 
CNTF is not. 
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Figure 5.2 Genes encoding the IL6-type ligands are developmentally 
regulated in the human fetal ovary.   
Genes encoding the IL6-type ligands are developmentally regulated in the human fetal 
ovary.  Expression of the four ligands (IL6, LIF, OSM and CNTF) was analysed by qRT-
PCR across gestation and split into age groups concordant with gestational events; PGC 
proliferation in 8-11 weeks (1st trimester), meiosis and germ cell nest formation in 13-16 
weeks (early 2nd trimester), and primordial follicle formation in 17-20 weeks (late 2nd 
trimester); n= 4-6 samples for each gestation).  (A) Expression of IL6 increased between 
1st and early 2nd trimester, and was subsequently decreased at late 2nd trimester 
(*=p<0.05).  (B)  LIF expression did not change during early ovarian development. (C)  
Transcript levels for OSM are significantly up-regulated across gestation (*=p<0.05, 
determined by test for linear trend).    (D) CNTF expression was variable but no 
significant change across gestation was determined.  Values denote mean ± standard 
error of the mean relative to the housekeeping gene GAPDH.   
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5.3.2 Expression of transcripts encoding IL6-type c ytokine 
receptors are developmentally-regulated  
 
We next examined the expression of transcripts encodi g the IL6-type cytokine 
receptors gp130, LIFR, OSMR, and IL6R across the gestational range outlined above 
(n=5-6 per gestational group).  Expression of transcripts encoding both of the 
common signalling receptor components (gp130 and LIFR) increased between first 
and second trimester.  Messenger RNA expression of gp130 was significantly greater 
at early second trimester (2.1±0.3 x10-2 relative to GAPDH, p=0.02) and late second 
trimester (2.1±0.3 x10-2 relative to GAPDH, p=0.05, Figure 5.3A) than at first 
trimester (1.0±0.1 x10-2 relative to GAPDH).  The mRNA expression of LIFR 
displayed a similar pattern, with expression at first t imester (1.3±0.2 x10-2 relative to 
GAPDH) significantly lower than that at both early (5.9±1.2 x10-2 relative to 
GAPDH, p=0.01) and late second trimester (7.4±1.6 x10-2 relative to GAPDH, 
p=0.01, Figure 5.3B).    IL6R, which is required for the IL6 signalling complex, but 
does not actively signal itself, was higher at latesecond trimester (8.8±0.9 x10-2 
relative to GAPDH) compared to both first (3.5±0.6 x10-2 relative to GAPDH, 
p=0.002) and early second trimester(1.8±0.7 x10-2 relative to GAPDH, p=0.0003, 
Figure 5.3C).  Expression of OSMR, which is also conducts intracellular signalling, 
displayed a similar trend to that of transcripts encoding gp130 and LIFR (i.e. 
increasing with gestation) but showed no significant changes across the gestational 
range examined (Figure 5.3D).  These data demonstrate the two common receptor 
components and the IL6 specific component increase with gestation. 
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Figure 5.3 Expression of the common receptor components for the 
IL6-type cytokines increases with gestation in the human 
fetal ovary. 
Expression of the common receptor components for the IL6-type cytokines increases with 
gestation in the human fetal ovary.  Expression of receptor components necessary for 
IL6-type signalling was analysed by qRT-PCR across gestation.  (A) Expression of IL6ST 
which encodes for gp130, was significantly higher in early and late 2nd trimester fetal 
ovaries than in 1st trimester samples (*=p<0.05).  (B) LIFR showed a similar pattern of 
expression, with a significant increase in transcript levels at 1st trimester compared to 
early and late 2nd trimester (*=p<0.05).  (C) IL6R was increased at late 2nd trimester 
compared to 1st and early 2nd trimester, concomitant with initiation of primordial follicle 
formation (***=p<0.001).  (D) Although sharing a similar trend to that of gp130 and LIFR 
expression, OSMR expression did not change across gestation.  Values denote mean ± 
standard error of the mean relative to the housekeeping gene GAPDH.    
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5.3.3 gp130 and LIFR are expressed exclusively by t he germ 
cells in the human fetal ovary 
 
To determine the cellular target(s) of IL6-type cytokine signalling in the human fetal 
ovary, we performed immunohistochemistry to detect the functional receptor 
components gp130 and LIFR across the developmental window outlined above.  At 8 
weeks gestation, gp130 expression was detected in germ cells, but staining was weak 
and sporadic and many germ cells displayed no staining (Figure 5.4A).  In contrast, 
from 14 weeks gestation, expression was stronger and estricted to germ cells, with 
stromal cell streams and pre-granulosa cells not showing any expression (Figure 
5.4B and C), a pattern maintained in later gestations (Figure 5.4D and E).  Staining 
was also detected in oocytes in primordial follicles at 20 weeks gestation (Figure 
5.4E inset), revealing that germ cells continue to xpress gp130 following nest 
breakdown and follicle assembly. 
The expression pattern of LIFR in the human fetal ov ry was similar to that of 
gp130, with staining detected exclusively in germ cells from 8 weeks of gestation 
onwards (Figure 5.5A-D).   Notably, germ cells displayed variability in the intensity 
of LIFR staining even within close proximity (Figure 5.5E).  At 20 weeks gestation, 
oocytes within primordial follicles expressed LIFR (Figure 5.5E inset).  The 
expression pattern of the two shared, functional signalling components indicates that 
IL6-type cytokines are able to signal to germ cells in the fetal ovary; indeed germ 
cells appear the sole cell type involved. 
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Figure 5.4 Immunohistochemical detection of gp130 in the fetal 
ovary. 
Immunohistochemical detection of gp130 in the human fetal ovary across gestation.  (A) 
At 8 weeks gestation, faint gp130 staining is detectable in some germ cells (GCs), but the 
majority show no expression. At 14 weeks (B and C) and 17 weeks (D), clear gp130 
expression can be seen in the GC clusters, whilst stromal somatic cell streams (SC) and 
pre-granulosal cells (PG) remain immuno-negative.  (D, Inset) Negative control sample, 
lacking primary antibody, is absent of any non-specific staining.   (E)  At 20 weeks 
gestation, gp130 staining is more distinct and with immuno-positive GCs  (E Inset) 
including oocytes within primordial follicles. Scale bars equal 10 µm in (A) (C) and (D), 25 
µm (B), and 50 µm in (E).  Images are representative of staining performed on at least 2 
specimens at roughly the same gestation. 
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Figure 5.5 Immunohistochemical detection of LIFR in the fetal ovary 
Immunohistochemical detection of LIFR, is expressed in the human fetal ovary.  (A) At 8 
weeks gestation, germ cell (GC)-specific staining for LIFR is detectable.  (B)  GC clusters 
at 14 (B) and 17 (C and D) weeks express LIFR, with no staining detected in stromal 
somatic cell streams (SC) and pre-granulosal cells (PG) interspersed within germ cell 
clusters. (C, Inset) No immunostaining was detected in the negative control, 
demonstrating antibody specificity.   (E)  LIFR receptor expression at 20 weeks was 
localized specifically to germ cells, but variations in the intensity of staining between 
neighbouring germ cells is apparent (white and black arrows denote germ cells with weak 
or strong LIFR expression respectively).  (E, Inset) oocytes in primordial follicles also 
expressed LIFR.  Scale bars equal 10 µm in D, 25 µm in (A) and (C), and 50 µm in (B) 
and (E).  Images are representative of staining performed on at least 2 specimens at 
roughly the same gestation. 
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5.4 Discussion 
Germ cell development and primordial follicle formation are vital to female fertility.  
Extensive in vitro studies have demonstrated roles for LIF and other IL6-type 
cytokines in the regulation of germ cell development (Matsui et al, 1991; Resnick et 
al, 1992; Cheng et al, 1994; Koshimizu et al, 1996; Chuma & Nakatsuji, 2001; 
Nilsson et al, 2001).  However, little evidence has been provided regarding their 
potential roles during human fetal ovarian development. The data presented here 
confirm that all IL6-type cytokines previously demonstrated to regulate murine germ 
cell development in vitro (LIF, IL6, OSM, and CNTF) are expressed in the human 
fetal ovary, as are their common receptor components.  Furthermore, the expression 
of the latter is confined to germ cells, revealing these cells to be the exclusive targets 
of IL6-type signalling in the human fetal ovary.   
Expression of the genes encoding IL6-type signalling components was found to be 
developmentally-regulated, a finding consistent with the immunohistochemistry data 
also presented here.  Unexpectedly, the finding that gp130 expression is low or 
undetectable in primordial germ cells in the first t imester human fetal ovary 
suggests that these cells have little or no capacity to receive and/or transduce IL6-
type cytokine signals, and implies that, as in rodents (Molyneaux et al, 2003a), 
gp130 signalling activity is not required for the survival of human PGCs, or their 
maintenance in an undifferentiated state in vivo.  The mRNA and protein levels of 
both gp130 and LIFR appear to be up-regulated in the early second trimester, 
however.    This coincides with the entry of the first germ cells into meiosis (Gondos 
et al, 1986; Hibi et al, 1990), and indicates that IL6-type signalling may be important 
in the regulation of this critical event.  As both LIF and IL6 are reported to inhibit the 
spontaneous initiation of meiosis of isolated mouse PGCs in culture (Chuma & 
Nakatsuji, 2001), it is possible that up-regulation of receptor expression functions to 
prevent precocious entry into meiosis, maintaining a  immature cell population that 
can still undergo further proliferation.  The absenc  of signalling in first trimester 
germ cells, and the lack of an apparent restriction of gp130 and LIFR expression to 
undifferentiated, pre-meiotic germ cells found at the periphery of the second 
trimester human fetal ovary (Anderson et al, 2007) casts doubt on this hypothesis.  
Chapter 5                                                                                            IL6-type cytokines 
179 
More likely, IL6-type cytokines play a role in promting the survival of 
differentiating/meiotic germ cells.  Consistent with this, a modest anti-apoptotic 
effect was reported when LIF treatment was applied to germ cells in 3-day cultures 
of fetal mouse ovaries isolated from e13.5 mice (a development stage comparable to 
that of the early second trimester (13-16 weeks gestation) specimens reported here) 
(Morita et al, 1999).  Of particular note is the striking variability in expression of 
LIFR in between germ cells, particularly at later gstations, similar to that we have 
reported recently for brain derived neurotrophic factor (BDNF) (Childs et al, 2010a).  
Given the anti-apoptotic role of IL6-type cytokines for germ cells at this 
developmental stage (Morita et al, 1999), it is possible that the germ cells expressing 
the highest level of LIFR may gain a selective survival advantage during the wave of 
oocyte death that accompanies nest breakdown and follicle formation.  The increased 
expression of IL6R specifically in the late second trimester (as nest breakdown and 
primordial follicle formation commence) is also consistent with this hypothesis.     
Expression patterns of the IL6-type ligand transcripts are more varied.  No changes 
were detected in the expression of LIF, which is postulated to be involved in ovarian 
development (Nilsson et al, 2002), or CNTF across the gestational range examined 
(although the high variability in CNTF expression between specimens may mask 
such a change).  Each of these ligands utilizes the ame LIFR/gp130 receptor 
complex, however, only OSM, displays increasing expression with gestation similar 
to that of the two receptor components.  The expression of both IL6 and its specific 
receptor IL6R are also increased in second trimester, albeit at slightly different 
developmental stages.  Together these data demonstrate that multiple components of 
the IL6-type cytokine signalling machinery are up-regulated in the second trimester 
human fetal ovary, suggesting potential roles for these factors in the later stages of 
germ cell development and primordial follicle formation.  
Signalling by IL6-type cytokines has been reported to interact with other key 
signalling pathways that regulate mammalian ovarian development.  OSM up-
regulates the growth factor bFGF in vitro (Wijelath et al, 1997), which promotes 
primordial follicle formation (Nilsson et al, 2001).  Similarly, KL expression is 
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regulated by LIF in rodent ovarian culture and is able to activate differentiation and 
promote survival in germ cells (Nilsson et al, 2002).   It has thus been proposed that 
bFGF, KL, and the IL6-type cytokines have similar functions and work 
synergistically in vivo in the ovary (Kezele t al, 2002).  
In addition to interactions with bFGF and KL, the IL6-type cytokines have been 
shown to interact in non-reproductive organs with cytokines known to regulate 
human ovarian development.  LIF and BMP2, signalling through STAT3 and 
SMAD1 respectively, are known to act synergistically in promoting the 
differentiation of astrocytes from cultures of fetal neuronal precursor cells 
(Nakashima et al, 1999).  We have recently reported increased expression of BMP2 
and SMAD1 in the second trimester human fetal ovary, and ident fi d germ cells to 
be the exclusive targets of BMP signalling in this tis ue (Childs et al, 2010b); thus 
the apparatus for such a synergistic interaction betwe n IL6-type cytokine and BMP 
signalling also exists in human fetal ovarian germ cells.  LIF also acts synergistically 
with the neurotrophin BDNF to promote cell survival and proliferation in the 
developing rodent brain (Marzella et al, 1999).  This is similar to the known role for 
BDNF in the rodent ovary (Spears et al, 2003; Paredes et al, 2004; Childs et al, 
2010a). 
To date, animal models have failed to determine in vivo roles for the IL6-type 
cytokines during ovarian development.  Female Lif-/- mice do manifest an infertility 
phenotype, but as a result of an implantation defect, rather than a disruption of germ 
cell development (Stewart e al, 1992; Escary et al, 1993).  Successful ovulation of 
viable oocytes was confirmed, but quantity of follicles and long term fertility were 
not examined.  Interestingly, LIF-deficient mice display a significant loss of stem 
cell populations in the spleen and bone marrow (Escary et al, 1993).  To bypass the 
difficulty of IL6 ligand redundancy, mouse models with targeted disruptions of the 
genes encoding the gp130 and LIFR receptors have been g nerated, however, both 
models were either embryonically or early postnatally lethal (Ware et al, 1995; 
Yoshida et al, 1996), precluding a detailed analysis of their fertility. A mouse model 
in which gp130 is conditionally disrupted only in germ cells (gp130∆/∆) has been also 
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been generated (Molyneaux et al, 2003a).  Embryonic day (e) 13.5 gp130∆/∆ males 
showed significantly fewer PGCs, but mature males wre fertile.  Embryonic females 
had no difference in germ cell number; adult homozyg us recessive females were 
infertile or produced small litters due to defects in ovulation or late oocyte 
maturation.  In addition gp130∆/∆ females also had fewer primary follicles, but no 
difference in the number of primordial follicles.  
Although this study does not explore the possible functions of the IL6-type 
cytokines, it does confirm they signal solely to the germ cells in the human fetal 
ovary at the gestations examined.  Both the shared signalling components gp130 and 
LIFR, one or both of which are necessary for formation of all IL6-type signalling 
complexes, were immunohistochemically localized in germ cells and primordial 
follicles, suggesting any role the IL6-type cytokines would be via direct regulation of 
the germ cells.  Previous reports regarding LIF localization in the human ovary 
suggest this is via juxtacrine signalling from pre-granulosa stromal cells or autocrine 
signalling from the germ cells themselves (Abir et al, 2004). 
In conclusion, these data demonstrate that IL6-type cytokines are expressed in the 
human fetal ovary during germ cell development, and that germ cells are the sole 
target of IL6-type action in the fetal ovary.  Additionally, transcripts for both ligands 
and receptors are developmentally regulated, increasing with gestation, suggesting 
that the IL6-type cytokines are important for in vivo development of the human 
ovary, predominantly regulating the transition of dif erentiating germ cells from the 
formation of germ cell nests, through the entry into meiosis and the formation of 
primordial follicles.  
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Chapter 6.    Prokineticins in fetal ovarian develo pment 
6.1 Introduction 
PROK1 and 2 are recently described proteins that are well characterised for their role 
in regulation of angiogenesis and inflammation ((Sales & Jabbour, 2003b; Ngan & 
Tam, 2008) as fully described in Chapter 1).  The PROK ligands signal 
interchangeably via two GPCR receptors (PROKR1 and PROKR2; (Lin et al, 2002; 
Soga et al, 2002); Figure 6.1), and function similarly to vascular endothelial growth 
factor (VEGF) but are restricted to steroidogenic organs (adrenals, placenta, gonads, 
etc).   
 
 
Figure 6.1 PROK signaling components 
PROK1 and 2 signal via two shared g-coupled protein receptors (GPCRs); PROK 
receptor 1 (PROKR1) and 2 (PROKR2).  Although the ligands are able to signal 
interchangeably, PROK2 has a higher affinity for both receptors compared to PROK1. 
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Angiogenesis is a key process in the cyclical activity of the normal adult ovary, as 
well as ovarian disorders including polycystic ovary syndrome (PCOS) and ovarian 
cancer (Bamberger & Perrett, 2002; Ferrara et l, 2003).  For this reason the PROKs 
have been characterised in the adult ovary.  In the human ovary, PROK1 mRNA is 
expressed highly in granulosa cells surrounding primo dial and primary follicles, but 
expression declines sharply as the follicles mature to form secondary and antral 
follicles (Ferrara et al, 2003).  PROK1 is also highly expressed in the remaining 
theca of atretic follicles and for this reason it has been suggested to function in 
remodeling and proliferation required for ovarian repair post-ovulation (Ferrara et al, 
2003).  In support of this hypothesis, studies in a bovine model have also suggested a 
role for PROK1 in proliferation and survival of cells within the corpus luteum 
(Kisliouk et al, 2003; Fraser et al, 2005).   
Little is known about the other PROK signaling components in the ovary.  It has 
been confirmed the two PROK receptors are expressed in the adult human ovary, 
however further localisation has not been performed (Lin et al, 2002; Soga et al, 
2002). Additionally, PROK2 mRNA was not detectible in the human adult ovary in 
previous studies (Ferrara et al, 2003).  Interestingly, homozygous deletion of the 
PROKR2 gene in a rodent model results in severe atrophy of the reproductive system 
including the ovary (Matsumoto et al, 2006; Pitteloud et al, 2007).  However, it was 
determined that this was not due to direct action on the reproductive tract, rather via 
PROKR2’s role in GnRH neuron development in the hypothalamus.  Further, the 
PROKR2-/- phenotype is distinctly similar to that of humans with Kallmann 
syndrome, and subsequent studies have identified PROK2 and PROKR2 mutations in 
several Kallmann patients (Dode et al, 2006). 
Further characterisation studies of the PROKs and their role in the human fetal ovary 
during development have not been performed.  However, two recent genetic array 
studies have examined the PROKs in the fetal ovary, with intriguing results. One 
transcriptome study suggested an increased role for PROK1 in the fetal mouse ovary 
compared to the fetal testis, as a result of increased transcript expression (Houmard 
et al, 2009).  Another study detected developmentally-regulated expression of 
PROK2 in the fetal ovary (Fowler et al, 2009). 
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Outwith the ovary PROK1 has been demonstrated to regulate several factors known 
to be expressed and/or involved in ovarian development including LIF, the IL6-type 
ligand and COX2 the prostaglandin synthase (Evans et al, 2008; Evans et al, 2009). 
With this data in mind, it was hypothesised that PROKs might play a role in 
regulating these factors, as well as others to promote proliferation, differentiation and 
possibly angiogenesis during the development of the etal ovary.  In order to 
determine further PROK function, the two PROK ligands and their shared receptors 
were characterised across early gestation in the human fetal ovary.  Functional 
investigation was then performed utilising the TCam-2 cell line, generated from adult 
(35 yrs) human testicular germ cell tumour (Mizuno et al, 1993). 
 
TCam-2 cells expresses several pluripotency and developmental genes similarly to 
PGCs (Eckert et al, 2008; Young et al, 2011; Childs et al, unpublished) (Figure 6.2).  
These PGC markers include NANOG, OCT4, KIT, and VASA, which are classically 
associated with early germ cells (roughly comparable to the first trimester specimens 
utilised in this study (8-12 weeks)).  The later gem cell marker DAZL, which is 
increasingly expressed in second trimester human fet l ovary (Anderson et al, 2007), 
is not detected in the TCam-2 cells at either the transcript or protein level supporting 
the comparability of these cells to PGCs.  The TCam-2 line was utilised for further 
functional exploration of possible connections between PROK signalling and the 
other factors discussed in this thesis, as well as regulators known to be involved in 
germ cell proliferation and development. 
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Figure 6.2 Previous characterization of the TCam-2 cell line 
TCam-2 cells (T) express several pluripotent and early germ cell markers similar to 
primordial germ cells. (A-B) RT-PCR comparison of several factors with another 
seminoma line JKT-1 (J) and human testis (hTestis) demonstrate the TCam-2 expression 
profile closely mimics that of early germ cells.  (C) TCam-2 cells also express 
pluripotent/germ cell markers at the protein level, as determined via immuno-
fluorescence.  Figure compiled (A) from (Childs et al, unpublished) (B) (Eckert et al, 
2008) (C) (Young et al, 2011). 
 
   
B A 
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6.2 Materials and Methods 
Tissue collection 
Human fetal tissue used in the following experiments was obtained and dissected as 
described previously (Section 2.1), with subsequent SRY genotyping to determine 
sex of first trimester specimens (Section 2.3). 
RNA extraction and cDNA synthesis 
Sample tissue was then processed to extract RNA and subsequently synthesis cDNA 
for genomic analysis as previously discussed (Section 2.4). 
Quantitative RT-PCR 
In order to determine if mRNA transcripts encoding PROK signalling targets 
(PROK1, PROK2, PROKR1 and PROKR1) expression varied across gestation, qRT-
PCR was performed using the ABI 7500Fast system and both Sybr Green and 
Taqman analysis as described in Section 2.5. 
Quantitative RT-PCR analysis of PROKR1 transfected T-Cam2 cells was also 
performed using the ABI 7900HTFast system and Sybr Green analysis to determine 
gene expression changes in possible PROK targets (LIF, OSM, IL6, CNTF, PTGES, 
ID3, BDNF, MCL-1) and Taqman analysis was also performed for targets with 
primer/probe sequences (COX2), details of this protoc l are also outlined in Section 
2.5. 
Immunohistochemistry 
Human fetal ovarian samples were used to localise PROK ligands (PROK1 and 2) 
and receptors (PROKR1 and 2) to determine cell-specific sites of PROK synthesis 
and action.  Protocols are described in detail in Section 2.8. 
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PROKR1 transfected T-Cam2 cell cultures 
T-Cam2 cells stably transfected with the PROKR1 receptor were created as 
described in previously in Section and cultured in media as described in Section 2.13.  
Cells were cultured under standard procedures as describ d, and plated for treatment 
with vehicle control or 40nM PROK1 over a 24 hour time course, with cells 
harvested at 0, 2, 4, 6, 8, 12, and 24 hours after treatment to determine down-stream 
gene regulation.  Cell cultures were collected in RLT buffer following culture and 
snap frozen for further RNA extraction and cDNA synthesis. 
Statistical Analysis 
Quantitative RT-PCR data were analysed with GraphPad Prism version 4 statistical 
software (GraphPad Software Inc).  Gestational comparision data were analysed 
using one-way ANOVA, data were then either analysed as escribed or log-
transformed for further analysis.  Log-transformation was performed in instances 
where data sets did not fit a Gaussian distribution.  The Kolmogorov-Smirnov 
normality test was used for this purpose.    
Data were then analysed utilising the Newman-Keuls Multiple Comparison post-test 
to determine significant changes between gestational values.  This post-test was 
chosen as has more strength than a Tukey post-test and the risk of type I error does 
not occur with only three groups (as in our study).  Some data was also analysed 
using a post-test for linear trend, this test was performed when data looked to be in a 
natural order (increasing or decreasing across gestation). 
Gene expression changes identified using qRT-PCR after PROK1 treatment of T-
Cam2 cells were also analysed using GraphPad Prism as above.  Data were analysed 
using paired t-tests comparing PROK1 treated cells to dH2O treated cells (as the 
appropriate control). 
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6.3 Results 
6.3.1  PROK signalling components are developmental ly 
regulated in the human fetal ovary 
To determine presence and pattern of expression of transcripts encoding PROK 
signalling components during human fetal ovarian development, qRT-PCR was 
performed for the two PROK ligands (PROK1 and 2) and the two PROK receptors 
(PROKR1 and 2) across a range of gestations.  Ovarian specimens w re grouped into 
three gestational stages, as in previous chapters to reflect broadly key developmental 
events; the proliferation of undifferentiated PGCs (8-11 weeks gestation; first 
trimester), the formation of germ cell nests and entry of the first germ cells into 
meiosis (13-16 weeks; early second trimester) and on-going meiotic entry and the 
onset of primordial follicle formation (17-20 weeks; late second trimester). 
Transcripts encoding PROK ligands and receptors were expressed in the human fetal 
ovary across all gestations investigated.  Expression of PROK1 increased 
significantly in late second trimester compared to both first and early second 
trimester (2.0±0.4 vs 0.4±0.1 and .9±0.3 x10-2 expression relative to the 
housekeeping gene GAPDH, p=0.02 and 0.05 respectively, Figure 6.3A).  PROK2 
also increased with gestation, with a significant increase in expression between first 
and early second trimester (0.1±0.03 vs 0.6±0.2 x10-6 relative to GAPDH, p=0.02).  
A further significant increase in PROK2 expression was demonstrated at late second 
trimester compared to both first and early second trimester (1.2±0.2 vs 0.1±0.03 and 
0.6±0.2 x10-6 relative to GAPDH, p=0.0001 and 0.03 respectively, Figure 6.3B).  
PROKR1 displayed a similar expression pattern to that of PROK1 with a significant 
increase specifically in late second trimester in comparison to both first and early 
second trimester (1.8±0.3 vs 0.7±0.1 and 0.8±0.1 x10-7 relative to GAPDH, p=0.008 
and 0.007 respectively, Figure 6.3C).  Conversely, no change gestational change in 
expression was determined for PROKR2 (p=0.4, Figure 6.3D).  These data 
demonstrate that both ligands and the PROKR1 receptor are developmentally 
regulated in the human fetal ovary. 
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Figure 6.3 PROK ligand and receptor expression is up-regulated 
across fetal ovarian development. 
Expression of the two ligands (PROK1 and 2) and their two shared receptors (PROKR1 
and 2) was analysed by qRT-PCR across gestation and split into age groups; 8-11 weeks 
(1st T), 14-16 weeks (Early 2nd T), and 17-20 weeks (Late 2nd T; n= 4-6 samples for each 
gestation).  (A) Expression of PROK1 increased at late 2nd trimester compared to both 1st 
and early second trimester.  (B)  PROK2 expression was up-regulated significantly at 
each gestation, with late 2nd trimester significantly increased compared to both 1st and 
early 2nd trimester.  (C) PROKR1 was significantly up-regulated specifically in late 2nd 
trimester, but (D) no change was seen in PROKR2 expression.  All data are expressed 
relative to the housekeeping gene GAPDH.  Significance is determined by one-way 
ANOVA with Newman-Keuls post-test (p*<0.05, p**<0.01, and p*** <0.001). 
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6.3.2 PROK ligands localised to the germ cell nests  in 
developing human fetal ovaries 
Further characterisation of the PROK ligands was performed via 
immunohistochemical localisation in the human fetal ovary across a range of 
gestations.  Expression was barely detectible for both ligands in first trimester (data 
not shown), with increased expression seen in second trimester.  PROK1 expression 
was germ cell-specific, with pairs or groups of germ cells staining intensely 
compared to other germ cells within the same nest (Figure 6.4A-C).  This expression 
pattern was seen throughout second trimester, with primordial follicles also 
demonstrating positive PROK1 expression (Figure 6.3 A inset), although not as 
intense as seen in the earlier germ cells).  PROK2 expression was weaker than that of 
PROK1 with weak expression seen in germ cell nests, including both germ and pre-
granulosa cells (Figure 6.4D-F).  This expression pattern was seen across second 
trimester, although definitive staining in primordial follicles was not seen.  Negative 
control tissue incubated without primary antibody confirmed the specificity of the 
PROK staining, with no positive immunostaining determined (Figure 6.4D inset).  
These results confirm the protein expression of the PROK ligands mimics that of 
mRNA, with increasing expression with gestation.  The specific intensity of PROK1 
in pairs or groups of germ cells suggests it might play a heighted role in these cells.  
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Figure 6.4 PROK ligands localised to the germ cell nests in the human fetal ovary 
PROK1 and 2 were immunolocalised in the human fetal ovary (14 weeks) using 3,3′-diaminobenzidine tetrahydrochloride staining (brown).  (A-C) 
PROK1 expression was germ cell (GC) specific in the human fetal ovary, with pairs or multiple closely associated germ cells displaying 
heightened PROK1 expression compared to others nearby.  (A inset)  PROK1 was also seen in primordial follicles (17 week).  (D-F)  PROK2 
expression was considerably weaker than PROK1 with staining localised to both germ cells and pre-granulosal cells (PG) within germ cell nests, 
with no staining seen in stromal cell streams (SC).  (D inset) No immunolocalisation was seen in negative control tissue in which primary antibody 
was omitted.  Sections were counterstained with hematoxylin and scale bars equal 50 microns in A,B,D, and E; and 20 microns in C and F.  
Images are representative of staining performed on at least three specimens at roughly the same gestation.  
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6.3.3 PROK receptors expressed by germ cells of the  fetal ovary 
 
In order to determine the targets of PROK action in the human fetal testis the PROK 
receptors were immunohistochemically located in human fetal ovarian tissue.  
PROKR1 was found to be strongly expressed by the germ c lls of the fetal ovary, 
with no staining seen in somatic cell streams or in negative control tissue incubated 
without primary antibody (Figure 6.5A).  Upon closer examination it was apparent 
that the blood vessels of the human fetal ovary were also positive for PROKR1 (in 
keeping with its role in angiogenesis) as were some pre-granulosa cells (Figure 
6.5B).  PROKR2 protein was less distinctly stained, in keeping with lower PROKR2 
mRNA compared to PROKR1 (Figure 6.5C).  However, staining was apparent in 
germ cells, with immuno-negative somatic and pre-granulosa cells (Figure 6.5D).  
These data suggests PROK signalling primarily targes the germ cells of the human 
fetal ovary, with additional targeting of the blood vessels by PROKR1. 
 
 




Figure 6.5 PROK receptor expression in the human fetal ovary 
PROK receptors were immunolocalised in human fetal ovarian tissue (14wk) using 3,3′-
diaminobenzidine tetrahydrochloride staining (brown).  (A-B) PROKR1 is primarily 
expressed by fetal germ cells (GC) as well as blood vessels (BV) in the fetal ovary, with 
some staining of pre-granulosa cells (PG).  However, no somatic cell (SC) streams were 
immuno-negative, as was negative control tissue (A-inset).  (C-D)  PROKR2 was not 
intensely expressed by the human fetal ovary, but was apparent in the germ cells.  
Sections were counterstained with hematoxylin and scale bars equal 50 microns.  Images 
are representative of staining performed on at least three specimens at roughly the same 
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6.3.4   T-Cam2 cells stably transfected with PROKR1  as a model 
for fetal germ cells 
As germ cells were determined as the primary target of PROK action, a cell model 
was created for further investigation of PROK regulation.  The TCam-2 cell line 
have been characterised as a model of fetal germ cells (Young et al, 2011), and thus 
were utilised for this purpose.  The cells were initially characterised for expression of 
the PROK ligands and receptor, but were found to express the PROK receptors at 
much lower levels than was seen in either the human fet l testis or ovary (as 
demonstrated later in figure 6.7).  For this reason, the TCam-2 cell line was stably 
transfected with the PROKR1 receptor, as similarly to what was performed 
previously in the Ishikawa cell line to investigate PROK signalling in endometrial 
carcinoma (Evans et al, 2008).   
Initial transfection was performed with both supercoiled and linearised plasmid, as it 
was unclear which protocol would be most successful in the TCam-2 cells (Figure 
6.6A).  Positive control plasmid, containing green fluorescent protein (GFP), was 
simultaneously transfected in order to visually determine positive colonies, which 
were only seen in cells transfected with supercoiled plasmid (Figure 6.6B-C).  These 







                
 
 




Figure 6.6 Transfection of TCam-2 cells with PROKR1 
(A) Plasmid containing the PROKR1 gene or GFP was enzymatically cut (C, linearised) 
or left uncut (U, supercoiled) for transfection of the TCam-2 cell line, and run via 
electrophoresis to detect successful linearisation as determined by a single high 
molecular weight band.  Uncut plasmid was run alongside, displaying a high molecular 
weight band (spontaneous linearisation) along with two other bands demonstrating 
circular and supercoiled plasmid.  GFP transfected positive control cells were examined 
24 hours post transfection to determine successful transfection. (B) Darkfield microscopy 
depicting a colony of transfected T-Cam2 cells.  (C) The same colony via fluorescent 
microscopy depicting successful transfection in the form of positively transfected cells 
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6.3.5 Characterisation of PROKR1 TCam-2 cells 
Before further experimentation, the PROKR1 TCam-2 line was fully characterised to 
ensure successful transfection.  RT-PCR confirmation of increased transcription of 
PROKR1 in transfected TCam-2 cells (Figure 6.7A), was furthe  supported by qRT-
PCR comparison of PROKR1 TCam-2 cells with untransfected TCam-2 cells, 
PROKR1 transfected Ishikawa cells and primary human gonadal tissue (Figure 
6.7B).  Increased expression in TCam-2 cells was also seen at the protein level, as 
determined via immuno-blotting (Figure 6.7C); this was comparable to levels seen in 
primary tissue.  A second band was seen in the immuno-blot, approximately double 
the size expected for PROKR1.  Although homodimerisation of PROKR2 has been 
confirmed (Marsango et al, 2010), it has only been hypothesised for PROKR1, 
although this is the likely cause of the larger band, also seen in testis extracts 
demonstrating the band is physiologically relevant and not an artefact of the cell line.  
These data determine the transfected TCam-2 cells express PROKR1 at a heightened 
level compared to untransfected cells at both the transcript and protein level.  This 
characterization also demonstrates that although PROKR1 transcript expression in 
the PROKR1 transfected T-Cam2 line is increased compared to primary tissue, and 










Figure 6.7 Confirmation of transfection of PROKR1 into TCam-2 
cells  
RT-PCR confirmed increased expression of PROKR1 in PROKR1 transfected TCam-2 
cells (PT) compared to wild-type T-Cams (WT).  PROKR1 transfected Ishikawa (PI) cells 
were run alongside as a positive control.  B) Quantitative RT-PCR further distinguished 
this heightened expression in comparison to primary tissue.  C)  Protein expression was 
also heightened compared to fetal ovarian (♀) and testicular (♂) tissue.  Additionally, a 
band double the size of PROKR1 was determined in both PROKR1 TCam-2 cells and 
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6.3.6   PROK regulation in model germ cells 
 
Previous studies of PROK signalling in the endometrium have suggested PROK is 
able to regulate both the PGs and the IL-6 type cytokines.  Initial investigation of this 
relationship in fetal germ cells was performed in untransfected/wild-type and 
PROKR1 transfected TCam-2 cells treated with 40nM PROK1 for 12 hours (n=6).  
No change was seen in any of the genes examined in untransfected cells, consistent 
with low expression of the PROK receptors before transfection. 
PROKR1 transfected TCam-2 cells displayed a significant increase in COX2 
transcript levels compared to untransfected cells (2.4±0.8 vs 6.9±2.4 x10-6 relative 
percentage compared to the housekeeping gene RPL32, p= 0.011, Figure 6.8A).  
However, no subsequent increase in the PGE2 specific enzyme PTGES was seen 
(Figure 6.8B).  Despite evidence in other reproductive tissues, no significant up-
regulation of any of the IL6-type cytokines was found (Figure 6.8C-F).  In contrast, 
both IL6 and LIF in transfected cells showed a trend for reduced expression, however 
this was not significant.  These data confirm PROK1 via PROKR1 is able to 
regulated COX2 expression in an in vitro model of fetal germ cells.  Additionally, 
unlike regulation seen in other tissues, the IL6-type cytokines do not respond to 
PROK1 treatment. 




Figure 6.8 Gene expression changes in PROKR1 transfected TCam-
2 cells with PROK1 treatment. 
Wild-type TCam-2 cells (WT T-Cams) and TCam-2 cells stably transfected with the 
PROKR1 gene (PROKR1 T-Cams) were treated for 12h with (PROK) or without (Control) 
40nM PROK1 and gene expression changes evaluated compared to control (Time 0).  
(A) The prostaglandin precursor enzyme COX2 was significantly up-regulated when 
compared to PROK1 treated WT T-Cams, PROKR1 Time 0, and PROKR1 Control (12h 
untreated).  No significant change was seen with treatment in (B) PTGES, (C) IL6, (D) 
LIF, (E) OSM, or (F) CNTF. (*=p<0.05)
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6.3.7 PROK1 regulation of PG signalling components 
As initial treatment of cells with PROK1 led to a significant change in COX2 at 12 
hours, a full time course was performed on several PG pathway components to 
identify when up-regulation of gene expression was occurring and what other 
signalling components might be regulated. In particular, the receptors localised to 
human fetal germ cells were investigated, as some of the EP receptors have been 
shown to work in a positive feedback loop with COX2.  PROK1-treated (40nM) and 
untreated PROKR1 transfected TCam-2 cells were collted 2, 4, 8, 12, and 24 hours 
after treatment along with time 0 control (n=6). 
In addition to confirming COX2 up-regulation at 12 hours, further timecourse 
analysis determined significant up-regulation at 4 nd 8 hour time points (4 hours: 
1.6±0.6 vs 3.2 ± 0.9 x10-6 relative to RPL32, p=0.02, 8 hours: 2.6 ± 0.6 vs 5.0 ± 1.6 
x10-6 relative to RPL32, p=0.03, Figure 6.9A).  None of the other PG precursor 
enzymes (COX1 and PTGES) were significantly up-regulated with PROK1 treatment 
(Figure 6.9B-C).  Similarly, the three PGE2 receptors localised to fetal germ cells; 
EP2, 3 and 4, were not significantly up-regulated with PROK1 treatment (Figure 
6.9D-E).  Interestingly, it does appear that EP3 may be up-regulated in response to 
continued serum starvation (Figure 6.9E).  These data etermine PROK1 is able to 
up-regulate COX2 specifically, and does not initiate a positive feedback loop of 
PGE2 signalling in this system modelling human fetal germ cells. 
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Figure 6.9 Specific up-regulation of COX2 compared with other prostaglandin signalling components 
Timecourse analysis of gene expression changes of prostaglandin signaling components after 40nM PROK1 treatment, at time 0 (T0), 2, 4, 8, 12, 
and 24 hours (H). (A) COX2 is significantly up-regulated with PROK1 treatment after 4 and 8 hours compared to control.  No change is seen in 
the other prostaglandin precursor enzymes (B) COX1 and (C) PTGES.  Additionally, no change is seen in the PGE2 receptors expressed by the 
germ cells (D) EP2 (E) EP3 or (F) EP4. *p<0.05.




Identifying novel regulators of fetal ovarian development is essential for further 
understanding of the processes which occur leading up to primordial follicle 
formation.  Fetal ovarian development is critical for adult fertility, thus making 
regulators of these processes are key to female reproduction.  The PROKs are 
recently identified proteins which have been demonstrated to regulate various other 
components of the female reproductive system, including the endometrium 
(Battersby et al, 2004; Evans et al, 2008; Evans et al, 2009), placenta (Hoffmann et
al, 2006; Hoffmann et al, 2007; Denison et al, 2008), and fallopian tube (Shaw et al, 
2010a; Shaw et al, 2010b; Shaw et al, 2011).  Additionally, studies have identified 
that PROKs may play a role in regulation of the granulosa cells in the adult ovary 
(Kisliouk et al, 2003; Fraser et al, 2005).   
However, this study is the first to examine possible roles for the PROKs during fetal 
ovarian development.  In doing so, it has been determin d that all PROK ligands and 
receptors are expressed in the human fetal ovary and that expression of both PROK1 
and 2 ligands and PROKR1 are up-regulated with human ovarian development 
leading to primordial follicle formation.  Unlike in the adult ovary, where most 
PROK expression is restricted to the granulosa cells (Kisliouk et al, 2003; Fraser et 
al, 2005), PROK ligands and receptors were predominantly localised to the fetal 
germ cells.  Additional expression was seen in vascul r endothelial cells, which is 
unsurprising based upon PROK’s well identified role in angiogenesis (LeCouter t 
al, 2001; LeCouter & Ferrara, 2003; Tanaka et l, 2006).  With primary expression 
of the PROK components in germ cells it is likely that signalling is autocrine or 
paracrine between other germ cells.   
As PROK signalling is predominately restricted to one cell type, we further 
examined function of the PROKs using a model cell line for primordial germ cells, 
the T-Cam2 cells.  Despite expression of several classical pluripotent and germ cell 
markers, the T-Cam2 cells only endogenously expressed low amounts of either 
PROK receptors.  In order to circumvent this, the T-Cam2 line was stably transfected 
with the PROKR1 gene, as this receptor was previously shown to be both 
developmentally regulated and more highly expressed in the fetal ovary in 
Chapter 6                                                                                            PROKs in the ovary 
204 
 
comparison to PROKR2.  This stably transfected germ cell line further identified 
PROK1 via PROKR1 signalling is able to up-regulated the prostaglandin precursor 
enzyme COX2 specifically, and that this ligand-receptor signalli g does not regulate 
IL6-type cytokine expression in the germ cells, as w  shown previously in other 
cells and tissues (Evans et al, 2009; Cook et al, 2010). 
PROK1 signalling via PROKR1 was able to induce COX2 signalling but did not 
further affect any of the other prostaglandin enzymes or receptors investigated.  This 
is in contrast to a study which was able to discern up-regulation of EP4 with PROK1 
treatment (Wade t al, 2010).  These data suggest that PROK1, by selectively 
signalling to COX2 over COX1, may be involved specific events in the fetal ovary 
rather than homeostatic function, as COX2 is the inducible enzyme which is 
expressed in response to cytokine signalling (Otto & Smith, 1995; Herschman, 
1996).  Further, COX2 seems to be important for germ cell development, as 
demonstrated in the previous study regarding paracetamol exposure during fetal 
development (as paracetamol is thought to act primarily via inhibition of COX2, 
Chapter 4).  However, the exact downstream effects of COX2 upon up-regulation by 
PROK1 remains unknown, with data presented here suggesting function downstream 
of PROK1 signalling may not be via PGE2 in fetal germ cells.  However, it is also 
possible that significant up-regulation of PGE2 components was not detected in this 
study due to limitations of this cell line, and further exploration in primary tissue 
would be informative. 
Additionally, it is possible that the PROK1 may regulate a different COX2-related 
prostaglandin other than PGE2, such as PGF2α or PGD2.  There is evidence that PGD2 
plays a role in early gonad development during sex determination (Malki et al, 2005; 
Wilhelm et al, 2005); however, little is known about the localist on or function of 
PGD2 or PGF2α in regards to germ cell development.  Data from other systems also 
suggests PROK1 is also able to regulate other downstream prostanoids, such as 
thromboxanes or prostocylin (Wade et al, 2010) which may be downstream of 
PROK1 and COX2 up-regulation in fetal germ cells.   
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Interestingly, PROK1 was not shown to up-regulate the IL6-type cytokines in this 
study.  Previous investigation in the human reproductive tract demonstrated a 
regulatory relationship between PROK1 and LIF specifically (Evans et al, 2009).  In 
addition, although protein localisation of the other IL6-type cytokines investigated in 
this study remains unknown in the human fetal ovary (IL6, OSM, CNTF), there is 
data to suggest LIF is expressed by the fetal oocytes in the human (Abir et al, 2004).   
This demonstrates PROK1 regulation of LIF in germ cell ultures is physiologically 
relevant.  However, PROK1 did not regulate any of the IL6 type cytokines in the 
PROKR1 T-Cam2 cells, suggesting this signalling pathw y may not play a role in 
early germ cell development. 
Several other possibilities may explain the lack of PROK1 regulation of these factors 
in the PROKR1 T-Cam2 cells.  Firstly, LIF localisation has only been performed in 
human fetal ovaries from 19 weeks gestation onwards (Abir et al, 2004).  Previous 
study of the T-Cam2 cells has identified that they more closely resemble germ cells 
from first trimester specimens (Eckert t al, 2008; Young et al, 2011; Childs et al, 
unpublished), which may not express LIF protein or the other IL6 type cytokines at 
physiologically relevant levels (although transcript expression of each was 
confirmed).  Further, although T-Cam2 cells do exprss early PGC markers, they 
were derived from male origin and thusly may not respond in the same fashion as 
germ cells generated from female specimens.  No data have been collected regarding 
IL6-type cytokine expression in the testis, so it is reasonable to conclude there may 
be gender differences in expression and function of these factors.  Additionally, as 
functional data was gathered from a germ cell specific line, it is possible that PROK1 
regulates these factors in another cell type in the fetal ovarian tissue, namely vascular 
endothelial cells.   
In conclusion, this study has examined the newly characterised regulatory proteins 
PROK1 and 2 in the human fetal ovary across early gestation.  We have determined 
that both ligands and one of their shared receptors, PROKR1, are developmentally 
up-regulated leading to primordial follicle formation and that all components are 
primarily expressed by the fetal germ cells suggesting autocrine signalling or 
paracrine signalling between germ cells.  However, there is also evidence for 
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expression in the endothelial cells of the vasculature suggesting PROKs may play a 
role in angiogenesis, for which they are well characterised in other tissues.  Further 
functional characterisation was performed on a novel PROKR1 stably transfected 
human germ cell line, in order to determine downstream targets of PROK1 signalling 
and possible function in germ cells.  These studies etermined that PROK1 is able to 
consistently regulate the prostaglandin precursor enzyme COX2, which is implicated 
in germ cell survival in previous chapters (Chapter 3 and 4).  Together these data 
suggest a novel role for PROKs in the human fetal ov ry in the regulation of COX2 
and possible downstream targets to promote pathways such as survival and/or 
angiogenesis.  However, additional investigation is eeded in primary tissue to 
further discern further exact function of the PROK ligands during human fetal 
ovarian development. 








Prokineticins in fetal testis 
development
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Chapter 7.    Prokineticins in fetal testis develop ment 
7.1 Introduction 
PROKs function to promote angiogenesis, proliferation, and migration in various 
reproductive organs (reviewed in (Maldonado-Perez t al, 2007) and discussed in 
detail in Section 6.1) but have yet to be described n the fetal testis.  Early 
characterisation of the PROKs identified they were active in steroidogenic organs of 
the body, including the prostate and the testis (Wechs lberger et al, 1999; LeCouter 
& Ferrara, 2003).  In fact, in the mouse and rat, the testis is described to have the 
highest level of Prok2 expression in the body, although Prok2’s best characte ised 
role is in the regulation of the hypothalamus (LeCouter et al, 2003).  Brief 
characterisation of PROK expression was also performed in the human testes when 
examining their possible function in testicular caner (Samson et al, 2004).  These 
studies determined PROK1 ligand is expressed in the Leydig cells of the adult testis 
rather than in the germ cells as demonstrated in the ovary in the previous chapter 
(LeCouter et al, 2003; Samson et al, 2004).  Further, gene expression array analysis 
of gonads from both male and female mice determined th re were differential 
expression patterns of some of the PROK signalling components during ovarian and 
testicular development (Menke & Page, 2002).  This differential localisation and 
transcript expression, along with the heightened expression of PROK2 in the testis 
compared to the rest of the body, led to the hypothesis that the PROKs might play a 
role during early testicular development. 
In the fetal testis, like the fetal ovary, several developmental processes take place in a 
complex and highly organised fashion in order to form a functional gonad for future 
adult fertility.  Male sex determination (as described in Section 1.3) occurs early in 
gestation, with testis differentiation becoming evident at ~week 8 of gestation in the 
human (Anderson et al, 2002a).  Testis development is initiated after Sertoli cell 
differentiation, which has been hypothesised to be the rate limiting step in further 
differentiation of other testicular cell types (Wilhelm et al, 2007).  Developing 
Sertoli cells appear to regulate a cascade of developmental and morphological 
changes in the testis via several growth factors.  One such factor is Anti-Müllerian 
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hormone (AMH), which is expressed by the differentiating Sertoli cells subsequent 
to SRY expression (Hacker t al, 1995) at ~8 weeks gestation in the human (Rajpert-
De Meyts et al, 1999; Barbara et al, 2000).  Sertoli cells then migrate and associate 
with germ cells to form sex cords (Hughes, 2001).  These cords provide the basis for 
future seminiferous tubules, being the first sign of testis specific differentiation, and 
after which point the germ cells are referred to gonocytes and pre-spermatagonia (as 
opposed to oogonia and oocytes in the ovary) (Cooke & Saunders, 2002; Gaskell t 
al, 2004). 
AMH released from the Sertoli cells promotes migration of cells from the 
mesonephros to further colonise the testis (Bezard et al, 1987; Behringer, 1995).  
However, AMH is not thought to be the only factor involved in mesonephros 
migration (Ross et al, 2003).  FGF9 is also postulated to aid in regulation of cell 
migration (Colvin et al, 2001).  Although the signalling mechanisms governing cell 
migration to the testis from the mesonephros are poorly understood, it is a process 
which appears to be essential for further testis cord f rmation in the rodent (Tilmann 
& Capel, 1999).  It is postulated the migratory cells then differentiate and give rise to 
the peri-tubular myoid (PTM) cells, peri-vascular cells, and a sub-set of the Leydig 
cells (Merchantlarios et al, 1993; Martineau et al, 1997; Merchant-Larios & Moreno-
Mendoza, 1998; Nishino et al, 2001).   
Leydig cells are evident in the human fetal testis from ~8 weeks gestation, and are 
formed from two distinct sub-sets of progenitors (Codesal et al, 1990; Ostrer et al, 
2007; DeFalco et al, 2011).  As described above, one of the cohorts of Leydig cell 
progenitors migrates from a specialised region betwe n the gonad and mesonephros 
border; while the other cohort of progenitor cells migrates from the coleomic 
ephithelium.  Sertoli cells then function in a paracrine fashion, secreting factors to 
promote Leydig cell differentiation (Karl & Capel, 1998; Ge et al, 2006; DeFalco et 
al, 2011).  Pdgfα, is one such factor secreted by the Sertoli cells, which signals to the 
interstitial cells in the fetal testis, and interruption of Pdgfα signalling leads to Leydig 
cell disruption (Brennan et al, 2003).  Another factor with similar function is Desert 
hedgehog (Dhh) (Bitgood et al, 1996).  In addition to Leydig cell disruption, Dhh-/- 
mice also display poor segregation of the tubules from the interstitial compartment 
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(Yao & Capel, 2002), suggesting Dhh might be involved outwith Leydig cell 
differentiation.  Mutations in DHH in humans are associated with fertility disorders, 
most often gonadal dysgenesis and infertility (Umehara et al, 2000; Canto et al, 
2004; Canto et al, 2005), and fetal testes collected from smoking mothers also 
displayed lowered DHH levels (Fowler t al, 2008). 
Leydig cells regulate further masculinisation of the estis and secondary sex organs 
via the secretion of androgens (Clark et al, 2000; Hu et al, 2002; Welsh et al, 2007).  
Testosterone is produced via a several step enzymatic process from cholesterol (as 
depicted in Figure 7.1).  Enzymes produced by the Leydig cells (eg StAR, 
CYP11A1), necessary for androgen production, and testosterone itself are detected 
around the start of Leydig cell differentiation and peak at early second trimester in 
the human (Tapanainen et al, 1981; O'Shaughnessy et al, 2007; Scott et al, 2009).  In 
addition to androgens, the Leydig cells also produce insulin-like3 (INSL3), a factor 
initially characterised in regulation of testicular descent (Ivell & Hartung, 2003; 
Klonisch et al, 2004).  In addition, INSL3 regulates germ cell survival directly via its 
receptor leucine-rich repeat-containing G-protein-coupled receptor 8 (LGR8) 
(Kawamura et al, 2003). 
 
Figure 7.1 Steroid synthesis pathway in the human testis. 
The human fetal Leydig cells produce testosterone via the degradation of cholesterol via 
several enzymatic steps as demonstrated briefly above.  Figure from (Hofland et al, 
2010). 
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After initial differentiation, the Leydig cells in the fetal testis undergo a 
proliferative/hyperplastic event from 14-18 weeks, increasing vastly in number, 
which also correlates with increased steroidogenesis during this time (Codesal et al, 
1990; Murray et al, 2000).   
Other cell types to migrate from the mesenphros to the testes are the PTM cells and 
the perivascular cells (Martineau et al, 1997; Nishino et al, 2001).  Both of these cell 
types become evident in the human fetal testis at ~12 weeks gestation (Ostrer t al, 
2007).  Once settled in the gonad, the PTM cells differentiate and migrate to 
surround the germ and Sertoli cell aggregations to form a flattened cell layer 
providing infrastructure to the seminiferous tubules (Wilhelm et al, 2007).  In the 
human, the PTM layer displays tight junctions similar to other connective tissues 
(Ross & Long, 1966) and demonstrates contractile properties later in adulthood 
aiding in release of elongated spermatids.  Perivascul r cells also migrate from the 
mesenephros to the fetal testis (Nishino et al, 2001) and are important for 
neoangiogenesis.  Blood vessel formation is heighted during fetal testis development 
and aids in trafficking of hormones within the testis and to other organs. 
In summary, early fetal testis differentiation is hghly organised and composed of 
several processes including: Sertoli cell differentiation, cord formation and AMH 
release; migration of multiple cell types to the testis; Leydig cell differentiation, 
proliferation and initiation of steroidogenesis; PTM differentiation and seminiferous 
tubule enclosure; and vascular formation (as summarised in Figure 7.2).  All of these 
events are important for the development and support of the gonocytes for future 
spermatogenesis during adulthood. 




Figure 7.2 Summary of human fetal testis development. 
Gonad formation initiates with the 1) migration of the primordial germ cells to the genital 
ridge.  At this point the gonad is bi-potential, but signaling from the SRY gene promotes 
2) Sertoli cell differentiation and migration.  This is followed by 3) migration of the Leydig 
cells to the testis from the mesonephros and the coelomic epithelium and promote further 
testis formation via secretion of androgens.  4) Further migration of peritubular myoid 
cells and peri-vascular cells form the infrastructure of the fetal testis.  Figure adapted 
from (Sharpe et al, 2006). 
 
Chapter 7                                                                                            PROKs in the testis 
213 
 
As in the ovary, little is known about the developmental pathways that regulate 
testicular formation.  The PROKs have been postulated by other groups to be 
involved in angiogenesis and steroidogenesis, which are two main functions required 
for testicular growth and development (Wechselberger et al, 1999; Samson et al, 
2004; LeCouter et al, 2003).  For this reason, the PROK ligands and receptors were 
characterised in the human fetal testis across early gestation, as was performed in the 
fetal ovary in the previous chapter.  Further dual immunohistochemical staining and 
cultures were performed in order to extrapolate a possible function for PROK 
signalling during early male development. 
In addition, PROK1 regulation of several factors was investigated, to determine 
changes in transcript expression.  These factors include components from previous 
studies (the PGE2 and IL6-type cytokine pathways), components of the 
steroidogenesis pathway (CYP11A1 and StAR), and factors found to be regulated by 
PROK1 in previous studies which are thought to be involved in testis development 
(DKK1 and ID3) (Macdonald et al, 2010).




7.2 Materials and Methods 
 
Tissue collection 
Human fetal tissue used in the following experiments was obtained and dissected as 
described previously (Section 2.1), with subsequent SRY genotyping to determine 
sex of first trimester specimens (Section 2.3). 
RNA extraction and cDNA synthesis 
Sample tissue was then processed to extract RNA and subsequently synthesis cDNA 
for genomic analysis as previously discussed (Section 2.4). 
Quantitative RT-PCR 
In order to determine if mRNA transcripts encoding PROK signalling targets 
(PROK1, PROK2, PROKR1 and PROKR1) were expressed differentially compared 
to the fetal ovary and to determine variation across gestation, qRT-PCR was 
performed using the ABI 7500Fast system and both Sybr Green and Taqman analysis 
as described in Section 2.5. 
Quantitative RT-PCR analysis of fetal interstitial cu tures was also performed using 
the ABI 7900HTFast system and Sybr Green analysis to de ermine any gene 
expression changes in possible PROK targets (PTGES, BDNF, MCL-1, LIF, OSM, 
IL6, CYP11A1, StAR, and ID3) and Taqman analysis was also performed for targets 
with primer/probe sequences (COX2, and DKK1), details of this protocol are also 









Human fetal testis samples were used to localise PROK ligands (PROK1 and 2) and 
receptors (PROKR1 and 2) to determine cell-specific s tes of PROK synthesis and 
action.  Further staining was then performed with cell specific markers 3β-HSD 
(Leydig) and SMA (blood vessels), to confirm cell specificity of the PROK 
receptors.  Finally, immunohistochemistry was also utilised to determine changes in 
apoptosis (CC3) and proliferation (BrdU).  Protocols f r these localisations can be 
found in Section 2.8. 
Human fetal testicular culture 
Second trimester fetal testes (n= 6, 14-17 weeks gestation) were cultured as small 
explants in hanging-drop culture as described previously (Zhang et al, 2008; 
Szczepny et al, 2009).  Tissue was cultured using organ culture media as described in 
Section 2.13.  Tissue was split into two treatment groups; vehicle control (H2O) or 
40nM PROK1.  Tissue was cultured for 24 hours for histological analysis and 
subsequently fixed in Bouins solution and processed as in Section 2.6. 
Further examination to determine gene expression cha ges resulting from PROK1 
treatment were performed by differential plating to is late fetal interstitial cells for 
culture (n= 6, 14-16 weeks gestation).  Testes were disaggregated and cultured 
overnight in 6-well plates with 0.01% gelatin coating to promote adhesion of 
interstitial cells.  Germ, Sertoli, and Leydig cells did not adhere and were removed 
12 hours post-plating, at which time the remaining interstitial cells were treated with 
40 nM PROK1 for 24 hours.  This allowed for additional isolation of the cells 
responding to PROK1 treatment, allowing for selective investigation of specific cell 
response.  Interstitial cell cultures were lysed in RLT buffer following culture and 








Histological changes after PROK1 treatment in the human fetal testis were 
determined via image analysis using various markers as described in Section 2.11.3. 
Measurements of proliferation and apoptosis were peformed using two slides from 
each sample at least 10 sections apart (50 microns).  Each slide contained sections 
from 4-6 pieces of hanging drop tissue.  Positive cells (BrdU or CC3) were counted 
and designated intra- or extra- tubular based upon their localisation within the tissue.  
Random frames were generated and all cells were counted within the frame until a 
quantity designated as significant (as determined based upon area of the tissue) by 
the image analysis software was achieved.  These counts were then corrected for area 
of the whole tissue and tubular area. 
Statistical Analysis 
Quantitative RT-PCR data were analysed with GraphPad Prism version 4 statistical 
software (GraphPad Software Inc).  Gestational comparision data were analysed 
using one-way ANOVA, data were then either analysed as escribed or log-
transformed for further analysis.  Log-transformation was performed in instances 
where data sets did not fit a Gaussian distribution.  The Kolmogorov-Smirnov 
normality test was used for this purpose.    
Data were then analysed utilising the Newman-Keuls Multiple Comparison post-test 
to determine significant changes between gestational values.  This post-test was 
chosen as has more strength than a Tukey post-test and the risk of type I error does 
not occur with only three groups (as in our study).  Some data was also analysed 
using a post-test for linear trend, this test was performed when data looked to be in a 
natural order (increasing or decreasing across gestation). 
Gene expression changes identified using qRT-PCR after PROK1 treatment of 
human fetal testes were also analysed using GraphPad Prism as above.  Data were 
analysed using paired t-tests comparing PROK1 treated tissue to dH2O treated tissue 
(as the appropriate control). 





7.3.1  Genes encoding PROK signalling components ar e 
developmentally-regulated in the fetal testis 
To determine presence and pattern of expression of the two PROK ligands and their 
shared receptors during human fetal testis development, qRT-PCR was performed 
across a range of gestations.  Testis samples were split in three gestational groups, 
similar to what was performed for ovarian gestational analysis in previous chapters.  
In the testis these ages also equate to developmental events: 1st trimester (8-10 
weeks), Sertoli cell differentiation; early second trimester (14-16 weeks), Leydig cell 
migration, differentiation, and testosterone secretion; and late second trimester (17-
21 weeks) PTM and peri-vascular cell differentiation and Leydig and germ cell 
proliferation. 
Transcripts encoding all four PROK signalling components were detected in the 
human fetal testis across all gestations examined.  Expression of PROK1 was 
significantly increased in early and late second trimester compared to first trimester 
(4.1±1.2 and 3.9±1.4 vs 0.4±0.1 relative expression compared to the housekeeping 
gene GAPDH, p=0.009 and 0.04 respectively, Figure 7.3A).  PROK2 expression 
increased linearly across gestation, with increased expression between first to early 
second trimester (0.2±0.04 vs 1.7±0.5 x10-2 relative to GAPDH) and again between 
early second and late second trimester (1.7±0.5 vs 3.3±0.7 x10-2 relative to GAPDH, 
linear trend p=0.005, Figure 7.3B).  Messenger RNA expression of both PROK 
receptors (PROKR1 and 2) displayed similar expression patterns across gestation, 
with significant increases in expression specifically t late second trimester 
compared to both first and early second trimester (PROKR1= 0.7±0.1 and 0.6±0.1 vs 
1.3±0.1 x10-2 relative to GAPDH, p=0.009 and 0.007 respectively, Figure 7.3C) 
(PROKR2= 2.4±0.7 and 1.5±0.6 vs 9.6±2.0 x10-3 relative to GAPDH, p=0.01 for 
both comparisons, Figure 7.3D). These data demonstrate that mRNA expression of 
both PROK ligands and receptors is increased with testis development. 
 





Figure 7.3 Messneger RNA expression of PROK components is up-
regulated with development in the fetal testis 
Expression of the two ligands (PROK1 and 2) and their two shared receptors (PROKR1 
and 2) was analysed by qRT-PCR across gestation and split into age groups; 8-10 weeks 
(1st T), 14-16 weeks (Early 2nd T), and 17-21 weeks (Late 2nd T; n= 4-6 samples for each 
gestation).  (A) Expression of PROK1 increased between 1st trimester and both early and 
late 2nd trimester (**=p<0.01).  (B)  PROK2 expression was significantly up-regulated 
across gestation (**=p<0.01, determined by test for linear trend).  (C) PROKR1 and (D) 
PROKR2 expression were significantly up-regulated specifically in late 2nd trimester 
(**=p<0.01).  All data are expressed relative to the housekeeping gene GAPDH.  
Significance is determined by one-way ANOVA with Newman-Keuls post-test, except in 
the case of PROK2 which was determined by post-test for linear trend. 
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7.3.2  PROK ligands are expressed in most cell type s of the 
human fetal testis 
DAB immunohistochemical detection was performed to etermine sites of PROK 
ligand protein expression in the human fetal testis.  PROK1 expression was diffuse 
with expression seen both within the seminiferous cords and in the interstitial 
compartment of the fetal testis (Figure 7.4A and B). PROK1 expression was also 
seen in blood vessels of the human fetal testis.  PROK1 expression does appear to be 
specific, as control tissue from the endometrium was run with the same concentration 
of primary antibody and clearly displays immuno-negative stromal cells along with 
immuno-positive glandular tissue (Figure 7.4 inset).  PROK2 expression was more 
restricted, with the interstitial compartment being the primary site of PROK2 
expression (Figure 7.4C and D).  Weak staining was also seen within seminiferous 
cords but was not seen in the epithelium.  Negative control tissue incubated without 
primary antibody was run alongside both PROK1 and 2 and detected no non-specific 
staining.  In comparison to second trimester, tissue from first trimester specimens did 
no readily express either ligand (data not shown), suggesting PROK protein 
expression is lower in earlier ages, similar to that of PROK transcript expression.   
These data suggest PROK1 is highly expressed in the human fetal testis and is not 
restricted to a specific cell type, whereas PROK2 is also highly expressed, but is 
primarily expressed by Leydig and interstitial cells in the interstitial compartment of 
the fetal testis.   




Figure 7.4 PROK1 and 2 are highly expressed in the human fetal 
testis 
Immunohistochemistry was performed for PROK1 and 2 in 15 week human fetal testis 
tissue.  (A-B) 3,3′-diaminobenzidine tetrahydrochloride staining (brown) determined 
PROK1 expression was diffuse throughout the fetal testis, localised both in the 
seminiferous cords (ST) as well as the interstitial compartment (INT). (A inset) This 
localisation appears to be specific as the same concentration of primary antibody stained 
glandular tissue (G) but not stroma (S) in endometrial control tissue.  (C) PROK2 was 
primarily localised to the interstitial compartment of the human fetal testis (D) with weak 
expression seen within the seminiferous cords.  (C inset) No staining was determined in 
the negative control testis tissue incubated without primary antibody.  All scale bars equal 
50 microns.  Images are representative of staining performed on at least three specimens 
at roughly the same gestation.   
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7.3.3 PROK receptors localised to the interstitial compartment of 
the human fetal testis 
Fluorescent immunohistochemistry was utilised to determine the protein expression 
of the two PROK receptors (PROKR1 and 2) in the human fetal testis.  Both 
receptors displayed similar sites of expression, with marked expression within the 
interstitial compartment of testis but no expression within the cords (Figure 7.5 A-B).  
However, it was noted that not all cells within theinterstitial compartment were 
immuno-positive for either PROKR1 or PROKR2.  These results suggest the two 
receptors may be specific to certain cell type, most likely being either Leydig or 
other interstitial cells.   
In order to determine the site specific expression of the two receptors, each was 
fluorescently co-localised with the Leydig cell marker 3β-HSD (an enzymes utilised 
in steroid synthesis).  PROKR1 did not display any co-localisation with 3β-HSD, 
demonstrating its primary site of localisation in the human fetal testis to be the non-
Leydig interstitial cells (Figure 7.6).  Conversely, PROKR2 was highly co-localised 
with 3β-HSD, signifying PROKR2 is primarily expressed by the Leydig cells of the 
human fetal testis (Figure 7.6).  These data indicate the PROK receptors are both 
expressed within the interstitial compartment of the fetal testis making this the 
primary site of PROK ligand action; however, the receptors are expressed on 
differing cell types, with PROKR1 targeting non-Leydig interstitial cells and 
PROKR2 targeting the Leydig cells.  In addition, expression of both receptors 
increased with gestation, in keeping with transcript expression data. 




Figure 7.5 PROK receptor expression restricted to interstitial 
compartment of the human fetal testis 
Fluorescent immunohistochemical detection of the PROK receptors (green) in 18 week 
human fetal testis tissue.  (A-B)  PROKR1 is restricted to the interstitial compartment 
(INT) of the human fetal testis with no expression determined in the semineferous tubules 
(ST) as is (C-D) PROKR2.  Not all cells in the INT are expressing the receptors 
suggesting a possible cell-specific target.  Propidium iodide used as a nuclear 
counterstain (red).  Scale bars equal 20 microns.  Images are representative of staining 
performed on at least three specimens at roughly the same gestation.   
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Figure 7.6 Co-localisation of PROK receptors with Leydig cell marker 3β-HSD 
Fluorescent immunohistochemical localisation in 18 wk human fetal testis of PROK receptors (green) with Leydig cell marker 3β-HSD (red).  (A) 
PROKR1 does not co-localise with 3β-HSD, and is therefore restricted to the non-Leydig cells of the human fetal testis.  (B)  PROKR2 does co-
localise with 3β-HSD, demonstrating Leydig cells are the primary site of PROKR2 signalling.  DAPI counterstain (blue) was utilised.  Scale bars 
equal 50 microns.  Images are representative of staining performed on at least three specimens at roughly the same gestation.  
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7.3.4  PROK receptors expressed by fetal testicular  vasculature 
PROK receptor localisation was also investigated in fetal vasculature.  The vascular 
marker α-smooth muscle actin (SMA) was utilised to identify blood vessels within 
human fetal testis tissue.  Both PROKR1 and 2 displayed distinct co-localisation with 
SMA throughout later gestations (distinct vasculature is not apparent until late 
second trimester, Figure 7.7).  These data determin PROK signalling may play a 
classical role in neo-angiogenesis in the testis as well as a possible role with 
interstitial cells in the human fetal testis. 
 
Figure 7.7 PROK receptors are co-expressed with SMA in fetal 
testicular vasculature. 
The PROK receptors (green) were co-immunolocalised with the vascular marker α-
smooth muscle actin (SMA, red) in human fetal testicular tissue (18 wks). Both (A) 
PROKR1 and (B) PROKR2 co-localised with SMA in the blood vessels (BV) of the fetal 
testis.  Scale bars equal 50 microns.  Images are representative of staining performed on 
at least three specimens at roughly the same gestation.   
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7.3.5 PROK1 functions as pro-survival factor in int ratubular cells 
in the human fetal testis 
As PROK1 mRNA expression was higher than that of PROK2 and protein 
expression was also heightened in the human fetal testis compared to the 
endometrium, where it is known to function, the role f PROK1 was investigated 
during development in the human fetal testis.  PROK1 function was examined via 
hanging drop culture (as in chapter 3) of fragments of fetal testis (14-17 weeks, n=6) 
with 40 nM PROK1 or vehicle control for 24 hours.  The testis tissue was then 
examined for histological changes in apoptosis or pr liferation as determined by the 
markers CC3 or BrdU respectively (Figure 7.8 and 7.9).  Positively stained cells 
were quantified and categorised as either extratubular (interstitial) cells or 
intratubular (within seminiferous tubules), to narrow function to a specific 
compartment.   
As PROK receptor localisation determined the primary site of PROK action was the 
interstitial compartment of the human fetal testis (both Leydig and non-Leydig cells), 
the extratubular compartment was postulated to be the main site of PROK1 action.  
However, upon quantification of apoptosis and proliferation in this compartment, no 
change in cell apoptosis or proliferation was determined (Figure 7.8).   
Apoptosis and proliferation were also quantified in the intratubular (germ and Sertoli 
cell) population of the human fetal testis.  Although no change was seen in 
proliferation of these cells, there was a significant difference in the rate of apoptosis, 
with a significant decrease in apoptosis with PROK1 treatment (5.7±4.5 vs 3.6±2.3 
x10-4, p=0.03, Figure 7.9).  These data suggest PROK1 does n t affect the rate of cell 
turn over in the extratubular compartment which is composed of PROK target cells.  
However, PROK1 treatment does affect cell turn over in the intratubular 
compartment suggesting PROK1 signals to the Leydig and/or non-Leydig interstitial 
cells to produce a paracrine factor that in turn promotes survival in the intratubular 
compartment consisting of Sertoli and germ cells.   
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Figure 7.8 No change in apoptosis or proliferation in the 
extratubular cells of the human fetal testis with PROK1 
treatment 
Apoptosis and proliferation in the extratubular (outwith the seminferous tubules outlined 
by dashed line) compartment of the human fetal testis was quantified with the apoptotic 
marker cleaved caspase-3 (CC3) and the proliferative marker BrdU (14-17 weeks 
gestation, n=6).  Positive cells were quantified and adjusted for extratubular area.  This 
determined PROK1 treatment did not induce a change in cell turnover in the extratubular 
compartment.   Sample BrdU staining from control and PROK1 treated testis, 
demonstrating no change in extratubular (arrowhead) staining.  Intratubular staining 
marked with arrows.  Scale bars equal 100 microns.  
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Figure 7.9 Significant reduction of apoptosis in intratubular cells 
with PROK1 treatment in the human fetal testis 
Apoptosis and proliferation in the intratubular compartment (seminferous tubules outlined 
by dashed line) of the human fetal testis was quantified with the apoptotic marker cleaved 
caspase-3 (CC3) and the proliferative marker BrdU (14-17 weeks gestation, n=6).  
Positive intratubular cells were quantified and adjusted for tubular area.  This determined 
PROK1 treatment significantly reduced apoptosis of intratubular cells (arrows) (*p=0.05) 
unlike in extratubular cells (arrowheads), but did not alter proliferation rate in either cell 
type.  Scale bars equal 100 microns. 
 
 




7.3.6  COX2 and DKK1 expression are up-regulated by  PROK1 
signalling via PROKR1 
PROK1 cultures suggest a paracrine downstream factor regulates intratubular cell 
survival in the human fetal testis.  Further investigation was performed to identify 
possible pathways affected by PROK1 signalling via differential plating of 
dissociated human fetal testes (n=6, 14-17 weeks gestation), which allowed for the 
segregation of the interstitial cell compliment from the intratubular cells and 
steroidogenic cells (germ, Sertoli, and Leydig cells do not adhere/survive after 
dissociation; Figure 7.10).  To determine true differential plating was successful, a 
sample was taken after dissociation of cells and compared to untreated control cells 
after passage and culture.   
A significant loss of germ, Sertoli and Leydig cells after passage was confirmed by 
significant reduction in cell-specific transcript expression.  The germ cell-specific 
marker VASA demonstrated the most significant loss after passage (3.3±1.8 vs 
0.1±0.05 x 10-3 relative to RPL32, p=0.0006), with both the Sertoli cell marker, AMH 
(7.3±2.7 vs 2.0±1.0 x10-3 relative to RPL32, p=0.02) and the Leydig cell marker 
3βHSD also reduced after passage (1.3±0.3 vs 0.2±0.1 x10-2 relative to RPL32, 
p=0.02).  There was no change in the non-Leydig interstitial cell marker Desmin 
demonstrating these cells were retained in culture (p=0.9). This segregation allowed 
for further culture and treatment of PROKR1 target cells specifically, rather than the 
whole testis.   




Figure 7.10 Characterisation of the testis interstitial cell cultures 
Differential plating of disaggregated fetal testis (n=6, 14-17 weeks gestation) were 
performed in order to culture PROK specific target cells from the human fetal testis.  qRT-
PCR analysis of cells before plating and after passage (untreated for 24 hours) was 
performed to confirm which cell types were sustained.  (A) The germ cell gene VASA, (B) 
Sertoli cell gene AMH and (C) Leydig cell gene 3βHSD were all significantly 
downregulated post-differential plating determining these cells did not adhere/survive to 
be PROK1 treated.  (D) No change was seen in the interstitial cell marker Desmin 
demonstrating these cells were able to adhere in culture. * p≤0.05, ***p≤0.001. 
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Several downstream pathways were investigated, including the PG pathway, which 
has been demonstrated to have pro-survival effects on germ cells in the fetal gonads 
(ovarian data in chapter 3 and 4, testis data not shown).  The PG precursor enzyme 
COX2 was significantly up-regulated with PROK1 treatment compared to control 
(9.7±3.8 vs 3.9±1.5 x10-5 relative percentage compared to the housekeeping gene 
RPL32, p=0.05, Figure 7.11A).  However, the PGE2 specific precursor enzyme 
PTGES (Figure 7.11B) and known downstream targets of PGE2 (identified by human 
fetal cultures in Chapter 3) were not affected (7.11C-D). 
Changes in the IL6-type cytokines were also investigated, as it has been postulated 
they target germ cells and in the endometrium data suggests they are direct targets of 
PROK1 action (Evans et al, 2008; Evans et al, 2009).  However, no change in 
expression levels after 24h treatment with PROK1 was identified in IL6, LIF, OSM 
or CNTF (Figure 7.11E-H).  
Additionally, the steroidogenic enzymes CYP11A1 and StAR were investigated, as it 
was postulated PROK1 could be affecting the steroidogenesis pathway either directly 
or via COX2 regulation, thereby affecting the intratubular cells.  However, no change 
was seen in either target (Figure 7.11I-J). 
Finally, two genes identified in an array identifying possible PROK1 targets (Evans, 
2008), and known to function in human gonad development were investigated; 
DKK1 and ID3.  DKK1 was significantly up-regulated with PROK1 treatment 
compared to control (4.5±1.1 vs 3.6±1.0x10-4 relative to RPL32, p=0.03, Figure 
7.11K), but no change was seen in ID3 (Figure 7.11L).
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Figure 7.11 Gene expression changes of fetal testis interstitial cells once cultured with PROK1 
Interstitial cells collected from human fetal testis samples (14-17 wks) were cultured with 40 nM PROK1 for 24h, resulting in (A) a significant up-
regulation of the prostaglandin (PG) pre-cursor enzyme COX2 (*=p≤0.05) but no change (B) in the PGE2 specific enzyme PTGES or (C-D) BDNF 
and MCL-1 known to be regulated by PGE2.   (E-H)  No significant change was detected in the IL-6 type cytokines.  (I-J)  No change was seen in 
steroidogenic enzymes.  (K)  Significant up-regulation of DKK1 (*=p<0.05) was detected but no change was seen in ID3 which is known to 
interact with DKK1 in the fetal gonad.  All data are expressed relative to the housekeeping gene RPL32.  Significance is determined by log 
transformation (COX2 only) and paired t-test. 
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7.4 Discussion 
As in the ovary, early development of the testis is imperative for adult fertility.  The 
PROK ligands are two recently described proteins involved in angiogenesis and 
proliferation in other tissues; however despite array data demonstrating that PROK2 
expression is high in the fetal testis compared to the ovary (LeCouter et al, 2003), 
PROK function has not been elucidated.  This study confirms that PROK ligands and 
receptors are expressed in the human fetal testis and all components are 
developmentally-regulated.  Additionally, it identifies the interstitial compartment as 
the site of PROK action in fetal testis, with primary expression of receptors on 
Leydig and non-Leydig cells as well as vasculature.   Notably, this study also 
identifies a novel function for PROK1 as a pro-survival factor in the fetal testis, in 
the intratubular cell population consisting of germ and Sertoli cells.  Localisation of 
the PROK receptors suggests this pro-survival effect is due to downstream paracrine 
signalling.  Dissociation and culture of the intersitial cell portion of fetal testes was 
utilised to determine changes in gene expression and further identify paracrine 
pathways contributing to increased survival.  These cultures identified key 
components of two pathways which were up-regulated with PROK1 treatment; 
COX2 a PG precursor enzyme and DKK1 an antagonist of the WNT pathway. 
As previously demonstrated, inhibition of COX2 via p racetamol exposure leads to 
germ cell loss in rodent fetal gonads (Chapter 4).  Additionally, human fetal ovarian 
cultures determined that PGE2 signalling downstream of COX2 is able to up-regulate 
known differentiation factors (Bayne et al, 2009) (Chapter 3).  Therefore, up-
regulation of COX2 by PROK1 may account for the pro-survival effects seen.  COX2 
regulation of steroidogenesis in Leydig cells has also been demonstrated, with 
inhibition of the enzyme resulting in increased testosterone production (Wang et al, 
2003b; Wang et al, 2005; Chen et al, 2007a).  Therefore, it was hypothesised that 
PROK1 regulation of COX2 might modulate expression of either PGE2 or 
steroidogenic components in order to exert pro-survival effects.  Factors from both 
downstream pathways were investigated; however, no significant regulation of either 
pathway was identified in this study.  As these altr tions would be secondary to the 
up-regulation of COX2 by PROK1 it is possible that subtle changes would not be 
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detected without additional sample numbers or at later time points.  Nevertheless, 
these data confirm that COX2 is up-regulated by PROK1 treatment, and that this 
treatment promotes intratubular survival further supporting the possible role of 
COX2 as an anti-apoptotic factor in the fetal gonads. 
DKK1 was also up-regulated by PROK1 treatment.   DKK1 (as briefly discussed in 
Chapter 1) functions in early gonad development by modulating WNT signalling 
necessary for ovarian development (Vainio et al, 1999; Jeays-Ward et al, 2003).  
DKK1 binds to low-density lipoprotein receptor-related protein 6 (LRP6) a necessary 
component for WNT signalling (Bafico et al, 2001; Mao et al, 2001; Semenov et al, 
2001), making cells less responsive to WNT signallig and preventing activation of 
downstream β-catenin signalling necessary for ovarian development (Bafico et al, 
2001; Mao et al, 2001; Semenov et al, 2001).  Dkk1 is sex-specifically increased in 
the fetal testis during development (Manuylov et al, 2008; Combes et al, 2011) and 
is thought to prevent inappropriate WNT signalling.  Loss of Wnt4 signalling using a 
homozygous null rodent model produced XX gonads with features normally 
associated with testis development (Yao et al, 2004). However, Dkk1-/- XY gonads 
do not show up-regulation of Wnt signalling nor areth y feminised (Combes et al, 
2011) leading to the hypothesis that Dkk1 plays a supportive role in repression of 
ovarian development, rather than being a sole protective factor.  The fetal testis 
interstitial culture data support this protective th ory, as up-regulation of DKK1 with 
PROK1 treatment is concomitant with survival of intratubular cells.  
Interestingly, the role for PROK1 in angiogenesis a demonstrated in the adult testis 
in previous studies (LeCouter t al, 2003; Samson et al, 2004), was not supported in 
the fetal testis, as no change was seen in proliferat on of the extratubular cell 
population (including vascular endothelial cells).  However, previous angiogenic 
studies in the testis were performed over 1 week (LCouter et al, 2003).  It is 
possible the cultures utilised in this study did not identify changes in vasculature due 
to the short period of culture (24h) or due to the stage of testis development, as 
vascularisation of the testis initiates at the beginning of second trimester with 
migration of endothelial cells (Nishino et al, 2001; Ostrer et al, 2007), but would not 
be as advanced as in later gestations or in the adult.  
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In addition to functional aspects of PROK1 in the human fetal testis, this study also 
demonstrates that PROK components are more highly expressed in the human fetal 
testis than in the ovary at similar gestations (Chapter 6), with developmental 
increases of PROK signalling components in both sexe , suggesting an increasingly 
important role for PROK during second trimester in both sexes.  The fetal testis is 
quite dynamic during early development, with several p ocesses occurring 
simultaneously.  Therefore, pinpointing which processes PROK might be involved in 
based upon expression levels is not possible.  However, PROK1 seems to be up-
regulated around the initiation of Leydig differentiation and initiation of 
steroidogenesis  (Codesal et al, 1990; Murray et al, 2000; Gaskell et al, 2004); 
whereas both receptors are up-regulated in late second trimester which is mostly 
associated with an increase in proliferation, differentiation, and vascular formation 
(Nishino et al, 2001).  It is likely, based upon culture and locaisation data, that 
PROK signalling is involved in regulation of some of these processes.  
In addition to differential transcript expression between the sexes, there is also a 
discrepancy in PROK protein localisation.  PROK targets the germ cells in the 
human fetal ovary, whereas in the testis the intersti ial compartment is the site of 
PROK action.  The two PROK receptors also display a striking difference in 
localisation, with PROKR1 primarily expressed in the non-Leydig interstitial cells 
and PROKR2 expressed by the Leydig cells.  Although bot  receptors were 
expressed by the testicular vasculature, this drastic difference in primary site of 
localisation suggests the two receptors play differing oles during testis development.  
As PROK1 is able to signal interchangeably via either PROK receptor, it is not 
known which receptor is responsible for demonstrated pro-survival effects.  
Regulation of COX2 and DKK1 in cell lines transfected with the PROKR1 gene 
(Chapter 6) (Evans et al, 2008; Evans et al, 2009; Macdonald et al, 2010) support 
this mechanism for regulation in the testis.  However, PROK1 treatment of PROKR1 
transfected cells has a negative effect on proliferation in an endometrial epithelial 
cell line in vitro (Macdonald et al, 2010).  Further investigation utilising receptor-
specific antagonists would be beneficial for dissecting specific roles for PROKR1 
and 2 in the fetal testis.  
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In conclusion, these data demonstrate that PROK ligands and receptor transcripts are 
developmentally-up-regulated and are expressed at higher levels in the human fetal 
testis than ovary.  Additionally, in the fetal testis PROKs primarily target the Leydig 
and non-Leydig interstitial cells with additional expression in the vasculature.  
Despite this localisation, it was determined that PROK1 was able to promote survival 
of intratubular cells, inferring paracrine signalling to these cells, which may be via 
DKK1, COX2, or another downstream target yet to be identified.  These data outline 
a novel role for PROK function in the human fetal testis and demonstrate it functions 
as a pro-survival factor during development.   
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Chapter 8.    General Discussion 
8.1 Introduction 
Fetal ovarian development encompasses several highly regulated events, from initial 
germ cell specification and migration to the proximal epiblast in formation the 
gonad, followed by sex determination, entry into meiosis and subsequent arrest, and 
concluding in germ cell nest breakdown and associati n of oocytes with granulosa 
cells to form primordial follicles.  In addition tohese developmental processes, germ 
cell number is also highly regulated across fetal ov rian development, the few germ 
cells generated at initial specification proliferat vastly, only for their number to be 
drastically reduced prior to primordial follicle formation.  The regulation of both 
germ cell survival and development leads to the establi hment of a primordial follicle 
pool, which defines the number of oocytes a woman will have for ovulation in 
adulthood, and thus determine her future fertility.  Regulation of germ cell 
differentiation is provided by autocrine, paracrine, and juxtacrine signalling from 
both the germ cells themselves and their somatic environment, collectively termed 
the germ cell niche.  Although identified as such, the factors which comprise the 
germ cell niche remain to be fully elucidated.  This thesis encapsulates several 
studies that aimed to identify novel regulators of ovarian development, in an effort to 
further clarify what governs germ cell development a d survival. 
Three signalling pathways were initially hypothesisd to regulate human fetal 
ovarian development, and thereby be part of the germ c ll niche: prostaglandins (and 
specifically PGE2), IL6-type cytokines, and the PROKs.  These postulated regulators 
were identified as germ cell niche candidates for several key reasons (interaction 
with established factors of the germ cell niche, regulation of the adult ovary, and/or 
differentially regulated during early ovarian development) and were further 
investigated in order to establish the role of each f tor, how they interact with 
established factors of the germ cell niche, and other postulated regulators. 
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8.2 Novel interactions in the germ cell niche 
The experimental studies which constitute this thesis have demonstrated several 
novel factors and mechanisms within the germ cell niche (summarised in blue in 
Figure 8.4).  These data provide further understanding of the inter-relationships 
between factors involved in germ cell development, as well as providing additional 
hypothesises for further interaction.   
These data demonstrated that PROK1 and PROK2 signal in an autocrine manner to 
both PROKR1 and R2 receptors which are solely expressed by germ cells in the 
human fetal ovary (Figure 8.1A).  Further, PROK1 via PROKR1 is able to up-
regulate COX2 expression (Chapter 6, Figure 8.1B), thereby demonstrating 
interaction between two of the postulated pathways.   
Outwith the characterisation of novel components of the germ cell niche in the ovary, 
the work included in this thesis has also identified differential roles for the PROKs in 
the human fetal testis (as compared to the ovary, Chapter 7).  These studies identified 
that not unlike in the ovary, PROK1 via PROKR1 is able to up-regulate COX2 and 
promote survival of cells (Figure 8.1D).  However, unlike the ovarian studies, PROK 
ligands were shown to solely target interstitial cel s in the human fetal testis (Leydig 
and non-Leydig) and act in a paracrine fashion affecting intratubular cells rather than 
in an autocrine manner (Figure 8.1C).  It was further demonstrated PROK1 is also able 
to regulate DKK1, a factor involved in sex determination, and thus may further 
promote survival via a male-specific pathway.  As in the ovary, it is postulated 
PROK1 via PROKR1 up-regulation of COX2 may be protective via interaction with 
the steroidogenesis pathway, whereby COX2 increases te tosterone production 
promoting intratubular survival. 
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Figure 8.1 Prokineticin signalling in the fetal gonads 
Summary of PROK signalling differences  in the human  fetal gonads as determined by 
studies this thesis.  A) In the ovary the PROK ligands are expressed by the germ cells as 
are the PROK receptors demonstrating an autocrine signalling mechanism, B) with 
further data demonstrating PROK1 via the PROKR1 receptor is able to regulate COX2 in 
the germ cells.  C) Conversely, in the fetal testis ligand expression is more diffuse and the 
PROK receptors are localised to interstitial cells.  D) However, as in the ovary, PROK1 
via PROKR1 is able to regulate COX2 expression as well as DKK1, a factor involved in 
sex-determination, both of which are expressed in other cells demonstrating paracrine 
downstream signalling. (Abbreviations: INT-interstitial, TUBULE- seminiferous tubule). 
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However, it is unlikely that all of the COX2 produced in the fetal ovary is a direct 
result of PROK1 signalling, as COX2 expression increases linearly with gestation; 
whereas PROK1 up-regulation is later in late second trimester.  Further, it is possible 
that signalling by PROK2 via the same receptor (PROK 1) may have an additive 
effect; as PROK signalling has the potential for redundancy.  In addition, PROK2 
unlike PROK1 displays a similar pattern of expression to that of COX2 in the ovary.  
Despite the possibility of an additive effect of PROK signalling, it is unlikely this is 
the only regulatory pathway up-stream of COX2 production in the ovary.  Data from 
mice homozygous null for PROKR1 and PROKR2 support this hypothesis, as neither 
demonstrate any alteration in ovarian function ((Negri t al, 2006; Matsumoto et al, 
2006) unlike COX2-/- and EP2-/- females, which are unable to ovulate normally 
(Dinchuk et al, 1995; Hizaki et al, 1999)).  These data suggest further regulators 
outwith the PROKs, are responsible for some of the COX2 production in the human 
fetal gonads, particularly in earlier gestation (14-16 weeks), at which time COX2 
expression is up-regulated but PROK1 expression is not. 
Following up-regulation via PROK1 and other possible pathways, COX2 and 
subsequently, PTGES synthesize and release PGE2 from fetal germ cells in the 
human fetal ovary, which then acts in an autocrine (via receptors EP2, 3, or 4, Figure 
8.2A) or paracrine fashion (via EP3 or 4, Figure 8.2B) in order to regulate 
downstream targets including Activin A (INHBA), BDNF, and MCL-1 (Chapter 3, 
Figure 8.2C).   
It is hypothesised that regulation of Activin A is downstream of PGE2 signalling via 
the EP2 receptor (Figure 8.2C), as this receptor is solely expressed by more mature 
germ cells, which are the site of Activin A expression and regulation, whereas EP3 
and 4 are expressed by both somatic and germ cells. It therefore appears that PGE2 
promotes the role of Activin A in germ cell survival and proliferation (Martins da 
Silva et al, 2004).  Further, data from this thesis suggest that PGE2 promotes the 
inhibition of membrane-bound KL via increased expression of Activin A, which was 
previously demonstrated in the human ovary (Childs et al, 2010a), thereby 
preventing precocious primordial follicle formation.  
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BDNF expression is also stimulated by PGE2 in the human fetal ovary, and may do 
so via two pathways.  As the PGE2 receptors EP3 and EP4 are expressed by somatic 
cells, the site of BNDF expression, PGE2 may directly up-regulate expression of 
BDNF in the somatic cells (Figure8.2C).  However, previous data have suggested a 
second mechanism, as BDNF is known to be regulated by Activin A in the human 
fetal ovary (Childs et al, 2010a) suggesting regulation may be via an indirect 
mechanism rather than via direct PGE2 action (Figure 8.2D).  Further, it is possible 
both mechanisms are functional in the regulation of BDNF expression.  In this 
regard, it would be beneficial to perform interstitial-only ovarian cultures and 
compare with whole ovarian cultures to determine the route of regulation.  However, 
as prostaglandins were initially identified as regulators of the neurotrophins in the 
endometrium (Jabbour, unpublished), a tissue which la ks a germ cell component, it 
is likely BDNF is up-regulated directly via PGE2 signalling to the somatic cells or via 
additive direct and indirect signalling.  Regardless of the initial mechanism, BDNF is 
then able signal via the TrkB receptor, which is know  to be essential for oocyte 
survival at this time (Spears et al, 2003; Kerr et al, 2009). 
Data from this study has also identified PGE2 regulation of the anti-apoptotic factor 
MCL-1.  As with BDNF, increased expression of MCL-1 is postulated to be either 
direct via PGE2 regulation (Figure 8.2C) or indirect (Figure 8.2D) downstream of 
regulation via Activin A (Hartley et al, 2002; Martins da Silva et al, 2004).  Data 
from lung adenocarcinoma cultures also demonstrate MCL-1 regulation downstream 
of COX2 signalling is a pathway that is conserved in several tissues (Lin et al, 2001; 
Chen et al, 2010).  Activation of this pathway further supports the hypothesis that 
PGE2 acts as a pro-survival factor during human fetal ov rian development, a 
hypothesis that was supported by studies inhibiting COX2 expression (and thereby 
PGE2 production)  in fetal rat ovaries in vivo (Chapter 4).  However, this thesis has 
demonstrated fetal COX2 inhibition lead to significant oocyte loss that was not via 
increased apoptosis or decreased proliferation.  It is hypothesised that part of this 
phenotype may be the result of decreased Activin A, BDNF and MCL-1 production 
via inhibition of PGE2 signalling, and that this signalling in turn may have some 
effect on maturation/development of germ cells, instead of affecting apoptosis.  
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However, an alternative hypothesis is that the reduction in germ cell number is a 
result of COX2 regulation of steroidogenesis (Figure 8.2E), which has been 
demonstrated in adult tissue (Wang et al, 2003b; Wang et al, 2005; Chen et al, 
2007a).  Testosterone production is indeed perturbed in the male counterparts 
exposed to COX2 inhibition in this study.  Therefor, it is suggested the loss of 
oocytes might be due to altered steroidogenesis in the ovary.  Although little is 
known about the role of steroid regulation in the human fetal ovary, estrogen has 
been established as a key factor necessary for germ c ll nest breakdown in the mouse 
thereby allowing for primordial follicle formation (Iguchi et al, 1986; Kezele & 
Skinner, 2003; Chen et al, 2009).  If steroidogenesis is altered by COX2 inhibition, 
thereby reducing testosterone or if indeed estrogen is directly affected by COX2 
inhibition, it is possible germ cell nests are precociously broken down, resulting in 
germ cell atresia out-with programmed cell death.  I  is also possible that alteration of 
testosterone alone could affect germ cell survival, as ARKO female mice undergo 
early ovarian failure (Shiina et al, 2006).   
Further, data from a non-human primate model suggests a imilar role for estrogen 
(Zachos et al, 2002) and has determined that estrogen may regulat  germ cell nest 
breakdown via up-regulation of microvilli expression, ECM proteins, and altering the 
Activin : Inhibin ratio (Billiar et al, 2003; Billiar et al, 2004; Zachos et al, 2004; 
Bocca et al, 2008; Zachos et al, 2008).  These data suggest a similar mechanism is 
also likely in the human, where expression of steroid eceptors and synthesis 
enzymes have been confirmed (Fowler et al, 2011).  
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Figure 8.2  Prostaglandin signalling in the fetal ovary 
Data from this thesis has determined that PGE2 is able to signal in both an A) autocrine 
and B) paracrine manner, with downstream up-regulation of Activin A, MCL1 and BDNF, 
which maybe via either C) direct or D) indirect mechanisms.  In addition, it is 
hypothesised that this pathway might also interact with the steroid hormone pathway to 
further regulate human ovarian development.
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Another further group of factors has further been characterised in the human fetal 
ovary, the IL6-type cytokines (Chapter 5).  Although function of these factors has not 
been investigated in this thesis, the present data demonstrate that they solely target 
germ cells in the human fetal ovary, as their shared receptor components gp130 and 
LIFR are exclusively localised to these cells (Figure 8.3A).  Investigation of the IL6-
type cytokines has further demonstrated developmentally-regulated transcript 
expression of the shared receptor components and the OSM ligand in the period 
leading up to primordial follicle formation.  Based on these data, it is hypothesised 
that the IL6-type cytokines are likely to function in later oocyte development.  As 
LIF has previously been shown to regulate the primordial to primary transition in the 
rodent ovarian culture, it may play a similar role in the human (Nilsson et al, 2002; 
Nilsson & Skinner, 2004).  Both KL and bFGF, which are well-established in 
cooperation with LIF in the maintenance of stem cell ulture, also function alongside 
LIF to promote follicle activation in these rodent ovarian cultures.  In addition, 
similar up-regulation of bFGF and KL (as compared to the IL6-type receptors) is 
noted in the human (Figure 8.3B) (Robinson et al, 2001; Quennell et al, 2004; Stoop 
et al, 2005) suggesting a mechanism of bFGF/LIF/KL interaction may be important 
in the human as well as in the rodent for follicle transition, however this remains 
speculative.  Further study of IL6-type cytokine interaction with bFGF and KL, as 
well other established regulators of follicle activa on including FOXO3a, GDF9 and 
BMP15, would further clarify the roles of these factors in the human fetal ovary. 
. 








Figure 8.3  IL6-type cytokine signalling in the fetal ovary 
This thesis has determined A) the IL6-type cytokines signal solely to the germ cells in the 
human fetal ovary as their two shared receptors (gp130 and LIFR), necessary for all IL6-
type signalling, are located on these cells.  In addition, mRNA expression patterns 
suggest the IL6-type cytokines may play a role in later follicular development, B) leading 
to the hypothesis that the IL6-type cytokines may interact with bFGF and KL, which are 
important  for later germ cell development in vivo and are known to interact with the IL6-
type cytokine in vitro.




In conclusion, this thesis has demonstrated PGE2, the IL6-type cytokines, and the 
PROKs are all expressed in the human fetal ovary, and signal directly to the germ 
cells (summarised in Figure 8.4).  Additionally, functional studies have identified 
PROK1 and PGE2 are up-stream of pro-survival and proliferation pathways and 
thereby play a role in regulating fetal oocyte development as part of the germ cell 
niche.  PROK1 also plays a similar pro-survival role in the fetal testis.  However, in 
both the fetal testis and the fetal ovary, it is likely that COX2 downstream of PROK1 
plays a larger role pro-survival/anti-apoptotic function, as COX2 is able to directly 
modulate these pathways via several downstream targets including Activin A, 
BDNF, and MCL-1, as well as a likely link with steroidogenesis.  In addition, this 
thesis further speculates that the COX2 produced by the fetal ovary is not solely the 
result of increased PROK1 signalling, and that other up-stream regulatory pathways 
have yet to be identified. 
These studies have contributed to the understanding of fetal ovarian development in 
the human, and as such have provided further knowledge regarding what factors 
influence germ cell death and survival prior to primordial follicle formation.  
Disruption of these developmental events can result in POI or infertility, and thus 
understanding these pathways is essential for women’s r productive health.   




Figure 8.4   Summary of the novel pathways involved in the germ 
cell niche and their likely interactions with established 
pathways 
Schematic representation of the newly characterised factors of the germ cell niche and 
their downstream interactions (blue), in corporation with suggested interactions with 
established signalling pathways essential for early germ cell survival and development 
(red).  Established pathways are demonstrated in solid lines whereas those hypothesised 
are represented by dashed lines.  In the case of EP2 regulation of Activin A, this pathway 
is not established, but is most likely. 
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8.4 Future Work 
Although this thesis initially established function for novel factors in the human fetal 
ovary and testis, further work is necessary to fully nderstand the mechanisms and 
overall function of these factors throughout ovarian biology.  Follow-up studies of 
particular importance are as follows: 
8.4.1 Paracetamol Exposure Study 
The paracetamol study is of particular interest for further work, as data from e17.5 
rats has demonstrated there is no change in germ cell number in early gestation, and 
there is no apparent mechanism for loss by e21.5 (no change in apoptosis or 
proliferation).  Therefore, further analysis of ovaries at this stage is necessary in 
order to establish possible mechanisms of action.  Data from the male paracetamol 
exposed pups has noted a change in steroidogenesis, suggesting it will be important 
to investigate levels of steroid expression in the female pups, as well as levels of 
PGE2 to identify the likely downstream targets of paracet mol action resulting in 
reduced germ cell number.  To that end, the levels of steroids and PGE2 will also be 
investigated in the dam to see how the maternal system is affected.  As discussed 
previously, estrogen is known to function in nest breakdown and alteration of the 
estrogen levels in the dam could possibly perturb this process in the pups. 
In addition, as a reduction in germ cell number is likely to impact on primordial 
follicle formation and thus affect adult fertility, future studies are planned to track 
effects of paracetamol exposure on primordial follicle formation in offspring, and 
throughout postnatal life in order to identify possible premature follicle depletion in 
aged paracetamol-exposed females.   
8.4.2 PROK1 effects in the human fetal testis 
Although it was determined that PROK1 functions to reduce apoptosis in intratubular 
cells of the human fetal testis, further study is necessary to determine if this increased 
survival is of Sertoli or germ cells (or both).  Identification of which cell type is 
being affected will aid in understanding downstream mechanism of PROK action, 
and will be performed by stereological analysis of dual detection for a germ cell 
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Appendix 1: Manufacturers’ Details: 
Company City  Country  
Abcam Cambridge UK 
Adobe San Jose, CA USA 
Ambion Austin, TX USA 
Applied Biosystems  Foster City, CA USA 
BD Franklin Lakes, NJ USA 
Bioline London UK 
Bio-Rad Hercules, CA USA 
Biotium Hayward, CA USA 
Caltag Buckingham UK 
Cayman Ann Arbour, MI USA 
Clintech Guilford UK 
Corning Corning, NY USA 
CoStar Schipol-Rijk Netherlands 
Dako Glostrup Denmark 
Eppendorf Hamburg Germany 
Eurogentec Liege Belguim 
Faithfull Tools Kent UK 
Fisher Scientific Loughborough UK 
Fitzgerald Acton, MA USA 
Gibco Carlsbad, CA USA 
GraphPad Software La Jolla, CA USA 
Histolab Gotheburg Sweden 
Invitrogen Carlsbad, CA USA 
Invivogen San Diego, CA USA 
Lab Vision Corp Now owned by Thermo Scientific (see below) 
Labsystems Vienna, VA USA 
Leica Wetzlar Germany 
Li -Cor Lincoln, NE USA 
Lifespan Seattle, WA USA 
Lonza Basel Switzerland 
Lymphotec Tokyo Japan 
Mazola Memphis, TN USA 
MBL  Woburn, MA USA 
Media Cybernetics Bethesda, MD USA 
Millipore  Billerica, MA USA 
Mirus  Madison, WI USA 
MJ Research Waltham, MA USA 
New England Biolabs Ipswich, MA USA 
Olympus Essex UK 
Qiagen Hamburg Germany 
Qimaging Surrey Canada 
Perkin Elmer Waltham, MA USA 
Phoneix Burlingham, CA USA 
Prior  Cambridge UK 
Promega Madison, WI USA 








Company City  Country  
Santa Cruz Santa Cruz, CA USA 
SDS Dundee UK 
Sigma St Louis, MO USA 
SPPS Argenteuil France 
Thermo Scientific Waltham, MA USA 
Upstate Now owned by Millipore (see above) 
Vector  Burlingame, CA USA 
VWR West Chester, PA USA 
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